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(57)	 ABSTRACT
Novel chimeric plant promoter sequences are provided,
together with plant gene expression cassettes comprising
such sequences. In certain preferred embodiments, the chi-
meric plant promoters comprise the BoxII cis element and/or
derivatives thereof. In addition, novel transcription factors are
provided, together with nucleic acid sequences encoding such
transcription factors and plant gene expression cassettes com-
prising such nucleic acid sequences. In certain preferred
embodiments, the novel transcription factors comprise the
acidic domain, or fragments thereof, of the RF2a transcrip-
tion factor. Methods for using the chimeric plant promoter
sequences and novel transcription factors in regulating the
expression of at least one gene of interest are provided,
together with transgenic plants comprising such chimeric
plant promoter sequences and novel transcription factors.
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METHODS AND COMPOSITIONS FOR	 known as the leucine zipper, the bZIP domain, the zinc-finger,
REGULATING GENE EXPRESSION IN	 the homeobox, the basic helix-loop-helix and others. The
PLANT CELLS
	
	
trans-acting domains of transcription factors are often char-
acterized as having a high content of specific amino acids,
CROSS-REFERENCE TO RELATED	 5 which include domains rich in acidic amino acids, proline or
APPLICATIONS
	
	 glutamine (Ginger et al., 1985; Meshi and Iwabuchi, 1995;
Mitchell and Tjian, 1989). Acidic domains have been
This application is a continuation-in-part and claims the	 reported to possess activation functions that include interac-
benefit of U.S. patent application Ser. No. 10/888,613, filed 	 tions with TATA-binding proteins ("TBP") (Truant et al.,
Jul. 9, 2004, now U.S. Pat. No. 7,517,689 which is incorpo-  io 1993), TBP-associated factors ("TAFs") (Uesugi et al.,
rated herein by reference. 	 1997), TFIIA (Pugh, 2000), TFIIB (Klemm et al., 1995) and
This invention was supported in part by grant number 	 other general transcription complexes (Stargell and Struhl,
NNA04CC29G from the National Aeronautics and Space 	 1995).
Administration (NASA). The U.S. Government may have 	 Beachy, in U.S. Pat. No. 5,824,857 entitled "Plant Pro-
certain rights in the invention.	 15 moter," described the promoter from the rice tungro bacilli-
form virus ("RTBV"). The '857 patent discloses that the
FIELD OF THE INVENTION	 RTBV promoter causes preferential gene expression in plant
vascular tissue. The patent also discloses that the RTBV pro-
The present invention relates to the field of molecular biol- 	 moter can be used to drive expression in most plants, whether
ogy. In particular, the invention relates to methods and com- 20 monocotyledonous or dicotyledonous, and is particularly
positions that can be used to regulate gene expression. Still 	 suited to rice. The patent further discloses the transformation
more particularly, the invention relates to methods and com- 	 of plants by inserting the coding sequence of the RTBV
positions that can be used to initiate and/or enhance the 	 promoter and a heterologous gene of interest to obtain trans-
expression of at least one gene of interest in plant cells.
	
	 genic plants that express the gene of interest in vascular
25 tissue.
BACKGROUND OF THE INVENTION
	
	
Yin and Beachy, in "The regulatory regions of the rice
tungro bacilliform virus promoter and interacting nuclear
Gene expression may be regulated in several ways, which 	 factors in rice (Oryza sativa L.), The Plant Journal, 7(6):
include the activation or suppression of transcription, the 	 969-980 (1995)," described the E fragment (-164 to +45 in
differential processing and stabilization of messenger RNA 30 relation to the transcription start site) within the RTBV pro-
("mRNA") and the extent of translation of the mRNA. The	 moter, which was shown to be sufficient to cause tissue-
control of transcription plays a particularly critical role in the 	 specific gene expression. The article also disclosed a critical
regulation of gene expression in eukaryotic cells. There are 	 cis element, Box II (-53 to –39), within the E fragment that
several structural elements that are involved in the regulation 	 was shown to be essential for promoter activity. The same
of transcription. 	 35 authors identified other cis elements of the RTBV promoter in
Promoters represent a class of nucleic acid structures that 	 "Promoter elements required for phloem-specific gene
are involved in the regulation of transcription. In general, 	 expression from the RTBV promoter in rice, The Plant Jour-
promoters are located next to the transcription start site and 	 nal: 12(5): 1179-1188 (1997)," including the ASL Box (-98
interact with RNA polymerase, either directly or indirectly.	 to –79) and a GATA motif (-143 to –135). Together, these cis
Promoters often comprise several discrete "cis elements," 40 elements were shown to confer phloem-specific reporter gene
each of which may be recognized by one or more trans-acting 	 expression.
regulatory proteins known as transcription factors. Among 	 Yin et al., in "RF2a, a bZIP transcriptional activator of
the various cis elements well-known in the art is the "TATA 	 phloem-specific rice tungro bacilliform virus promoter, func-
box," which is known to interact with certain regulatory pro-	 tion in vascular development, The EMBO Journal, 16(17):
teins, e.g., transcription factors, and is generally located about 45 5247-5259 (1997)," identified a 1.8 Kb transcription factor
20-30 base pairs upstream from the transcription initiation	 consisting of 368 amino acids—designated as RF2a. The
site.	 RF2a transcription factor is currently known to represent a
The binding of such transcription factors to promoters or 	 bZIP transcription activator found in rice plants that contains
other regulatory sequences is often responsible for the initia- 	 acidic, proline-rich and glutamine-rich putative functional
tion, maintenance and/or down-regulation of transcription. A 5o domains. RF2a has been shown to bind the Box II element of
typical gene-specific eukaryotic transcription factor includes 	 the RTBV promoter and stimulate Box II-dependent tran-
a DNA-binding domain and one or more additional domains 	 scription in vitro. Another bZIP protein, RF2b, has been
that influence the activation or repression of transcription,	 isolated through interaction with RF2a, which also has been
e.g., "trans-acting domains." Transcription factors bind in the 	 shown to interact with the Box II element.
general proximity (although occasionally at great distances) 55	 The inventors have discovered that the Box II cis-element
of the point of transcription initiation of a gene. Such tran- 	 of the RTBV promoter is portable and that it can be used to
scription factors often act to influence the efficiency of for- 	 modulate gene expression in unrelated promoters in connec-
mation or function of a transcription initiation complex at the 	 tion with RF2a and/or RF2b. That is, until now, it was not
promoter. Transcription factors can act in a positive fashion 	 known that the Box II element, and similar sequences, could
(transactivation) or in a negative fashion (transrepression). 6o be used in chimeric promoters to regulate gene expression in
Furthermore, the effect that transcription factors may have on 	 connection with RF2a and/or RF2b. What's more, the inven-
gene expression can be constitutive (always "on") or condi- 	 tors have discovered that the acidic domain of RF2a is par-
tional.	 ticularly critical to the activation function of this transcription
Over the years, several classes of DNA-binding domains of
	
factor and, moreover, that it can be transferred to unrelated
various transcription factors have been characterized and the 65 DNA-binding proteins to modulate gene expression. Accord-
nucleic acid sequences to which such domains interact iden- 	 ingly, the inventors have discovered a new system for modu-
tified. Non-limiting examples of such domains include motifs 	 lating gene expression, as described further below.
US 7,847,064 B2
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SUMMARY OF THE INVENTION
Until now, it was not known that the Box II element of the
RTBV promoter is portable and that it can be used in connec-
tion with unrelated promoters to activate and/or enhance gene 5
expression in the presence of RF2a and/or RF2b. Similarly,
the inventors have discovered that operational derivatives of
the Box II element can be used to regulate gene expression in
like fashion. Still further, the inventors have discovered that
the acidic domain of RF2a is also portable and that it can be io
transferred to unrelated DNA-binding proteins to activate
and/or enhance gene expression.
Accordingly, the present invention exploits the portability
of the Box II sequence, its operational derivatives and its
interaction with RF2a and/or RF2b to provide novel compo- 15
sitions and methods that canbe used to control the expression
of one or more genes of interest. Further, thepresent invention
provides novel transcription factors, which contain at least
one domain that comprises an amino acid sequence that is at
least substantially similar to the acidic domain of RF2a, 20
which can be used in connection with unrelated DNA-binding
domains to regulate gene expression.
In one preferred embodiment, the invention provides novel
chimeric promoters, which comprise (a) nucleic acid
sequences derived from any promoter (other than the RTBV 25
promoter), or promoter fragment, that are capable of driving
gene expression in plant cells and (b) at least one nucleic acid
sequence selected from the group consisting of: (i) SEQ ID
NO:1; (ii) SEQ ID NO:2; (iii) SEQ ID NO:3; and (iv)
sequences that are substantially similar to either SEQ ID 30
NO: 1, 2, or 3. The nucleic acid sequence consisting of SEQ
ID NO: 1, 2, 3 or sequences substantially similar to any of the
foregoing sequences, is, preferably, located in a position that
is approximately 7 nucleotides from the TATA box of the
promoter, orpromoter fragment, plus one or more full turns of 35
DNA helix.
In another preferred embodiment, the invention provides
plant gene expression cassettes that comprise a first chimeric
promoter, which comprises a nucleic acid sequence selected
from the group consisting of: (i) SEQ ID NO: 1; (ii) SEQ ID 40
NO:2; (iii) SEQ ID NO:3; and (iv) sequences that are sub-
stantially similar to either SEQ ID NO: 1, 2, or 3. The first
chimeric promoter is operatively linked to any gene of inter-
est. The nucleic acid sequence consisting of SEQ ID NO: 1, 2,
3 or sequences substantially similar to any of the foregoing 45
sequences, is, preferably, located in a position that is approxi-
mately 7 nucleotides from the TATA box of the promoter, or
promoter fragment, plus one or more full turns of DNA helix.
The expression cassettes may further comprise a second pro-
moter operatively linked to a nucleic acid sequence that 50
encodes a polypeptide, which comprises an amino acid
sequence selected from the group consisting of: (i) SEQ ID
NO:4; (ii) SEQ ID NO:5; (iii) SEQ ID NO:6; and (iv)
sequences that are substantially similar to either SEQ ID
NO: 4, 5 or 6.	 55
In a related embodiment, the invention provides plant gene
expression cassettes similar to those described above,
wherein the expression of the second promoter is capable of
being chemically-induced. Accordingly, expression of the
nucleic acid sequence to which the second promoter is opera- 60
tively linked is stimulated or enhanced by applying an effec-
tive amount of the chemical inducer to the plant cells,
embryos, or tissues that have been transformed with the
expression cassette of the present invention.
In a further embodiment, the present invention provides 65
plant gene expression cassettes comprising (i) a first pro-
moter, which comprises a nucleic acid sequence that is
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capable of interacting with at least one DNA-binding domain
of at least one polypeptide, operatively linked to a gene of
interest and (ii) a second promoter operatively linked to a
nucleic acid sequence that encodes a polypeptide, which
comprises an amino acid sequence that is at least substantially
similar to SEQ ID NO:6 and a DNA-binding domain that is
capable of interacting with the corresponding nucleic acid
sequence of the first promoter. In a related embodiment, the
present invention provides that the expression of the second
promoter may be chemically-induced.
In other embodiments, novel transcription factors and uses
thereof are provided. In particular, the inventors have discov-
ered that the acidic domain of RF2a (SEQ ID NO:6), and
sequences substantially similarto SEQIDNO:6, canbefused
to unrelated transcription factors, or transcription factor-like
complexes, to regulate gene expression. More specifically,
the invention provides that novel transcription factors, which
comprise the acidic domain of RF2a and at least one DNA-
binding domain, can be used to modulate the expression of
one or more genes of interest, which are driven by promoters
that comprise nucleic acid sequences recognized by at least
one DNA-binding domain of such novel transcription factors.
In other embodiments, the invention provides methods of
regulating the expression level of at least one gene of interest
comprising transforming a plant cell with at least one plant
gene expression cassette of the present invention. Still further,
the invention provides methods of regulating the expression
level of at least one gene of interest comprising (a) transform-
ing plant cells with at least one plant gene expression cassette
of the present invention, wherein the cassette comprises a
chemically-inducible promoter operatively linked to a
nucleic acid sequence that encodes a polypeptide comprising
(i) an amino acid sequence that is at least substantially similar
to SEQ ID NO:6 and (ii) an amino acid sequence that is
capable of interacting with another promoter operatively
linked to a gene of interest, wherein the interaction initiates
and/or enhances the expression of the gene of interest and (b)
contacting plant cells, embryos, tissues, roots, etc., directly or
indirectly, derived from the transformed plant cells with an
activating amount of the expression-inducing chemical.
In other embodiments, the invention provides that two or
more chimeric promoters containing the Box II element and/
or its operational derivatives, which are operatively linked to
one or more genes of interest, can be used in connection with
RF2a- and/or RF2b-encoding sequences to achieve a "cas-
cade-type" system. In this embodiment, the expression of
RF2a and/or RF2b activates and/or enhances the expression
of the nucleic acid sequences to which the one or more chi-
meric promoters are operatively linked. Still further, the
nucleic acid sequence encoding the RF2a and/or RF2b pro-
tein may be operably linked to a chemically-inducible pro-
moter. In such embodiment, upon contacting plant cells,
embryos, or tissues, which have been transformed with such
nucleic acid sequences, with the expression-inducing chemi-
cal, the RF2a and/or RF2b transcription factor is produced
and subsequently interacts with the Box II element and/or its
operational derivatives to regulate gene expression. This
interaction, of course, results in the synchronized activation
or enhancement of expression of all Box II-dependent genes
(or all genes operatively linked to promoters containing
operational derivatives of Box II).
In other embodiments, the invention provides that at least
one chimeric promoter containing the Box II element and/or
its operational derivatives, which is operatively linked to one
or more genes of interest, can be used in combination with
RF2a- and/or RF2b-encoding sequences to "turn-off' or
modulate the expression of one or more unrelated endog-
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enous and/or exogenous genes of interest. The foregoing	 described herein. pE(IIml) comprised the E fragment,
combination, for example, can be used to activate or enhance 	 wherein the wild type Box II was replaced with the Box IIml
the expression of particular sequences that encode molecules 	 element; pE(IIm2) comprised the E fragment, wherein the
that selectively hybridize to specific target nucleic acid	 wild type Box II was replaced with the Box IIm2 element; pE
sequences. The hybridization of an oligomeric compound, for 5 comprised the E fragment and the wild type Box II element;
example, with its target nucleic acid sequence can have the 	 and the bar labeled `BY--2" represents non-transgenic proto-
effect of interfering with the normal function of the target	 plasts.
sequence (this effect is generally referred to as "antisense"). 	 FIG. 8: Comparative analysis of DNA binding affinities of
The functions of DNA that can be affected in this embodi- 	 RF2a and RF2b.
ment, for example, include replication and transcription. The 10	 FIG. 9: The pE(Box IIml):GUS construct was co-trans-
functions of RNA that can be affected include translocation of
	
fected into tobacco BY-2 protoplasts with CSVMV::RF2b,
the RNA to the site of protein translation, translation of pro- 	 CaMV 35S::RF2a and 35S::RF2a/CSVMV::RF2b. All
tein from the RNA, splicing of the RNA to yield one or more 	 samples were normalized with GFP internal control.
mRNA species, and catalytic activity that may be imparted or 	 FIG. 10: The pE(Box IIm2):GUS construct was co-trans-
facilitated by the RNA. The effect of such interference with 15 fected into tobacco BY-2 protoplasts with CSVMV::RF2b,
target nucleic acid function may provide the ability to modu- 	 CaMV 35S::RF2a and CaMV 35S::RF2a/CsVMV::RF2b. All
late the expression of particular gene products. 	 samples were normalized with GFP internal control.
In yet a further embodiment, the invention provides plant 	 FIG. 11: Diagram of Box II and CaMV 35S chimeric
cells, plant embryos, plant tissues, whole plants and seeds that 	 promoters (and control). The chimeric promoters were
have been transformed with at least one plant gene expression 20 ligated with a plasmid cassette that contained the uidA coding
cassette of the present invention. 	 sequence followed by a Nos terminator. The names of the
The above-mentioned and additional features of the 	 derived plasmids are shown to the right side of the diagram.
present invention are further illustrated in the Detailed 	 The positions of Box II in the various constructs are in rela-
Description contained herein. All references disclosed herein, 	 tion to the site of transcription initiation ("+1").
including U.S. patents, are hereby incorporated by reference 25	 FIG. 12: Primers used in generating the chimeric promot-
in their entirety as if each was incorporated individually. 	 ers containing the Box II element and portions of the CaMV
35S promoter, which are illustrated in FIG. 11. To facilitate
DESCRIPTION OF THE FIGURES	 the cloning process, a HindIII restriction site was added to the
5' end of the primers (underlined). Box II elements are shown
FIG. 1: Comparison of RTBV promoter activity with dif- 30 in bold and upper case letters. The sequences from the CaMV
ferent constitutive promoters in BY-2 protoplasts. "RTBV" 	 35S promoter are shown in lower case italic letters.
represents the promoter of RTBV; "E" represents the E frag-	 FIG. 13: Relative GUS activities in non-transgenic BY-2
ment of the RTBV promoter; "35S" refers to the enhanced	 protoplasts of constructs in which uidA was driven by pro-
35S promoter of CaMV; "35S(-46)" refers to the 5' deletion 	 moters that comprised Box II and portions of the CaMV 35S
mutation of the CaMV 35S promoter, which ends at position 35 promoter, which are illustrated in FIG. 11. The GUS activity
—46 as described herein; "CSVMV" represents the promoter	 of each sample was normalized against the GFP internal
of CsVMV. The results presented are the mean value of three 	 control.
independent experiments with standard variations. Each 	 FIG. 14: A: Relative GUS activities of constructs in which
experiment included three repeats and all data were normal- 	 the uidA gene was driven by Box II and CaMV 35S fusion
ized against GFP as internal control. 	 40 promoters (which are illustrated in FIG. 11), wherein the
FIG. 2: Relative GUS activity of each plasmid driven by 	 constructs were inserted into BY-2 protoplasts that produce
truncated mutants of the RTBV promoter. The results pre-	 RF2a. B: Relative GUS activities of the constructs referenced
sented are the mean value of three independent experiments. 	 in (A) above, wherein the constructs were inserted into BY-2
Each experiment includes three repeats and all data were 	 protoplasts that produce RF2a and RF2b. The GUS activity of
normalized against GFP as internal control. 	 45 each sample was normalized against the GFP internal control.
FIG. 3: Diagram of constructs that were prepared with the	 FIG. 15: A: Diagram of the T-DNA regions of binary plas-
Box II element inserted into different locations in the context 	 mids used for Agrobacterium -mediated transformation of
of the E fragment of the RTBV promoter. The modified pro-	 Arabidopsis thaliana. B: GUS activity of T, transgenic Ara-
moters were then inserted into a vector, wherein the modified 	 bidopsis plants. The results present the mean value of at least
promoters were operatively linked to the uidA coding 50 15 independent transgenic plants. The relative GUS activity
sequence and Nos terminator. The names of derived plasmids 	 was calculated by comparison with E::GUS (=1).
are shown to the right side of each diagram. 	 FIG. 16: Electrophoretic mobility shift assay of protein-
FIG. 4: Activities of the modified promoters shown in FIG. 	 DNA complexes formed between mutants of RF2a and the
3. The results presented are the mean value of three indepen- 	 Box II element. A: Schematic diagram of mutants of RF2a.
dent experiments with standard variation. Each experiment 55 A" represents the acidic domain; "P" represents the proline-
included three repeats and all data were normalized against 	 rich domain; and "Q" represents the glutamine-rich domain.
GFP as internal control.	 B: SDS-PAGE analysis of the purified RF2a mutant proteins.
FIG. 5: E fragment of the RTBV promoter was activated in 	 C: Gel mobility shift assay using purified mutant proteins of
tobacco BY-2 protoplasts by co-transfection of E::GUS with 	 RF2a as labeled. A control lane without protein (labeled
CSVMV::RF2b; CaMV 35S::RF2a and CaMV 35S::RF2a/ 60 "Free") was included in the assay. Box IIml DNA was
CSVMV::RF2b.	 labeled with 32P, and radioactivity was detected by autorad-
FIG. 6: Sequences of wild type Box II (labeled Box II) and 	 iography.
two non-limiting examples of its operational derivatives (la- 	 FIG. 17: Effects of RF2a and mutants of RF2a on gene
beled as Box IIml and Box IIm2). The mutated nucleotides in	 expression in BY-2 protoplasts. A: Reporter and effector gene
each operational derivative are identified in bold underline. 65 constructs. The GUS reporter gene (uidA sequence) was
FIG. 7: Relative GUS activity of constructs pE(IIml):: 	 driven by a promoter that comprised the Box II element
GUS, pE(IIm2)::GUS and pE::GUS in BY-2 protoplasts as 	 operatively linked to nucleotides —48 to +8 of the CaMV 35S
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promoter, and was followed by a nopaline synthase Y termi-
nator sequence ("pBII-48Ca:GUS"). Effectors included
sequences encoding RF2a and RF2a mutants operatively
linked to the CaMV 35S promoter and nopaline synthase
terminator. B: Relative GUS activities in BY-2 protoplasts
that were co-transfected with Reporter and Effector gene
constructs described herein. The results represent the aver-
ages of detected GUS activities (with S.D.) of three indepen-
dent experiments, three samples per experiment, after nor-
malization with GFP.
FIG. 18: The effects of RF2a domains on gene expression
when in fusion with the 2C7 DNA-binding domain. A: Dia-
gram of reporter and effector constructs used for transient
assays involving fusion proteins of RF2a functional domains
with the 2C7 synthetic zinc finger DNA-binding domain. B:
Relative GUS activities in BY-2 protoplasts that were co-
transfected with the reporter and effector gene constructs as
indicated herein. The results represent the averages (with
S.D.) of three independent experiments, three samples per
experiment, after normalization with GFP.
FIG. 19: Impact of RF2a and RF2a mutants on develop-
ment of transgenic tobacco plants. A: Two-month old trans-
genic tobacco plants with RF2a and mutants of RF2a driven
by the 35S promoter were grown under greenhouse condi-
tions. Only transgenic plants with mutants lacking the acidic
domain (RF2a-APAA and RF2a-3A) showed severe stunting
phenotype. B: Transgenic plants at 105 days. Leaves of plants
with RF2a-APAA and RF2a-3A were curved downward, and
flowering time was significantly delayed. C: Panel 1: Trans-
versal section of the stem of transgenic plants with RF2a-
APAA in low magnification; Panel 2-4: Transverse sections of
the lower part of stems of two-month old tobacco plants
stained with toluidine blue O. Panel 2, transgenic plant with
RF2a-APAA. Panel 3, transgenic plant with RF2a-3A. Panel
4, Non-transgenic plant.
FIG. 20: Correlation between severity of abnormal pheno-
types shown in FIG. 19 and accumulation of RF2a-APAA.
Severity of the abnormal phenotype of transgenic tobacco
plants was marked with "+++" for stunting and "++++" for
severe stunted phenotype, whereas "—" indicates that no
abnormal phenotype was observed. Upper panel, 40-µg pro-
tein samples were separated by 10% SDS-PAGE and detected
with antibody against full-length RF2a after blotting to nitro-
cellulose membrane. The band that contains RF2a-APAA is
marked on the right. Lower panel, the membrane used in the
immunoblot was stained with Ponceau S (Sigma Chemical
Company, St. Louis, Mo.) prior to the antibody reaction.
FIG. 21: Activation of GUS expression in non-vascular
tissues by induction of RF2a. Leaf tissues from transgenic
Arabidopsis plants were stained in buffer containing X-Gluc
to detect GUS expression. The transgenic Arabidopsis plants
(shown at the top of FIG. 21) included the E:GUS, 5G35m:
RF2a, and Cs:VGE cassettes described herein. "Treated" leaf
tissue was subjected to applications of Intrepid® 2F as
described herein, whereas "Untreated" leaf tissue was not
subjected to Intrepid® 2F. The shaded leaf tissue in the
"Treated" leaf correlates with the GUS expression pattern
observed. Leaf tissue transformed with only E:GUS is shown
at the bottom of FIG. 21.
FIG. 22: Quantitative analysis of the activation of the E
fragment by RF2a upon chemical induction. A: Relative GUS
activity of Tz transgenic Arabidopsis plants, which comprise
the E:GUS, 5G35Sm:RF2a, and Cs:VGE sequences
described herein. Each set of bars represents 1 of 12 groups of
transgenic plant lines, namely, EGaV-3, EGaV-5, EGaV-17,
EGaV-31, EGaV-50, EGaV-51, EGaV-56, EGaV-59, EGaV-
63, EGaV-70, EGaV-72, and E:GUS. Each bar represents the
8
average of three repeats, three plants for each repeat (with
standard deviation). Open bars represent control leaf tissue
that was not subjected to Intrepid 2F8 treatment. Solid bars
represent leaf tissue treated with 1:8,000 dilution of
5 Intrepid® 2F. B: Western Blot showing expression of RF2a in
a limited number of samples analyzed in FIG. 22A. The lower
panel shows the SDS-PAGE gel described below, whereas the
upper panel shows the detected RF2a protein on the nitrocel-
lulose membrane. The mark "—" refers to control leaf tissue
10 that was not treated with Intrepid® 2F, whereas "+" refers to
leaf tissue that was treated with 1:8,000 dilution of Intrepid®
2F. The RF2a-arrow indicates the band position of the RF2a
protein.
FIG. 23: A bar graph summarizing the expression-enhanc-
15 ing activity of various fragments of the acidic domain of
RF2a, as further described in Example 14.
FIG. 24: A: Diagram of the different constructs used to
transform BY-2 protoplasts, as further described in Example
15. B: A bar graph showing the relative GUS activity pro-
20 duced by the various constructs transformed into such BY-2
protoplasts, as further described in Example 15 below.
FIG. 25: A diagram of the full-length RF2a protein, show-
ing proline-rich, acidic, VIP, and glutamine-rich domains.
FIG. 26: A bar graph summarizing the expression-enhanc-
25 ing activity of the acidic domain of RF2a in Arabidopsis
thaliana plants, as further described in Example 16.
FIG. 27: A: Diagram of the different constructs used to
transform BY-2 protoplasts, as further described in Example
17. B: A bar graph showing the relative GUS activity pro-
30 duced by the various constructs transformed into such BY-2
protoplasts, as further described in Example 17 below.
FIG. 28: Analysis of T, generation Arabidopsis thaliana
plants transformed with VGE, AGE, or A5A5GE (and GUS
reporter) constructs, as further described in Example 18
35 below. Top: A bar graph showing the relative GUS activity
produced by the various VGE constructs. Middle: Abar graph
showing the relative GUS activity produced by the various
AGE constructs. Bottom: A bar graph showing the relative
GUS activity produced by the various A5A5GE constructs.
40 FIG. 29: Analysis of Tz generation Arabidopsis thaliana
plants transformed with VGE, AGE, or A5A5GE (and GUS
reporter) constructs, as further described in Example 18
below. Top: A bar graph showing the relative GUS activity
produced by the various VGE constructs. Middle: Abar graph
45 showing the relative GUS activity produced by the various
AGE constructs. Bottom: A bar graph showing the relative
GUS activity produced by the various A5A5GE constructs.
DESCRIPTION OF THE SEQUENCE LISTING
50
SEQ ID NO. 1: The nucleic acid sequence of the Box II
element.
SEQ ID NO. 2: The nucleic acid sequence of the Box IIml
element an operational derivative of the Box II element.
55 SEQ ID NO. 3: The nucleic acid sequence of the Box IIm2
element an operational derivative of the Box II element.
SEQ ID NO. 4: The amino acid sequence of the RF2a
transcription factor.
60 SEQ ID NO. 5: The amino acid sequence of the RF2b
transcription factor.
SEQ ID NO. 6: The amino acid sequence of the acidic
domain of the RF2a transcription factor.
SEQ ID NO. 7: Non-limiting example of nucleic acid
65 sequence that encodes the RF2a transcription factor.
SEQ ID NO. 8: Non-limiting example of nucleic acid
sequence that encodes the RF2b transcription factor.
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SEQ ID NO. 9: Non-limiting example of nucleic acid 	 SEQ ID NO. 101: Amino acid sequence of A5" minimal
sequence that encodes the acidic domain of the RF2a tran- 	 acidic domain of RF2a, described in Example 17.
scription factor.	 SEQ ID NO. 102: Nucleic acid sequence encoding the
SEQ ID NO. 10: Primer sequence of BoxII-del-3'. 	 A5" minimal acidic domain of RF2a, described in Example
SEQ ID NO. 11: Primer sequence of BoxII-del-5'. 	 5 17.
SEQ ID NO. 12: The nucleic acid sequence of the E frag- 	 SEQ ID NO. 103: Amino acid sequence of GE domain (of
ment (promoter) of the RTBV promoter sequence. 	 VGE receptor).
SEQ ID NO. 13-35: Primer sequences referenced in Table 	 SEQ ID NO. 104: Nucleic acid sequence encoding the GE
1/Example 2.	 domain.
SEQ ID NO. 36: The GUS 3' primer.	 10 SEQ ID NO. 105: Amino acid sequence of E domain (of
SEQ ID NO. 37-42: Primer sequences referenced in Table 	 VGE receptor).
2/Example 6.	 SEQ ID NO. 106: Nucleic acid sequence encoding the E
SEQ ID NO. 43: Control primer 1.5h-53CaMV-c. 	 domain.
SEQ ID NO. 44: Control primer —3.5h-74CaMV-c. 	 SEQ ID NO. 107: Amino acid sequence of G domain (of
SEQ ID NO. 45: Control primer —5.5h-95CaMV--c. 	 15 VGE receptor).
SEQ ID NO. 46-52: Primer sequences referenced in Table 	 SEQ ID NO. 108: Nucleic acid sequence of 5XG (a Gal4
3/Example 8.	 binding domain) the sequence recognized by the G domain
SEQ ID NO. 53: Primer sequence of BII-48Ca 5'. 	 of the VGE receptor.
SEQ ID NO. 54: The amino acid sequence of the proline-
rich domain of the RF2a transcription factor. 	 20	 DETAILED DESCRIPTION OF THE INVENTION
SEQ ID NO. 55: The amino acid sequence of the
glutamine-rich domain of the RF2a transcription factor. 	 The following will describe in detail several preferred
SEQ ID NO. 56-61: Primer sequences referenced in Table 	 embodiments of the invention. These embodiments are pro-
4/Example 10.	 vided by way of explanation only, and thus, should not unduly
SEQ ID NO. 62: Nucleic acid sequence of the RTBV 25 restrict the scope of the invention. In fact, those of ordinary
promoter.	 skill in the art will appreciate upon reading the present speci-
SEQ ID NO. 63: Nucleic acid sequence of the E fragment 	 fication and viewing the present drawings that many varia-
containing the Box IIml element. 	 tions and modifications of the invention may be employed,
SEQ ID NO. 64: Nucleic acid sequence of the E fragment 	 used and made without departing from the scope and spirit of
containing the Box IIm2 element. 	 30 the invention.
SEQ ID NO. 65: Nucleic acid sequence of E(ABox II) 	 The present invention can be viewed as having at least two
fragment.	 components. The first of the at least two components relates to
SEQ ID NO. 66: Nucleic acid sequence of the CaMV 35S	 the Box II element; operational derivatives of the Box II
minimal (1-108) promoter.	 element; chimeric promoters containing one or more of these
SEQ ID NO. 67: Nucleic acid sequence of the CsVMV 35 elements; plant gene expression cassettes containing at least
promoter.	 one chimeric promoter of the present invention; plant cells,
SEQ ID NO. 68: Amino acid sequence of RF2a-AP. 	 embryos and tissues transformed with at least one expression
SEQ ID NO. 69: Amino acid sequence of RF2a-AQ.	 cassette of the present invention and methods of using the
SEQ ID NO. 70: Amino acid sequence of RF2a-APAA. 	 foregoing compositions in connection with RF2a and/or
SEQ ID NO. 71: Amino acid sequence of RF2a-APAQ. 40 RF2b to regulate the expression of at least one gene of inter-
SEQ ID NO. 72: Amino acid sequence of RF2a-3A.	 est. The second of the at least two components relates to (i)
SEQ ID NO. 73: "R" Reverse Primer sequence. 	 novel transcription factors that comprise at least one DNA-
SEQ ID NO. 74: Nucleic acid sequence of the 2C7 cis 	 binding domain and an amino acid sequence that is at least
element (i.e., the domain to which the 2C7 zinc finger protein 	 substantially similar to the acidic domain of RF2a and (ii)
binds).	 45 methods of using the novel transcription factors to regulate
SEQ ID NO. 75: Amino acid sequence of the synthetic 2C7 	 the expression of at least one gene of interest.
domain.	 Novel Chimeric Promoters
SEQ ID NO. 76: Nucleic acid sequence used to express the 	 In one preferred embodiment, the invention provides novel
2C7 domain (SEQ ID NO. 75). 	 chimeric promoters. The promoters of the present invention
SEQ ID NO. 77-83: DNA cis elements referenced in Table 50 comprise a first nucleic acid sequence derived from any pro-
5/Example 12.	 moter (other than the RTBV promoter (SEQ ID NO: 62)), or
SEQ ID NO. 84-91: DNA binding domains and related cis 	 promoter fragment, that is capable of driving gene expression
elements referenced in Table 6/Example 12.	 in plant cells. The promoters further comprise at least one
SEQ ID NO. 92: Nucleic acid sequence of chimeric pro- 	 nucleic acid sequence selected from the group consisting of:
moter with Gal4 DNA binding sites and CaMV 35S minimal 55 (i) the Box II element (SEQ ID NO:1); (ii) the Box IIml
promoter.	 element (SEQ ID NO:2); (iii) the Box IIm2 element (SEQ ID
SEQ ID NO. 93: Nucleic acid coding sequence of VGE. 	 NO:3); (iv) sequences that are substantially similar to either
SEQ ID NO. 94: PrimerA-2C7 5'. 	 SEQ ID NO: 1, 2 or 3, or (v) other operational derivatives of
SEQ ID NO. 95: PrimerA-2C7 3'. 	 the Box II element. As used herein, the term "operational
SEQ ID NO. 96: PrimerA68-2C7 5'.	 6o derivative" shall refer, generally, to the Box IIml element, the
SEQ ID NO. 97: PrimerA96-2C7 3'.	 Box IIm2 element, sequences that are substantially similar to
SEQ ID NO. 98: Primer used to amplify the 35S-56/84- 	 the Box II, Box IIml or Box IIm2 element and other nucleic
2C7 construct described in Example 15. 	 acid sequences that are capable of interacting with RF2a
SEQ ID NO. 99: Primer used to amplify the 35S-56/84- 	 and/or RF2b to regulate gene expression.
2C7 construct described in Example 15. 	 65	 It will be understood by those skilled in the art that two
SEQ ID NO. 100: Amino acid sequence of the chimeric	 nucleic acid sequences are "substantially similar" when
VGE receptor. 	 approximately 70% or more (preferably at least about 80%,
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and most preferably at least about 90% or 95%) of the nucle-
otides match over the defined length of the nucleic acid
sequence. Sequences that are substantially homologous can
be identified by comparing the sequences using readily acces-
sible computer software, or in a Southern hybridization
experiment under, for example, stringent conditions as
defined for that particular system. Defining appropriate
hybridization conditions for a particular system is within the
skill of the art. It will be further understood by those skilled in
the art that the phrase "at least substantially similar" refers to
sequences that are "substantially similar" as described above
or, alternatively, identical to one another.
As used herein, "substantially similar" is further meant to
include a nucleic acid sequence which, by virtue of the degen-
eracy of the genetic code, is not identical with that shown in
any of the sequences shown in the Sequence Listing, but
which still encodes the same amino acid sequence; or a modi-
fied nucleic acid sequence that encodes a different amino acid
sequence that retains substantially the same activities of the
original proteins, either because one amino acid is replaced
with a similar amino acid, or because the change (whether it
be substitution, deletion or insertion) does not affect the
active site of the protein. Thus, it is contemplated by the
inventors that various changes may be made in the nucleic
acid sequences disclosed, and, of course, the encoded
polypeptides, without appreciable loss of their biological
activity or utility in the present invention.
The chimeric promoters of the present invention are, pref-
erably, constructed by combining the first nucleic acid
sequence derived from any plant functional promoter, or pro-
moter fragment, with at least one nucleic acid sequence
selected from the group consisting of SEQ ID NO: 1, 2, 3 and
sequences substantially similar to SEQ ID NO: 1, 2 or 3. More
preferably, however, the chimeric promoters of the present
invention are constructed by combining the first nucleic acid
sequence derived from any plant functional promoter, or pro-
moter fragment, with at least one nucleic acid sequence
selected from the group consisting of SEQ ID NO: 1, 2 and 3.
The term "chimeric promoter," as used herein, refers to any
plant functional promoter sequence, or promoter fragment,
that comprises SEQ ID NO: 1, 2, 3, or sequences substantially
similar thereto, wherein such plant functional promoter
sequence is not derived from the RTBV promoter.
The nucleic acid sequences consisting of SEQ ID NO: 1, 2,
3, and sequences substantially similar thereto, may be posi-
tioned within the first nucleic acid sequence described above,
which comprises any plant functional promoter (or promoter
fragment). Alternatively, the nucleic acid sequences consist-
ing of SEQ ID NO: 1, 2, 3, and sequences that are substantially
similar to SEQ ID NO: 1, 2 or 3, may be fused to the 5' or 3' end
of such plant functional promoter (or promoter fragment).
Although SEQ ID NO: 1, 2, 3, and sequences substantially
similar thereto, may be positioned within, or fused to the end
of, a chimeric promoter, such sequences are, preferably, posi-
tioned in specific locations of the DNA helix. In particular,
such nucleic acid sequences are, preferably, operably linked
to the 5' end of the selected promoter, or promoter fragment,
with a space of approximately 7 nucleotides from the TATA
box plus one or more full "turns of DNA helix." It is well-
known in the art that one turn of DNA helix equals, approxi-
mately, 10.4 base pairs. Furthermore, the TATA box, which,
generally, is the module within a promoter that functions to
position the start site for RNA synthesis, and its location in a
promoter can be easily identified by those skilled in the art. In
many cases, the TATA box consensus sequence (TATAAT) is
12
20 to 30 base pairs upstream (i.e., 5') of the transcription start
site (by convention —30 to —20 base pairs relative to the
transcription start site).
The Box II element and its operational derivatives may be
5 used in connection with a variety of promoters, or promoter
fragments, to create novel chimeric promoters. Preferably,
however, the Box II element and/or its operational derivatives
are operably linked to a promoter, or promoter fragment, that
comprises a transcription initiation domain. The term "tran-
io scription initiation domain" refers to a sequence having at
least an RNA polymerase binding site and an mRNA initia-
tion site.
Such basic guidelines for promoter, or promoter fragment,
selection emphasize the notion that the Box II element and its
15 operational derivatives are, indeed, "portable" and can be
transferred to a plurality of promoter sequences. Of course,
the promoter sequence with which the Box II element and/or
its operational derivatives will be used, preferably, relates to
the target cell-type in which gene expression is desired.
20 For example, some promoters are known to be active in
particular cell-types, in certain tissues, under certain abiotic
conditions and/or in the presence of certain inducible agents.
Thus, the cell-type and/or conditions in which gene expres-
sion is desired will impact the identity of the promoter
25 sequence with which Box II and/or its operational derivatives
will be used. Although the endogenous promoter of the gene
of interest may be utilized herein for transcriptional regula-
tion, preferably, the promoter is a foreign regulatory
sequence. Forplant expression vectors, suitable viral promot-
30 ers include, for example, the RTBV promoter; the 35S RNA
and 19S RNA promoters of the cauliflower mosaic virus
("CaMV"); the full-length transcript promoter from figwort
mosaic virus ("FMV"); and the cassava vein mosaic virus
("CsVMV") promoter.
35 The Box II element, of course, can be isolated from natural
sources, e.g., the Box II element can be isolated from the E
fragment of the RTBV promoter (SEQ ID NO:62) using
techniques well-known in the art. More preferably, however,
the Box II element and its operational derivates are synthe-
40 sized using standard DNA synthesis techniques (see, for
example, Current Protocols in Molecular Biology, Unit 2.11,
eds. Ausubel, et al., John Wiley & Sons, 1995).
Expression Cassettes Comprising Novel Chimeric Pro-
moters
45 The present invention further provides plant gene expres-
sion cassettes that comprise a first chimeric promoter of the
present invention operatively linked to one or more genes of
interest. The expression cassettes may further comprise a
second promoter operatively linked to a nucleic acid
50 sequence that encodes a polypeptide, which comprises an
amino acid sequence selected from the group consisting of:
(a) SEQ ID NO:4; (b) SEQ ID NO: 5; (c) SEQ ID NO:6 and (d)
sequences that are substantially similar to either SEQ ID
NO:4, 5 or 6. Non-limiting examples of nucleic acid
55 sequences that encode the amino acid sequences set forth in
SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 are shown in
SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9, respectively.
The one or more genes of interest operatively linked to a
first chimeric promoter of the present invention, when includ-
60 ing an open reading frame ("ORF"), may encode a protein. Of
course, the gene of interest can be an endogenous or exog-
enous sequence. In addition, the ORE may include certain 5'
and 3' untranslated sequences. Still further, appropriate tran-
scription termination and polyadenylation sequences may,
65 preferably, be included.
Genes of interest, the expression of which may be regu-
lated according to the present invention, may include, for
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example, sequences that naturally exist in plants, animals,
bacteria, viruses or fungi; synthetic DNA sequences that
encode a specific RNA or protein product; cDNA sequences
derived from mRNA; DNA sequences modified by mutagen-
esis, for example, through site specific mutagenesis; chimeras 5
of any of the above (to produce fusion proteins); and DNA
sequences encoding complementary RNA molecules (for
"antisense" applications); and combinations and/or frag-
ments of the above.
Examples of proteins that can be encoded by the gene of io
interest include, but are not limited to, nutritionally important
proteins; growth promoting factors; proteins for early flow-
ering in plants; proteins that impart protection to the plant
under certain environmental conditions, e.g., proteins confer-
ring resistance to metals or other toxic substances, such as 15
herbicides or pesticides; stress related proteins that confer
tolerance to temperature or hydration extremes; proteins con-
ferring resistance to fungi, bacteria, viruses, insects and
nematodes; and proteins of specific commercial value, e.g.,
enzymes involved in metabolic pathways, proteins having 20
therapeutic activity in humans, and others.
The term "operably linked," as used herein, refers to the
functional linkage between, for example, the Box II element
and/or its operational derivatives and a plant functional pro-
moter or promoter fragment; between a promoter sequence, 25
including the novel chimeric promoters of the present inven-
tion, and any gene of interest; and between a promoter
sequence and any sequence encoding the RF2a protein, RF2b
protein, a protein comprising the acidic domain of RF2a
and/or any protein that is substantially similar to the forego- 30
ing proteins.
The second promoter operatively linked to a nucleic acid
sequence that encodes a polypeptide, which comprises an
amino acid sequence selected from the group consisting of:
(a) SEQID NO: 4; (b) SEQID NO: 5; (c) SEQID NO: 6; and 35
(d) sequences that are substantially similar to either SEQ ID
NO: 4, 5, or 6, may constitute any promoter that is capable of
driving gene expression in the target plant cells. As described
above, certain promoters are known to be active in particular
cell-types, in certain tissues, under certain abiotic conditions 40
and/or in the presence of certain inducible agents. Thus, the
cell-type and/or conditions in which gene expression is
desired will impact the identity of the promoter that is
selected to drive expression of sequences encoding RF2a,
RF2b, polypeptides comprising the acidic domain of RF2a or 45
polypeptides that are substantially similar to any of the fore-
going. Of course, such promoters may include both constitu-
tive, e.g., the CaMV promoter, and inducible promoters.
By placing the nucleic acid sequence encoding RF2a,
RF2b, polypeptides comprising the acidic domain of RF2a or 50
polypeptides that are substantially similar to any of the fore-
going, under the control of a chemically-inducible promoter,
the gene expression system can be activated at will. The use of
inducible promoters in this capacity provides control over the
effect that the encoded proteins may have on the expression of 55
promoter sequences (and genes operatively linked to such
sequences) comprising the Box II element and/or its opera-
tional derivatives. In short, expression of the nucleic acid
sequence to which the second promoter is operatively linked
is stimulated and/or enhanced by applying an effective 60
amount of the chemical inducer to the plant cells, embryos or
tissues that have been transformed with the appropriate
expression cassette of the present invention. Application of
the inducer, therefore, allows the expressed transcription fac-
tor to interact with, and stimulate (or enhance) the expression 65
of, the chimeric promoter and the one or more genes of
interest to which it is operatively linked.
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To be most useful, an inducible promoter should 1) provide
low expression in the absence of the inducer; 2) provide high
expression in the presence of the inducer; 3) employ an induc-
tion scheme that does not interfere with the normal physiol-
ogy of the plant; and 4) has no effect on the expression of
other genes. Examples of inducible expression schemes use-
ful in plants include those induced by chemical means, such
as the ecdysone agonist-inducible gene expression systems
(Christopherson et al., 1992; Martinez et al., 1999). The
ecdysone agonist-inducible gene expression systems, prefer-
ably, employ commercially-available non-steroidal ecdysone
agonists, such as tebufenozide and methoxyfenozide.
Additional examples of inducible promoters useful in
plants include, but are not limited to, promoters that respond
to tetracycline (Gatz et al., 1992; Weinmann et al., 1994); the
yeast metallothionein promoter, which is activated by copper
ions; the In2-1 and In2-2 regulator sequences, which are
activated by substituted benzenesulfonamides, e.g., herbicide
safeners; and GRE regulatory sequences, which are induced
by glucocorticoids. In addition, plant promoters such as the
light-inducible promoter from the small subunit of ribulose
bis-phosphate carboxylase (ssRUBISCO); mannopine syn-
thase promoter; nopaline synthase ("NOS") and octopine
synthase ("OCS") promoters (carried on tumor-inducing
plasmids of Agrobacterium tumefaciens) or heat shock pro-
moters, e.g., soybean hspl7.5-E or hspl7.3-B, may be used.
Other promoters, both constitutive and inducible, will be
known to those of skill in the art.
It will be appreciated by those skilled in the art that the first
chimeric promoter, which is operatively linked to at least one
gene of interest, and the second promoter, which is opera-
tively linked to a sequence encoding RF2a, RF2b, polypep-
tides comprising the acidic domain of RF2a or polypeptides
that are substantially similar to any of the foregoing, may
exist in a single gene expression cassette (or vector), or,
alternatively, in separate cassettes (or vectors). Still further,
those skilled in the art will appreciate that an expression
cassette may comprise a single chimeric promoter, or, alter-
natively, a plurality of chimeric promoters, each operatively
linked to at least one gene of interest. Moreover, the plurality
of chimeric promoters may be substantially similar in
sequence, or, alternatively, may comprise significantly differ-
ent sequences.
Novel Transcription Factors
Over the years, several classes of DNA-binding proteins
have been characterized and the nucleic acid sequences with
which such proteins interact identified. For example, zinc
finger proteins represent a class of motifs that are known to be
involved in the sequence-specific recognition of DNA. As the
name implies, this DNA-binding domain is folded around a
zinc ion. To date, more than two hundred proteins, many of
them transcription factors, have been shown to possess zinc
finger domains. In general, zinc fingers connect transcription
factors to their target locations by binding to specific DNA
sequences.
The RF2a and RF2b transcription factors described herein
represent yet another class of DNA-binding proteins. Specifi-
cally, RF2a and RF2b are representative examples of what are
commonly referred to as VIP transcription factors. The VIP
transcription factors are generally characterized by a bipartite
DNA-binding domain consisting of a basic region involved in
sequence-specific binding, and a leucine zipper region
required for dimerization. The VIP domain of RF2a shares
high similarity with VIP proteins that exist naturally in
plants such as Arabidopsis, tobacco, tomato, and other plants
(Fukazawa et at, 2000; 7akoby et al., 2002; Ringli and Keller,
1998). In particular, this group of proteins is known to have a
US 7,847,064 B2
15
	
16
lysine residue at the —10 position relative to the first leucine 	 ment of the acidic domain" includes an amino acid sequence
residue of the leucine zipper region (Yin et al., 1997). The 	 encompassing at least 30%, 40%, 50%, 60%, 70%, 80%, or
amino acid sequence signature of the DNA-binding regions	 90% of SEQ ID NO: 6, wherein such amino acid sequence is
of this class ofproteins is NXXXSAXXSK (Fujii et al., 2000) 	 substantially similar to the corresponding region of the full-
(SEQ ID NO: 109).	 5 length SEQ ID NO:6.
The present invention provides novel transcription factors,	 While the acidic domain of RF2a (SEQ ID NO: 6) (and/or
and uses thereof, which provide the ability to regulate the 	 amino acid sequences substantially similar to SEQ ID NO:6)
expression of at least one gene of interest. In particular, the 	 and fragments of the acidic domain may be fused to any class
inventors have discovered that the acidic domain of RF2a 	 of DNA-binding domains (and/or unrelated transcription fac-
(SEQ ID NO:6), and amino acid sequences substantially io tors comprising such domains) to create novel transcription
similar to SEQ ID NO:6, can be fused to unrelated transcrip- 	 factors as described herein, the invention provides that such
tion factors, or transcription factor-like complexes, to regu-	 sequences may act in the absence of DNA-binding domains to
late gene expression. In certain embodiments, the invention	 regulate gene expression. In such embodiment, the acidic
provides that novel transcription factors, which comprise the 	 domain of RF2a may be used alone or in connection with
acidic domain of RF2a and at least one DNA-binding domain, 15 other regulatory proteins or domains to modulate gene
can be used to modulate the expression of one or more genes 	 expression. For example, the invention provides novel tran-
driven by promoters that comprise nucleic acid sequences 	 scription factors that comprise the acidic domain of RF2a and
recognized by such DNA-binding domain of the novel tran- 	 any other amino acid sequence not derived from RF2a or
scription factors.	 RF2b, which are capable of regulating the expression of at
In certain embodiments, the acidic domain of RF2a (SEQ 20 least one gene of interest. The numerous mechanisms by
ID NO:6), and/or amino acid sequences substantially similar 	 which such transcription factors may regulate expression are
to SEQ ID NO:6, can be fused to any class of DNA-binding 	 well-known to those skilled in the art, which include, for
domains (and/or unrelated transcription factors comprising	 example, affecting the formation of the transcription initia-
such domains). The acidic domain of RF2a, and/or substan- 	 tion complex and recruiting other regulatory proteins to the
tially similar sequences, can be fused, for example, to any 25 transcription initiation region.
polypeptide comprising a leucine zipper, VIP domain, zinc- 	 Expression Cassettes Encoding Novel Transcription Fac-
finger, homeobox, basic helix-loop-helix domain, or other 	 tors
DNA-binding domains currently known in the art (or discov- 	 The present invention further provides plant gene expres-
ered hereafter). It should be appreciated, however, that the 	 sion cassettes comprising (i) a first promoter, which com-
DNA-binding domain selected (or the polypeptide compris- 30 prises a nucleic acid sequence that is capable of interacting
ing such domain) must be capable of interacting with the 	 with at least one DNA-binding domain of at least one
promoter operatively linked to the gene of interest for which 	 polypeptide, operatively linked to a gene of interest and (ii) a
control of expression is desired. 	 second promoter operatively linked to a nucleic acid
It will be appreciated by those skilled in the art that two	 sequence that encodes a polypeptide, which comprises an
amino acid sequences are "substantially similar" when 35 amino acid sequence that is at least substantially similar to
approximately 70% or more (preferably at least about 80%, 	 SEQ ID NO:6 and a DNA-binding domain that is capable of
and more preferably at least about 90% or 95%) of the amino 	 interacting with the corresponding nucleic acid sequence of
acids match over the defined length of the sequences. The 	 the first promoter.
term "substantially similar" is further meant to refer to amino	 Of course, in light of the foregoing, nucleic acid sequences
acid sequences that have been modified from an original 40 encoding the acidic domain of RF2a, and/or substantially
sequence, wherein the modified amino acid sequence retains	 similar amino acid sequences, may be operatively linked to,
substantially the same level of activity as the original amino 	 for example, nucleic acid sequences that encode polypeptides
acid sequence. This retention in activity, of course, may occur 	 comprising any motif known to interact with the first pro-
when one or more amino acids are replaced with similar 	 moter (or, more specifically, elements contained within or
amino acids, or because the change (whether it be substitu-  45 near the first promoter), which is operatively linked to the one
tion, deletion or insertion) does not affect the active site of the 	 or more genes of interest. This interaction will, preferably,
protein. Thus, it is contemplated by the inventors that various 	 initiate and/or enhance the expression of the one or more
changes may be made to the acidic domain of RF2a, without 	 genes of interest. An example of a nucleic acid sequence that
appreciable loss of its biological activity and utility in the 	 encodes the acidic domain of RF2a (SEQ ID NO: 6) includes,
present invention. It will be further understood by those 5o but is not limited to, the sequence shown in SEQ ID NO: 9.
skilled in the art that the phrase "at least substantially similar" 	 Examples of nucleic acid sequences encoding DNA-bind-
as it is used herein with respect to amino acid sequences refers 	 ing domains that can be used in this capacity include, but are
to sequences that are "substantially similar" as described 	 not limited to, sequences encoding a leucine zipper, the VIP
above or, alternatively, identical to one another. 	 domain, the zinc-finger, the homeobox, the basic helix-loop-
In certain embodiments, for example, novel transcription 55 helix domain or others. It will be appreciated by those skilled
factors are provided, which comprise a fragment of the acidic 	 in the art that the selected DNA-binding domain must be
domain of RF2a (SEQ ID NO:6). More particularly, the 	 capable of interacting with the promoter operatively linked to
present invention contemplates that internal regions and frag- 	 the one or more genes of interest for which control of expres-
ments of the acidic domain of RF2a (SEQ ID NO:6) may be	 sion is desired. Still further, it will be appreciated by those
used to form novel transcription factors, which are capable of 60 skilled in the art that sequences encoding the acidic domain of
regulating gene expression as described herein. 	 RF2a, for example, and at least one DNA-binding domain
As used herein, "fragments of the acidic domain" and 	 may be tethered directly to one another, or, alternatively, may
"fragment of the acidic domain" refer to amino acid
	
be connected indirectly through intervening sequences, e.g.,
sequences comprising less than all of the amino acid residues 	 spacers, other polypeptide-encoding sequences, etc.
of SEQ ID NO: 6, wherein such amino acid sequence is sub- 65	 In certain alternative embodiments, the second promoter is
stantially similar to the corresponding region of the full- 	 operatively linked to a nucleic acid sequence that encodes a
length SEQ ID NO:6. More particularly, for example, a "frag-	 novel transcription factor, which comprises an amino acid
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sequence that is at least substantially similar to SEQ ID NO:6
and is capable of modulating the expression level of the
nucleic acid sequence operatively linked to the first promoter
through means other than direct DNA binding or interaction.
As described above, such transcription factors may be used to 5
regulate the expression level of one or more genes of interest
by, for example, affecting the formation of the transcription
initiation complex or recruiting other regulatory proteins to
the transcription initiation region.
Any promoter, or promoter fragment, capable of driving 10
gene expression in plant cells may be operatively linked to
sequences encoding the novel transcription factors of the
present invention. The promoter selected for any given sys-
tem or application may confer constitutive expression in the
transformed plant cell, or, alternatively, inducible expression. 15
Furthermore, as described above with respect to other
embodiments, certain promoters are known to be active in
particular cell-types, in certain tissues and/or under certain
abiotic conditions. Thus, the cell-type and/or conditions in
which gene expression is desired will impact the identity of 20
the promoter selected to drive expression of sequences encod-
ing the novel transcription factors of the present invention.
Thus, in one embodiment, the nucleic acid sequences
encoding the novel transcription factors of the present inven-
tion may be placed under the control of chemically-inducible 25
promoters. In this embodiment, the gene expression system
may be activated at will, which provides control over the
effect that the encoded novel transcription factors may have
on the expression of promoter sequences (and genes opera-
tively linked to such sequences) that comprise the element to so
which the expressed DNA-binding domain, for example, is
capable of interacting. As described above with respect to
other embodiments, several inducible promoters well-known
in the art could be used in this capacity to drive the expression
of novel transcription factors.	 s5
It will be appreciated by those skilled in the art that the first
promoter, which is operatively linked to at least one gene of
interest, and the second promoter, which is operatively linked
to a sequence encoding a novel transcription factor of the 40present invention, may exist in a single gene expression cas-
sette (or vector), or, alternatively, in separate cassettes (or
vectors). Still further, those skilled in the art will appreciate
that a single promoter, or, alternatively, a plurality of promot-
ers, each operatively linked to at least one gene of interest, 45
may contain a sequence and/or element capable of interacting
with the encoded novel transcription factors. Moreover, the
plurality of promoters can be substantially similar in
sequence, or, alternatively, may comprise significantly differ-
ent promoter sequences.	 50
Methods of Regulating Gene Expression
The invention further provides methods of regulating the
expression level of at least one gene of interest, which com-
prise transforming a plant cell with at least one plant gene
expression cassette of the present invention. Still further, the 55
invention provides methods of regulating the expression level
of at least one gene of interest, which comprise (a) construct-
ing at least one plant gene expression cassette of the present
invention; (b) transforming a plant cell with the plant gene
expression cassette of the present invention; and (c) regener- 60
ating whole plants from the transformed plant cell. In a
related embodiment, forplants, plant tissues orplant cells that
have been transformed with a gene expression cassette com-
prising a chemically-inducible promoter operatively linked to
a nucleic acid sequence that encodes a polypeptide compris- 65
ing an amino acid sequence that is at least substantially simi-
lar to SEQ ID NO:4, 5 or 6, the method further comprises
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contacting the transformed plants, plant tissues or plant cells,
directly or indirectly, with an activating amount of the expres-
sion-inducing chemical.
In other embodiments, plant gene expression cassettes
comprising two or more chimeric promoters of the present
invention, which are operatively linked to one or more genes
of interest, can be transformed into a plant cell in connection
with, for example, RF2a- and/or RF213-encoding sequences
to achieve a "cascade-type" system. In such embodiments,
the expression of RF2a and/or RF2b activates and/or
enhances the expression of the nucleic acid sequences to
which the two or more chimeric promoters are operatively
linked. Still further, the nucleic acid sequences encoding the
RF2a and/or RF2b proteins, for example, may be operably
linked to chemically-inducible promoters. In such case, upon
contacting plants, plant tissues or plant cells, which have been
transformed with such sequences, with the expression-induc-
ing chemical, the RF2a and/or RF2b transcription factors are
produced. The RF2a and/or RF2b transcription factors sub-
sequently interact with the Box II elements (and/or opera-
tional derivatives of Box II) to regulate gene expression. This
interaction, of course, results in the synchronized activation
and/or enhancement of expression of all Box II-dependent
genes (or all genes operatively linked to promoters containing
operational derivatives of Box II).
In other embodiments, plant gene expression cassettes
comprising at least one chimeric promoter of the present
invention, which is operatively linked to one or more genes of
interest, can be transformed into plant cells in connection
with RF2a- and/or RF2b-encoding sequences to "turn-off' or
modulate the expression of one or more unrelated endog-
enous and/or exogenous genes. The foregoing expression
cassettes can be used, for example, to activate and/or enhance
the expression of the one or more genes of interest that encode
molecules that selectively hybridize to specific target nucleic
acid sequences, e.g., endogenous and/or exogenous genes.
The hybridization of an oligomeric compound, for example,
with its target nucleic acid sequence can have the effect of
interfering with the normal function of the target sequence
(this effect is generally referred to as "antisense"). The func-
tions of DNA that can be affected in this embodiment, for
example, include replication and transcription. The functions
of RNA that can be affected include all vital functions such as
translocation of the RNA to the site of protein translation,
translation of protein from the RNA, splicing of the RNA to
yield one or more mRNA species, and catalytic activity that
may be imparted or facilitated by the RNA. The effect of such
interference with target nucleic acid function provides the
ability to modulate the expression of particular gene products.
The transformation of plant cells in accordance with the
present invention may be carried out in essentially any of the
various ways known to those skilled in the art of plant
molecular biology. That is, the method employed for trans-
formation. of target plant cells is not relevant to the present
invention and any method suitable for the target plant cell-
type may be utilized. As used herein, the term "transforma-
tion" refers to the alteration of the genotype of a host plant,
including within plant cells, embryos and tissues, by the
introduction of exogenous or endogenous nucleic acid
sequences. Further, the terms "transfection" and "transforma-
tion," as used herein, may be used interchangeably, wherein
the meaning accorded to both terms is, generally, as described
above with respect to "transformation."
Neither is the plant species to which the methods and
compositions of the present invention relate particularly ger-
mane to the invention. For example, dicotyledonous and
monocotyledonous plants can be transformed. Thus, the vari-
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ous embodiments of the present invention may be applied to
any plant, plant tissue, seed or plant cell for which transfor-
mation techniques are, or become, available.
In general, to commence a transformation process in accor-
dance with the present invention, it is first necessary to con- 5
struct a suitable vector and properly introduce the vector into
a plant cell. The details of the construction of vectors utilized
herein are known to those skilled in the art of plant molecular
biology. As described above, one or more plant gene expres-
sion cassettes may be constructed to practice the methods, 10
and to generate the plants, plant tissues and plant cells of, the
present invention. In practice, the construct or constructs
comprising the expression cassettes of the present invention
will be inserted into a plant cell by transformation.
For example, constructs that include chimeric promoters of 15
the present invention, which comprise the Box II element
and/or its operational derivatives, can be introduced into plant
cells using Ti plasmids, root-inducing (Ri) plasmids, and
plant virus vectors. In the first instance, for example, the
nucleic acid sequences of the present invention can be intro- 20
duced into plant cells through Agrobacterium-mediated
transformation. Methods involving the use of Agrobacte-
rium-mediated transformation include, but are not limited to:
1) co-cultivation of Agrobacterium with cultured isolated
protoplasts; 2) transforming (or infecting) plant cells or tis- 25
sues with transformed Agrobacterium (as described herein);
or 3) transformation of seeds, explants, apices or meristems
with Agrobacterium. Under appropriate conditions known in
the art, the transformed plant cells may be grown to form
shoots, roots, and develop further into plants. 	 so
In some cases, it may be preferred to introduce the nucleic
acid sequences of the present invention into plant cells utiliz-
ing Agrobacterium tumefaciens containing the Ti plasmid.
When using an A. tumefaciens culture as a transformation 35
vehicle, it is most advantageous to use a non-oncogenic strain
of the Agrobacterium as the vector so that normal non-onco-
genic differentiation of the transformed tissues is possible. It
is also preferred that the Agrobacterium harbor a binary Ti
plasmid system. Such a binary system comprises 1) a first Ti 40plasmid having a virulence region essential for the introduc-
tion of transfer DNA (T-DNA) into plants and 2) a chimeric
plasmid. The chimeric plasmid contains at least one border
region of the T-DNA region of a wild-type Ti plasmid flanking
the nucleic acid sequence to be transferred. Binary Ti plasmid 45
systems have been shown to be effective in transforming plant
cells.
Alternatively, the nucleic acid sequences of the present
invention can be introduced into plant cells using mechanical
or chemical means. For example, nucleic acid sequences can 50
be mechanically transferred by direct microinjection into
plant cells utilizing micropipettes. Still further, the nucleic
acid sequences may be transferred into plant cells using poly-
ethylene glycol, which is capable of forming a precipitation
complex with nucleic acid sequences that is taken up by target 55
plant cells.
The nucleic acid sequences of the present invention can
also be introduced into plant cells by electroporation. In this
technique, plant protoplasts, for example, are electroporated
in the presence of vectors or nucleic acid sequences to be
transformed into the protoplasts. Electrical impulses of high
field strength reversibly permeabilize plant membranes
allowing the introduction of nucleic acids. Electroporated
plant protoplasts reform the cell wall, divide and form a plant
callus. Selection of the transformed plant cells with the trans-
formed gene can be accomplished using, for example, phe-
notypic markers.
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Another well-known method for introducing nucleic acid
sequences of the present invention into plant cells is high
velocity BIOLISTICO penetrationby small particles withthe
nucleic acid sequences to be introduced contained either
within the matrix of small beads or particles, or on the surface
thereof. See, for example, U.S. Pat. Nos. 5,932,479 and
5,693,507.
Additionally, DNA viruses may be used as vectors for
introducing heterologous nucleic acid sequences into plant
cells. See, for example, U.S. Pat. No. 4,407,956. Non-limiting
examples of such DNA viruses include the Cauliflower
mosaic virus ("CaMV") and the Geminivirus. The CaMV
viral DNA genome, for example, may be inserted into a parent
bacterial plasmid creating a recombinant DNA molecule
which can be propagated in bacteria. After cloning, the
recombinant plasmid may be re-cloned and further modified
by introduction of the desired nucleic acid sequence of the
present invention. The modified viral portion of the recombi-
nant plasmid is then excised from the parent bacterial plas-
mid, and used to inoculate the target plant cells.
In any of the foregoing methods of transformation, a select-
able marker may, optionally, be associated with constructs
comprising nucleic acid sequences of the present invention.
As used herein, "marker" refers to a gene that encodes a
protein that confers a particular trait or a phenotype that
permits the selection of, or the screening for, a plant or plant
cell containing the marker. In some cases, the marker gene
may encode a protein that confers antibiotic resistance to
transformed plant cells, whereby the appropriate antibiotic
can be used to select for transformed plant cells among cells
that are not transformed. Examples of suitable selectable
markers include adenosine deaminase, dihydrofolate reduc-
tase, hygromycin-B-phosphotransferase, thymidine kinase,
xanthine-guanine phosphoribosyltransferase and amino-gly-
coside 3'-O-phosphotransferase II (kanamycin, neomycin
and G418 resistance). Other suitable markers will be known
to those of skill in the art. For example, screenable markers,
such as the uidA gene, which encodes P-glucuronidase
("GUS"), luciferase or the gene encoding the green fluores-
cent protein ("GFP"), may also be used.
Plants and Plant Parts
Still further, the invention provides plant cells, plant
embryos, plant tissues, whole plants and seeds that have been
transformed with at least one plant gene expression cassette
of the present invention. Methods of regenerating whole
plants from transformed plant cells, embryos and tissues are
well-known to those skilled in the art.
The following Examples are included to demonstrate cer-
tain embodiments of the invention. It should be appreciated
by those skilled in the art that the techniques disclosed in the
Examples that follow represent techniques discovered by the
inventors to function well in the practice of the invention, and
thus, can be considered to constitute preferred modes for its
practice. However, those of ordinary skill in the art should, in
light of the present disclosure, appreciate that many changes
can be made in the specific embodiments that are disclosed
and still obtain a like or similar result without departing from
the spirit and scope of the invention.
60	 EXAMPLES
Example I
Analysis of the Box II Sequence in BY-2 Protoplasts
65 Until now, the behavior of the RTBV promoter in the
tobacco BY-2 cell line and the contribution of its various cis
elements to the promoter activity in BY-2 cells was unknown.
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To compare the relative activity of the RTBV promoter with
other constitutive promoters, tobacco BY-2 protoplasts were
transfected with gene constructs in which the uidA open
reading frame ("ORF") was driven by the enhanced cauli-
flower mosaic virus ("CaMV") 35S promoter, the enhanced
CaMV promoter with a 5' deletion (at position —46 in relation
to the transcription start site), the cassava vein mosaic virus
("CsVMV") promoter, the RTBV promoter or the E fragment
of the RTBV promoter. The results are shown in FIG. 1, which
indicate that the RTBV promoter and, more particularly, the E
fragment of the RTBV promoter exhibit strong activity in
BY-2 cells. Specifically, the E fragment exhibited more than
one third of the activity that was observed with the CaMV 3 5S
promoter, which is generally considered a strong promoter in
plant cells.
To evaluate the functional contribution of different cis ele-
ments to the activity of the RTBV promoter, deletion mutants
were generated from the E fragment by removing the GATA
motif, ASL box and the Box II element at positions —100, —68
and —32, respectively. In FIG. 2, "pE" represents the entire E
fragment; "p-100" represents a truncated E fragment at posi-
tion —100, which excludes the GATA motif, "p-68" represents
a truncated E fragment at position —68, which excludes the
GATA motif andASL box; and "p-32" represents a truncated
E fragment at position —32, which excludes the GATA motif,
ASL box and Box II element. All of the foregoing fragments
included the TATA box and Box I element of the RTBV
promoter.
The mutated promoters were then fused with the uidA
gene. The GUS expression levels of the derived plasmids
were determined in BY-2 protoplasts. The data in FIG. 2 show
that the Box II element is crucial for promoter function in
BY-2 protoplasts. As long as the Box II element was retained,
the minimal promoter exhibited an expression level similar to
that of the full E fragment. Once the Box II element was
removed, however, the promoter activity decreased to less
than 20% of the E fragment.
Example 2
The Optimal Position of the Box II Sequence
The optimal spacing of the Box II element, relative to the
TATA box, for maximal effect on expression of the host
promoter was determined. The original Box II sequence was
deleted from the RTBV promoter in the context of the E
fragment and re-inserted into the promoter at different loca-
tions, as indicated in FIG. 3. The mutated promoters were
inserted into a cassette which contained the uidA coding
sequence and Nos terminator. The derived plasmids are illus-
trated in FIG. 3.
Construction of Plasmids with Relocated Box II in the E
promoter To relocate the Box II element in the E promoter
(fragment), the Box II element was first removed from the E
promoter using fusion PCR strategy to generate E(ABox II).
Next, the Box II element was re-introduced back into E(ABox
11) (SEQ ID NO:65) at varied positions. In the first PCR
reactions, two products were generated using the primer set R
(SEQ ID NO:73)/BoxII-del-3' (SEQ ID NO: 10) and BoxII-
del-5' (SEQ ID NO:11)/GUS3' (SEQ ID NO:13) with
pE:GUS as templates, wherein E represents the E fragment
(SEQ ID NO: 12) and GUS represents the uidA sequence,
which is well-known in the art. The PCR products were gel
purified and then used as templates for a second PCR reaction
employing the R (SEQ ID NO:73)/GUS3' (SEQ ID NO: 13)
primer set.
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The PCR product from the second reaction was restricted
with HindIII/NcoI and cloned into pE:GUS to replace the E
promoter with the same set of restriction sites. The resultant
construct was named pE(ABoxII):GUS. The Box II element
5 was re-introduced into pE(ABoxII):GUS using the same
fusion PCR strategy as described above. To generate the
E-Box II+11, E-Box II-9, E-Box II-17, E-Box II-58, E-Box
II-63, E-Box II-74, E-Box II-79, E-Box II-100, E-Box
10 II-116, E-Box II-147 and E-Box II-164 promoters, the first
PCR reactions were carried out using the primer sets shown in
the following Table 1:
TABLE 1
15
Promoters Primer Sets Respective SEQ ID NOs.
E-Box II+11 R/mtEBoxII(-0.5 h)-3' SEQ ID NO: 73/14
mtEBoxII(-0.5 h)-5'/GUS3' SEQ ID NO: 15/13
E-Box II-9 R/mtEBoxII(-1.0 h)-3' SEQ ID NO: 73/16
20 mtEBoxII(-1.0 h)-5'/GUS3' SEQ ID NO: 17/13
E-Box II-17 R/mtEBoxII(-2.0 h)-3' SEQ ID NO: 73/18
mtEBoxII(-2.0 h)-5'/GUS3' SEQ ID NO: 19/13
E-Box II-58 R/mtEBoxII(-2.5 h)-3' SEQ ID NO: 73/20
mtEBoxII(-2.5 h)-5'/GUS3' SEQ ID NO: 21/13
25	 E-Box II-63 R/mtEBoxII(-4.5 h)-3' SEQ ID NO: 73/22
mtEBoxII(-4.5 h)-5'/GUS3' SEQ ID NO: 23/13
E-Box II-74 R/mtEBoxII(-6.0 h)-3' SEQ ID NO: 73/24
mtEBoxII(-6.0 h)-5'/GUS3' SEQ ID NO: 25/13
E-Box II-79 R/mtEBoxII(-9.0 h)-3' SEQ ID NO: 73/26
mtEBoxII(-9.0 h)-5'/GUS3' SEQ ID NO: 27/13
30	 E-Box II-100 R/mtEBoxII(-111 nt)-3' SEQ ID NO: 73/28
mtEBoxII(-111 nt)-5'/GUS3' SEQ ID NO: 29/13
E-Box II-116 R/mtEBoxII(+2.0 h)-3' SEQ ID NO: 73/30
mtEBoxII(+2.0 h)-5'/GUS3' SEQ ID NO: 31/13
E-Box II-147 R/mtEBoxII(+29 nt)-3' SEQ ID NO: 73/32
mtEBoxII(+29 nt)-5'/GUS3' SEQ ID NO: 33/13
35	 E-Box II-164 R/mtEBoxII(+6.0 h)-3' SEQ ID NO: 73/34
mtEBoxII(+6.0 h)-5'/GUS3' SEQ ID NO: 35/13
The PCR products generated in the first reaction were used
40 as templates for the second PCR reaction using R/GUS3' as
primers (SEQ ID NO:73/13). The PCR products from the
second reactions were purified and cloned into the pE:GUS
vector to replace the E promoter through the restriction sites
45 HindIII/NcoI. The resultant plasmids were named pE-BoxII+
I I:GUS, pE-BoxII-9:GUS, pE-BoxII-17:GUS, pE-BoxII-
58:GUS, pE-BoxII-63:GUS, pE-BoxII-74:GUS,
pE-BoxlI-79:GUS, pE-BoxII-100:GUS, pE-BoxII-116:
GUS, pE-BoxII-147:GUS and pE-BoxII-164:GUS, respec-
50 tively.
BY-2 protoplasts were transfected with the foregoing con-
structs and tested for GUS activity. Protein samples from such
protoplasts were prepared using protein extraction buffer
55 (Jefferson et al., 1987) and quantified using the DC protein
assay kit (Bio-Rad Laboratories, Hercules, Calif.). Quantita-
tive analysis of GUS activity was performed as described by
Jefferson et al. (1987) using the substrate 4-methylum-bel-
liferyl-p-D-glucuronide ("MUG") with the Spectra Max
60 Gemini instrument (Molecular Devices Corp., Sunnyvale,
Calif.).
As shown in FIG. 4, the E promoter activity dramatically
decreased when the Box II element was removed (see con-
65 structpEABoxII). Additionally, when the Box II element was
removed and inserted in locations other than its native loca-
tion, the mutated promoters exhibited similar activity as pEA-
US 7,847,064 B2
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BoxII, which indicates that the position of the Box II element	 8. In general, RF2a has relatively higher binding affinities to
in its native promoter is important. 	 the Box II, Box IIml and Box IIm2 elements when compared
to RF2b. Furthermore, the DNA binding behavior of RF2a
Example 3	 and RF2b are quite different from each other. RF2a appears to
5 bind rapidly to the DNA target and slowly dissociates from
Effect of RF2a and RF2b on Expression of a	 the target, while RF2b binds slowly to the DNA target and
Reporter Gene	 releases from the target relatively quickly. The differences in
the affinity of RF2a to the Box II element and its mutants,
As shown in FIG. 1, the E fragment of the RTBV promoter 	 however, are not as dramatic as the differences of RF2b, while
showed strong activity in tobacco BY-2 protoplasts, presum-
 io the relative order of affinities to the different target elements
ably because the BY-2 cell line contains RF2a- and RF2b-like 	 is the same for both proteins (FIG. 8).
transcription factors (Fukazawa et al., 2000). Nevertheless, 	 To illustrate the biological relevance of the differences in
the E fragment may be further stimulated by co-transfecting	 the binding affinities described above, the pE::GUS, pE(Box
the BY-2 protoplasts with constructs that encode the RF2a 	 IIml)::GUS andpE(Box IIm2)::GUS constructs wereused as
and/or RF2b transcription factors. In this Example, the E 15 reporters in BY-2 protoplast transient assays. In these assays,
fragment was activated in tobacco BY-2 protoplasts by co- 	 CaMV 35S::RF2a, CSVMV::RF2b and CaMV 35S::RF2a/
transfection of E::GUS with CSVMV::RF2b, CaMV 35S:: 	 CSVMV::RF2b were used as effectors. All results were nor-
RF2a and CaMV 35S::RF2a/CSVMV::RF2b using methods	 malized against the GFP internal control. The relative GUS
well-known in the art. As shown in FIG. 5, the E fragment can 	 activities of different sets of transfection assays are shown in
be activated above a strong background expression by over- 20 FIG. 9 for the Box IIml element, and FIG. 10 for the Box
expression of RF2a and/or RF2b. 	 IIm2 element.
When the foregoing constructs were co-transfected with
Example 4	 CaMV 35S::RF2a, the promoter activity of E(Box IIml) and
E(Box IIm2) increased 5 to 7 fold (FIGS. 9 and 10). Further-
Mutants of Box II
	
	
25 more, there was no apparent difference between the activation
of promoters containing the Box IIml and Box IIm2 ele-
To investigate the possibility of reducing the background 	 ments. Different results were observed when the foregoing
expression level in BY-2 protoplasts, the activities of certain	 constructs were co-transfected with CSVMV::RF2b. The
Box II mutants (or "operational derivatives"), as shown in 	 E(Box IIm2) promoter was activated about 5.8 fold by RF2b,
FIG. 6, were tested in BY-2 protoplasts. Specifically, the 30 while the E(Box IIml) promoter was activated about 7 fold
operational derivatives Box IIml (SEQ ID NO:2) and Box 	 (FIGS. 9 and 10). Importantly, this Example shows that the
IIm2 (SEQ ID NO:3) were tested in the context of the E	 activity of the E(Box IIml) promoter with RF2b was as high
fragment (SEQ ID NO: 63 and SEQ ID NO: 64, respectively). 	 as the expression of the E wild type promoter in BY-2 proto-
The mutated promoters were ligated with the uidA coding 	 plasts.
sequence to create fusion genes, which are referred to herein 35	 The foregoing data related to the interactions between the
as pE(Box IIml)::GUS and pE(Box IIm2)::GUS. BY-2 pro- 	 RF2a and/or RF2b transcription factors and the target chi-
toplasts were then transfected with the pE(Box IIml)::GUS 	 meric promoters suggestthat suchpromoters may, optionally,
and pE(Box IIm2)::GUS constructs. When the Box IIml and 	 be designed to comprise the Box IIml and/or Box IIm2 ele-
Box IIm2 elements were used, the GUS activity relative to the 	 ments to create a "zero" background expression level. In such
wild type Box II element (pE:GUS) dropped significantly 40 case, the chimeric promoters may be activated by initiating
(FIG. 7).	 the expression of the RF2a and/or RF2b transcription factors,
In the case of the chimeric sequence pE(Box IIm2)::GUS,	 which, of course, would interact with the Box IIml and/or
there was little, if any, GUS activity above that of non-trans- 	 Box IIm2 elements of the chimeric promoters, using compo-
fected BY-2 cells (FIG. 7). These data suggest that there are 	 sitions and methods described herein.
endogenous transcription factors in BY-2 cells that can inter- 45
act with the wild type Box II element, which results in expres- 	 Example 6
sion of pE:GUS in protoplasts (FIGS. 1, 2 and 7). When
operational derivatives of the Box II element were used, e.g., 	 Use of Box II and RF2a to Control Expression of
Box IIml and Box IIm2, the promoter activity was signifi- 	 Novel Chimeric Promoters
cantly abolished.	 50
The following shows that the Box II element can be trans-
Example 5	 ferred to unrelated promoters, or promoter fragments, in a
position dependent manner to control heterologous gene
Binding Affinities of RF2a and RF2b	 expression. To show that the Box II element is portable, Box
55 II was fused with different lengths of the CaMV 35S  promoter
A previous report showed that RF2a binds to the Box II 	 (FIG. 11). Specifically, the Box II element was fused to the 5'
element and its mutants with different affinities (Yin et al., 	 end of the chimeric promoters with a space of 7 nucleotides
1997). To compare the binding affinities of RF2a and RF2b 	 from the TATA box plus 1, 1.5, 3.0, 3.5, 5.0 and 5.5 "turns of
with the Box II element and its mutants, real time Surface	 DNA helix" (one turn-10.4 base pairs). The chimeric pro-
Plasmon Resonance ("SPR") measurements were conducted 60 moters were then inserted into a cassette with the uidA coding
using a BIAcore 2000 instrument. The binding affinities of 	 sequencing and Nos terminator.
RF2a and RF2b to these DNA targets were measured on chips 	 Construction of Plasmids Comprising the Box II Element
on which biotin labeled-Box II, -Box IIml and -Box IIm2 	 and Different Lengths of the CaMV 35S Promoter To con-
elements were immobilized. 	 struct Box II and CaMV 35S chimeric promoters, the Box II
The association and de-association constants were deter- 65 element was introduced into CaMV 35S promoter sequences
mined using BIAevaluation 3.1 software using 1:1 binding 	 of different lengths through PCR reactions using Pfu DNA
with a mass transfer model. The results are presented in FIG. 	 polymerase (Stratagen Systems, Kirkland, Wis.). Forward
US 7,847,064 B2
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primers for the PCR reactions were designed to have a Hin-
dIII restriction site, followed by the Box II sequence, which
was followed by part of the 5' CaMV promoter at desired
positions (see FIG. 12 and Table 2 for specific primer
sequences). The GUS 3' primer (SEQ ID NO:36) was used as
reverse primer for all reactions.
TABLE 2
Promoter Primer Set 5' Primer
1 -1.0hBoxII-48CaMV -1.0hBoxII-48CaMV/GUS 3' SEQ ID
NO: 37
2 -1.5hBoxII-53CaMV -1.5hBoxII-53CaMV/GUS 3' SEQ ID
NO: 38
3 -3.0hBoxII-69CaMV -3.0hBoxII-69CaMV/GUS 3' SEQ ID
NO: 39
4 -3.5hBoxII-74CaMV -3.5hBoxII-74CaMV/GUS 3' SEQ ID
NO: 40
5 -5.0hBoxII-90CaMV -5.0hBoxII-90CaMV/GUS 3' SEQ ID
NO: 41
6 -5.5hBoxII-95CaMV -5.5hBoxII-95CaMV/GUS 3' SEQ ID
NO: 42
The p35S:GUS plasmid was used as template in the fore-
going reactions. In the p35 S:GUS plasmid, a NcoI restriction
site was located between the CaMV 35S promoter and the
GUS coding sequence. Thus, a NcoI site was present in all
PCR products. The PCR products were restricted with Hin-
dIII/NcoI and cloned into a pE:GUS vector to replace the E
promoter through the same set of restriction sites. The con-
structed plasmids containing the chimeric promoters labeled
1 through 6 in Table 2 were named p-1.0hBoxII-48CaMV:
GUS, p-1.5hBoxII-53CaMV:GUS, p-3.OhBoxII-69CaMV:
GUS, p-3.5hBoxII-74CaMV, p-5.0hBoxII-90CaMV:GUS,
and p-5.5hBoxII-95CaMV:GUS, respectively. The controls
for this set of plasmids were generated using primer sets
1.5h-53CaMV-c (SEQ ID NO:43)/GUS3 ; -3.5h-74CaMV-c
(SEQ ID NO:44)/GUS3' and -5.5h-95CaMV-c (SEQ ID
NO:45)/GUS3', which products were cloned into pE:GUS
with HindIII/NcoI to replace the E promoter. The derived
plasmids/constructs were named p-53CaMV:GUS,
p-74CaMV:GUS and p-95CaMV:GUS, respectively.
The foregoing constructs were then transfected into non-
transgenic BY-2 protoplasts, and the resulting GUS activity
determined. The data in FIG. 13 show that when the Box II
element is fused withthe CaMV 35S promoter with a space of
7 nucleotides from the TATA box plus one or more full turns
of DNA helix (p1.0hBoxII-48CaMV and p5.0hBoxII-
90CaMV), gene expression was dramatically stimulated,
compared to reporter genes that lack Box II (p-48CaMV and
p-90CaMV, respectively). The p1.0hBoxII-48CaMV and
p5.0hBoxII-90CaMV constructs yielded 6.9 and 4.7 fold
increases in expression level above p-48CaMV and
p-90CaMV, respectively, which did not contain the Box II
element.
In contrast, when the Box II element was fused to frag-
ments of the CaMV 35S promoter at positions of 7 nucle-
otides from the TATA box plus multiples of 0.5 turns of DNA
helix (p-1.5hBox II-53CaMV versus p-53CaMV, p-3.5hBox
II-74CaMV versus p-74CaMV; and p-5.5hBox II-95CaMV
versus p-95CaMV), there was much less or no stimulation of
gene expression. Of course, these results indicate that the Box
II element, and its operational derivatives, can be used to
control and/or enhance gene expression in unrelated promot-
ers, preferably, when it is located approximately 7 nucle-
otides from the TATA box plus one or more full turns of DNA
helix.
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To illustrate the regulatory effect of transcription factors
RF2a and RF2b on the activity of the Box II element and
novel chimeric promoters containing the Box II element, each
plasmid/construct illustrated in FIG. 11 was tested in trans-
5 genic BY-2 protoplasts that produce RF2a, or RF2a plus
RF2b. In these experiments, as shown in FIG. 14, the trend of
promoter stimulation was consistent with that shown in non-
transgenic BY-2 cells, i.e., activation of promoters that con-
tain the Box II element at 7 nucleotides plus 1.0 and 5.0
to helices distance from the TATA box was higher than that of
the promoters in which the Box II element was placed 1.5,
3.5, and 5.5 helices distance from the TATA box. The total
amount of GUS expression exhibited by the chimeric pro-
moter constructs, however, was much greater in transgenic
15 cell lines that produce elevated levels of RF2a (FIG. 14(A)),
or RF2a plus RF2b (FIG. 14(B)), than in non-transgenic
protoplasts that did not contain elevated levels of such pro-
teins (compare the relative GUS expression levels in FIG. 14
to FIG. 13).
20 The foregoing data from BY-2 wild type and transgenic cell
lines indicate that the Box II element, and its operational
derivatives, can regulate the expression of unrelated promot-
ers, e.g., the CaMV 35S chimeric promoters described above,
as it can in the RTBV promoter. Furthermore, the data indi-
25 cate that the effect of the Box II element, and its operational
derivatives, is, preferably, imparted in a position and/or ori-
entation dependent manner as described above.
Example 7
30
Validation of Transient Assay Data From Tobacco
BY-2 Protoplasts in Transgenic Arabidopsis
To evaluate the data presented above from the transient
35 assays, binary vectors were built and transformed into Ara-
bidopsis plants through Agrobacterium -mediated transfor-
mation. The set of binary vectors that were transformed into
plants were constructs with different deletions of the RTBV
promoter, which comprised the various portions of the E
40 fragment described in Example 1; the E fragment containing
either the Box IIurl or Box IIm2 element; or the wild type E
fragment (See FIG. 15A). In the transformed Arabidopsis
plants, the activity of the chimeric promoters, which com-
prised the Box IIurl or Box IIm2 element, was near the basal
45 level of expression, which was observed for the construct
p-E(32)::GUS, in which all the cis elements of RTBV pro-
moter up-stream of the TATA box were removed (FIG. 15B).
Thus, the foregoing data agree with the data generated in the
transient protoplasts analysis described in Example 5,
50 wherein the chimeric promoters of the present invention may,
for example, be designed to comprise the operational deriva-
tives Box IIurl and/or Box IIm2 to create a near "zero"
background expression level in the absence of RF2a and/or
RF2b.
55
Example 8
RF2a Mutants with Deletions of Functional Domains
60 It has been shown that the bZIP protein RF2a enhances
transcription in vivo and in vitro. It is further known that the
RF2a transcription factor comprises a proline-, acidic- and
glutamine-rich domain. To analyze the function of each
domain, mutants of RF2a were created by removing one or
65 more of the foregoing putative domains as shown in FIG.
16(A). More particularly, mutants of RF2a were created in
which the proline-rich domain was removed (RF2a-AP); the
US 7,847,064 B2
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glutamine-rich domain was removed (RF2a-AQ); the proline-
rich and acidic domains were removed (RF2a-APAA); the
proline- and glutamine-rich domains were removed (RF2a-
APAQ); and the glutamine-rich, proline-rich and acidic
domains were removed (RF2a-3A). The coding sequence for
each mutant was cloned into the bacterial expression vector
pET28a, in which a His, tag was placed at the N-terminus of
the fusion protein. The derived plasmids were named pET-
RF2a (encoding full-length RF2a), pET-RF2a-AP, pET-
RF2a-AQ, pET-RF2a-APAA, pET-RF2a-APAQ, and pET-
RF2a-3A.
Plasmid Construction for Protein Purification The
sequences encoding the foregoing mutants of RF2a were
created through PCR amplification. A NdeI restriction site
was added to the 5' end of all primers, and the ATG in the
restriction site was in frame with the His, tag in vector
pET28a (Invitrogen Corp., Carlsbad, Calif.) and served as the
transcription start codon for the plasmids described in
Example 9. A BamHI site was added to all the 3' primers with
a stop codon in front of the restriction site. The primers used
for amplification of the various fragments of RF2a are listed
in Table 3 below:
TABLE 3
RF2a 5' SEQ ID NO: 46
RF2a-AP 5' SEQ ID NO: 47
RF2a-APAA 5': SEQ ID NO: 48
RF2a 3' SEQ ID NO: 49
RF2a-AQ 3' SEQ ID NO: 50
From a complete RF2a-encoding sequence (SEQ ID
NO:7), the AP fragment was amplified using primers RF2a-
AP 5' and RF2a 3'; AQ was amplified using primers RF2a 5'
and RF2a-AQ 3'; APAA was amplified using primers RF2a-
APAA 5' and RF2a 3'; and APAQ was amplified using primers
RF2a-AP 5' and RF2a-AQ 3'. The construction of pET-RF2a-
3A and pET-RF2a were described by Petruccelli et al. (2001).
All of the fragments were restricted with NdeI and BamHI
and were cloned into pET28a through the same set of restric-
tion sites. All of the mutations were verified by DNA
sequence analysis. The derived plasmids were designated
pET-RF2a-AP, pET-RF2a-AQ, pET-RF2a-APAA, pET-RF2a-
APAQ, pET-RF2a (encoding full-length RF2a), and pET-
RF2a-3A.
Protein Purification The pET28a-derived plasmids were
transformed into Escherichia coli strain BL21 (DE3)pLysS
for protein expression. Protein expression was induced with
0.5 mM isopropyl-p-D-thiogalactopyranoside at room tem-
perature for 3 hours after the cell density reached A600 of —0.6.
The His-tagged proteins were purified according to proce-
dures provided by Novagen, Inc. (Madison, Wis.) under non-
denaturing conditions. The purified recombinant proteins
were dialyzed in lx phosphate-buffered saline with 20%
glycerol to remove imidazole and stored at —70° C.
The purified mutant proteins were then analyzed by SDS-
PAGE to confirm that each protein was its expected size (FIG.
16(B)). To confirm that each of the mutant proteins bind to the
DNA target, i.e., the Box II element and/or its operational
derivatives, gel mobility shift assays were carried out with the
purified recombinant proteins (FIG. 16(C)). The electro-
phoretic mobility shift assays were carried out essentially as
described in Yin and Beachy (1995). 100 ng of proteins puri-
fied from the transformed E. coli were incubated with 32p_
labeled Box IIml DNA probe followed by electrophoresis in
a 5% acrylamide gel (Yin et al., 1997) (FIG. 16(Q). The data
presented in FIG. 16(C) demonstrate that proteins AP (SEQ
28
ID NO:68), AQ (SEQ ID NO:69), APAA (SEQ ID NO:70),
APAQ (SEQ ID NO:71), and 3A (SEQ ID NO:72) of RF2a
bind to the Box IIml element.
5	 Example 9
Contribution of RF2a Domains to Activity
The relative activity of RF2a and the RF2a mutants (de-
I0 scribed in Example 8) was then measured. First, a chimeric
promoter was developed with a single copy of the Box II
element fused to the 5' end of a minimal CaMV 35S promoter
comprising nucleotides —48 to +8 (SEQ ID NO:66). The
chimeric promoter was ligated to the uidA coding sequence to
15 create the reporter pBII-48Ca::GUS.
To analyze the function of the several domains of RF2a,
effectors were created by inserting coding sequences of RF2a
or the mutants of RF2a (described in Example 8) downstream
of the enhanced CaMV 35 S promoter in thepMON999 vector
20 (a gift from Monsanto Company, St. Louis, Mo.). The result-
ant constructs, p35S::RF2a, p35S::RF2a-AP, p35S::RF2a-
AQ, p35S::RF2a-APAA, p35S::RF2a-APAQ and p35S::
RF2a-3A, were co-transfected into BY-2 protoplasts with
pBII-48Ca::GUS (FIG. 17(A)). Plasmid pCat-GFP, in which
25 the GFP gene was driven by CaMV 35S promoter, was co-
introduced to serve as an internal control. The following
describes, in greater detail, the construction of these vectors
and the methods employed in transfecting the same into BY-2
protoplasts.
30 Plasmids for protoplast transfection The coding
sequences for mutants of RF2a were released from pET28a-
derived plasmids and cloned into the plant expression vector
pMON999 (a gift from Monsanto Company, St. Louis, Mo.)
to place each gene downstream of an enhanced CaMV 35S
35 promoter, followed by a nopaline synthase terminator
sequence. The resulting effector constructs were named
p35S::RF2a, p35S::RF2a-AP, p35S::RF2a-AQ, p35S::RF2a-
APAA, p35S::RF2a-APAQ and p35S::RF2a-3A. The reporter
gene construct, pBII-48Ca::GUS, was built using PCR to
40 introduce the Box II element into a minimal CaMV 35S
promoter comprising nucleotides —48 to +8 with primers
BII-48Ca 5' (SEQ ID NO:53) (which contained the Box II
element) and GUS 3' (SEQ ID NO:36) using a p35S:GUS
plasmid as template. The PCR product was restricted with
45 HindIII and NcoI, and the resulting fragment was inserted
into p35S::GUS to replace the original 35S promoter.
Transfection of tobacco BY-2 protoplasts The proto-
plasts were isolated from tobacco cell line BY-2 as described
by Watanabe et al. (1987). Approximately one million proto-
50 plasts were transfected by electroporation with 20 µg of effec-
tor construct DNA, 15 µg of herring sperm DNA, 2.5 µg of
reporter gene construct DNA, and 15 µg of pCat-GFP DNA.
In samples with reporter gene alone, the total amount of DNA
was adjusted by adding 20 µg of herring sperm carrier DNA.
55 The electroporation parameters used were 300 V and 250
microfarads with the Bio-Rad electroporation system (Bio-
Rad Laboratories, Hercules, Calif.). Protoplast samples were
cultured in Murashige and Skoog medium with 0.4 M man-
nitol, pH 5.8, at 28° C. The protoplasts were collected 24
6o hours after electroporation.
As shown in FIG. 17(B), the transactivation function of
RF2a was not decreased by removing either the proline-rich
(35S::RF2a-AP) or glutamine-rich (35S::RF2a-AQ) domains
or both of the domains (35S::RF2a-APAQ). In fact, the acti-
65 vation function of each of these mutants was greater than that
of full-length RF2a. RF2a-AP was significantly different
from RF2a at the P0.05 level, whereas RF2a-AQ and RF2a-
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APAQ were significantly different from RF2a at the P, level
(Student's t test). Also, the difference between the activity of
RF2a-AP and RF2a-AQ was significant at the Pool level, and
there was no difference between RF2a-AQ and RF2a-APAQ.
The data suggest that the proline-rich and glutamine-rich
domains do not contribute in a positive way to the activation
function of RF2a. In contrast, the activity dropped to near
basal level when the acidic domain was removed (RF2a-
APAA and RF2a-3A) (FIG. 17(B)). These results suggest that
the acidic domain is responsible for the activation of gene
expression by RF2a.
Example 10
Functions of RF2a Domains in Fusion Proteins
To determine whether domains of RF2a can serve as inde-
pendent modules to regulate transcription, the various puta-
tive functional domains were fused with the synthetic 2C7
protein (SEQ ID NO: 75), a synthetic zinc finger DNA-bind-
ing domain that specifically binds to the 2C7 DNA-binding
site (SEQ ID NO:74), to create various "effector" constructs
(FIG. 18(A)). The various RF2a domains were placed either
at the N-terminus or the C-terminus of the 2C7 DNA-binding
domain ("DBD"). The "reporter" constructpC7er2:GUS car-
ried the uidA coding sequence located downstream of a chi-
meric promoter comprising 6x2C7-binding sites ligated with
the minimal promoter of erbB-2 ("er2"). p35S:2C7 encoded
the 2C7 protein without an activation domain and served as a
control (FIG. 18(A)).
To create effectors with RF2a domains fused to the N-ter-
minus of 2C7 DBD, coding sequences for the acidic domain
(A) (SEQ ID NO:9), proline-rich domain (P) (SEQ ID
NO:54) and glutamine-rich domain (Q) (SEQ ID NO:55)
were amplified using primer pairs A-2C7 5'/A-2C7 3', P-2C7
5'/P-2C7 3', and Q-2C7 5'/Q-2C7 3', respectively, with pET-
RF2a as template. Bg1II and BamHI restriction sites were
introduced into the 5' and 3' primers, respectively. The par-
ticular sequences of the foregoing primers are referenced in
Table 4 below:
TABLE 4
A-2C7 5' SEQ ID NO: 56
A-2C7 3' SEQ ID NO: 57
P-2C7 5' SEQ ID NO: 58
P-2C7 3' SEQ ID NO: 59
Q-2C7 5' SEQ ID NO: 60
Q-2C7 3' SEQ ID NO: 61
The products created by the foregoing PCR reactions were
restricted with the Bg1II and BamHI and cloned into
pMON999 through Bg1II and EcoRl sites along with the
DNA fragment that encoded the 2C7 DNA-binding domain
(SEQ ID NO:76) (The 2C7 DNA-binding domain coding
sequence was previously released from p35S:2C7 using
BamHI and EcoRI). The resulting plasmids were designated
p35S:A-2C7, p35S:P-2C7, andp35S:Q-2C7.
For effectors with RF2a domains at the C-terminus of the
2C7 DBD, coding sequences fortheA, P, Q, andP plusA (PA)
domains were released from pET-RF2a-A, pET-RF2a-P,
pET-RF2a-Q, and pET-RF2a-PA using the enzymes XbaI and
EcoRl and cloned into p35S:2C7-VP16 to replace the VP 16
domain with the same restriction sites. The resultant plasmids
were named p35S:2C7-A, p35S:2C7-P, p35S:2C7-Q, and
p35S:2C7-PA.
Each of the foregoing effector constructs, as illustrated in
FIG. 18(A), were co-transfected into BY-2 protoplasts along
30
with the reporter construct. The relative GUS activities of the
transfected protoplasts were subsequently determined. As
shown in FIG. 18(B), when domains of RF2a were placed at
the C-terminus of the 2C7 protein, 2C7-A and 2C7-PA
5 showed significant activation function. When the domains
were fused individually at the N-terminus of 2C7, the acidic
domain (A-2C7) conferred stronger activation than the P(P-
2C7) or Q (Q-2C7) domains. The function of the acidic
domain in the fusion proteins is consistent with its function in
10 RF2a, although the position of this domain in the fusion
proteins appears to affect its activity. The proline- and
glutamine-rich domains had no effect on gene expression
when they were placed at the C-terminus of the 2C7 DBD;
however, these domains showed mild activation function
15 when they were fused at the N-terminus of the 2C7 DBD.
Example I I
Impact of Mutants of RF2a on Plant Development
20
Previous studies have shown that transgenic rice and
tobacco plants that overexpressed RF2a were normal in
appearance and reproduction. (Yin et al., 1997; Petruccelli et
al., 2001). To determine whether mutants of RF2a in which
25 one or more domains were removed had a positive or negative
effect on plant development, transgenic plants that overex-
press mutants of RF2a were produced. Fifteen or more inde-
pendent transgenic tobacco lines were developed with the
constructs described below through Agrobacterium -medi-
3o ated transformation.
Plasmids for Agrobacterium -mediated transformation—
The fusion genes described above relating to the plant expres-
sion constructs comprising RF2a deletion mutants were
35 released from pMON999-derived plasmids using NotI
(blunted) and cloned into the binary vector pGA-E::GUS
(Petruccelli et al., 2001) using the blunt HindIII site (down-
stream of a CaMV 35S promoter sequence). The final plas-
mids were named pGA-E:: GUS/P-3 5 S:: AP, pGA-E:: GUS/P-
40 35S::AQ, pGA-E::GUS/P-35S::APAA and pGA-E::GUS/P-35S::APAQ. A plasmid encoding full-length RF2a, p35S::
RF2a, was also constructed using the methods described
herein.
Tobacco transformation the plasmids described above
45 were introduced into Agrobacterium tumefaciens strain
LBA4404 and used for tobacco transformation. Leaf discs
from Nicotiana tabacum cv. Xanthi NN were transformed
with the various plasmids following the protocol of Horsch et
al. (1988). At least 15 independent transgenic lines were
50 produced with each gene construct. Transgenic plants were
self-fertilized, and T, seeds were collected. The T, seeds were
germinated on Murashige and Skoog medium (Murashige
and Skoog, 1962) with kanamycin (100 mg/L) selection, and
Kan" seedlings were grown in a greenhouse for observation.
55 Following PCR analysis, transgenic lines expressing each
mutant were observed for phenotypic changes. T, generation
plants with 35S::RF2a, 35S::RF2a-AP, 35S::RF2a-AQ, and
35S::RF2a-APAQ did not exhibit abnormal phenotypes (FIG.
19(A)). However, I I of 15 independent transgenic lines with
6o 35S::RF2a-APAA exhibited mild to severe stunting with
curved leaves and substantial delay in flowering times (FIGS.
19(A) & (B)). Furthermore, the internodal elongation of
transgenic plants was strongly repressed by RF2a-APAA
(FIG. 19(C), Panel 1). The phenotype caused by 35S::RF2a-
65 APAA was similar to, but less severe than, the phenotype
caused by 35S::RF2a-3A. Cross-sections of the stem of trans-
genic plants with either RF2a-APAA or RF2a-3A showed that
US 7,847,064 B2
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the xylem of stunted plants was not uniformly lignified and
that phloem development was altered. (FIG. 19(C)).
To confirm that the phenotype was related to transgene
expression, protein extracts of the transgenic plants were
analyzed via a Western blot assay using an antibody against
RF2a. Protein samples from the transgenic leaf tissues were
extracted in buffer (50 mM Na3PO41 pH 7.0, 10 mM EDTA,
0.1% Triton X-100, 0.1% sodium lauryl sarcosine) and quan-
tified using the DC protein assay kit (Bio-Rad Laboratories,
Hercules, Calif.). 40 µg of each protein sample was separated
via SDS-PAGE and blotted onto nitrocellulose membrane.
The membrane was stained with Ponceau S (Sigma Chemical
Company, St. Louis, Mo.) to monitor protein loading prior to
immuno-detection. The primary antibody used in the immu-
nodetection was raised in rabbits against full-length RF2a; 15
the secondary antibody was horseradish peroxidase-conju-
gated to goat anti-rabbit antibody (Southern Biotechnology
Associates, Inc., Birmingham, Ala.). FIG. 20 shows that there
is a direct correlation between the abnormal phenotype and
	
the accumulation of RF2a-APAA.	 20
Example 12
Versatility of the Gene Regulation System
25
As shown herein, the acidic domain of RF2a may be linked
to any DNA binding domain to regulate the expression of
corresponding promoters. More specifically, the novel tran-
scription factors of the present invention that comprise the
acidic domain of RF2a (or substantially similar sequences) 30
and at least one DNA binding domain ("DBD"), may be used
to regulate the expression of plant functional promoters that
comprise one or more cis elements wherein such elements
are capable of interacting with such DNA binding domain.
The interaction between such novel transcription factors 35
through such DNA binding domains with corresponding cis
elements, preferably, results in the initiation, or enhancement
of, transcription.
Similarly, the chimeric promoters of the present invention
have been shown to regulate transcription in the presence of 40
RF2a and/or RF2b. More particularly, the inventors have
demonstrated that the Box II element and/or its operational
derivatives (or substantially similar sequences) may be used
in connection with any plant functional promoter to regulate
gene expression in the presence of RF2a, RF2b, and/or any 45
novel transcription factor contemplated herein which com-
prises an amino acid sequence at least substantially similar to
the acidic domain of RF2a. Accordingly, it is contemplated
that a plurality of different combinations of novel transcrip-
tion factors and/or novel chimeric promoters of the present 50
invention may be employed to regulate gene expression.
For example, in addition to the Box II element and its
operational derivatives described herein, the RF2a and RF2b
transcription factors (and related bZIP proteins) have been
found to interact with certain additional cis elements to 55
impart regulation of transcription. Non-limiting examples of
such additional cis elements are summarized in Table 5
below:
TABLE 5	 60
Common Name
	
of cis Element DNA Sequence	 SEQ ID NO.
rbe	 CCCCAAAGTCCAGCTTGAAAT SEQ ID NO:77
65
G3	 TTAATCCAACTTGGAAAATG SEQ ID NO:78
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TABLE 5-continued
Common Name
	
of cis Element DNA Sequence	 SEQ ID NO.
AC-II	 CCACCACCCCC	 SEQ ID NO:79
AHA3	 AGGTCACCCCATT	 SEQ ID NO:82
Vs-1	 TGGATGTGGAAGACAGCA	 SEQ ID NO:83
The present invention contemplates that such additional cis
elements, including, without limitation, the elements refer-
enced in Table 5, may be used to construct novel chimeric
promoters in accordance with the present invention. Of
course, such novel chimeric promoters may be used, for
example, to regulate gene expression in connection with
RF2a and/or RF2b transcription factors similar to the chi-
meric promoters shown and described in previous Examples.
It will be appreciated by those skilled in the art that chimeric
promoters of the present invention, which comprise, for
example, one or more of the additional cis elements listed in
Table 5 (or substantially similar sequences), may be con-
structed and used in a manner similar to that described above
with respect to chimeric promoters comprising Box II and/or
its operational derivatives.
Still further, the present invention contemplates that the
acidic domain of RF2a (SEQ ID NO: 6), or substantially simi-
lar sequences, may be used with other DNA binding domains
in the art. More particularly, the present invention contem-
plates that the acidic domain of RF2a, or substantially similar
sequences, may be linked to any DNA binding domain from
a plurality of classes of such domains to create novel tran-
scription factors capable of regulating gene expression
(which was demonstrated in Example 10). The invention
provides, for example, that the following classes of DNA
binding domains may be used in such capacity: (i) basic
helix-loop-helix domains ("bHLH"); (ii) DNA binding
domains of bZIP proteins; (iii) native or synthetic zinc finger
DNA binding domains; and (iv) DNA binding domains of the
E2F/DP family of transcription factors. Non-limiting
examples of such DNA binding domains for each class are
listed in Table 6 below. Additionally, Table 6 references the
specific cis element with which such DNA binding domains
are known to interact (and affect gene expression).
TABLE 6
Class of
DBD	 Representative DBD Sequence of DBD cis Element
bHLH "b/HLH/Z domain SEQ ID NO. 84 SEQ ID NO. 85
of USF" - from
H. Sapiens
bZIP "Jun" - from SEQ ID NO. 86 SEQ ID NO. 87
H. Sapiens
Zinc-Finger "C=" SEQ ID NO. 88 SEQ ID NO. 89
E2F/DP "=4" SEQ ID NO. 90 SEQ ID NO. 91
Many of the DNA binding domains and cognate cis ele-
ments referenced in Table 6 are described in the literature
(among others). See, for example, Ferre-D'Amare, R. et al.
(1994); Toledo-Ortiz, G. et al. (2003); Jakoby, M. et al.
4CL-1	 CTTCACCACCCCACT	 SEQ ID NO:80
10	 Shl	 TGGACCCTACCA	 SEQ ID NO:81
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	(2002); Segal D. J. et al. (2003); Wolfe, S. A. et al. (2001); 	 RF2a sequence in pSL-5G35Sm:RF2a through NdeI
	
Zheng, N. et al. (1999); and Ramirez-Parra, E. et al. (2003). 	 (blunted)/BamHI restriction sites (pSL-E:GUS/5G35Sm:
	
In light of the foregoing, the present invention contem- 	 RF2a). The sequences encoding E:GUS, together with
	
plates that the DNA binding domains listed in Table 6 may be 	 5G35Sm:RF2a, were released from pSL-E:GUS/5G35Sm:
tethered to the acidic domain of RF2a (SEQ ID NO: 6), or to 5 RF2a through HindIII restriction. The excised fragment was
	
substantially similar sequences, to create novel transcription 	 then made blunt using Klenow treatment in the presence of
	
factors. The methods employed to produce such novel tran-	 dNTPs.
	
scription factors may parallel those described above with 	 The excised GUS- and RF2a-encoding fragment was sub-
	
respect to the transcription factors comprising, for example, 	 sequently cloned into the binary vectorpCa-5GRbm:DsRed-
the 2C7 domain. Those of skill in the art, however, will io E5/Cs:VGE, which carried the chimeric receptor gene VGE
	
appreciate that any number of methods may be used to 	 (SEQ ID NO: 93) under the control of a cassava vein mosaic
	
express such novel transcription factors based on the amino 	 virus promoter (Cs). The resulting plasmid (pCa-EG2aV)
acid sequences described herein. 	 carried the E:GUS, 5G35Sm:RF2a, and Cs:VGE sequences,
	
The novel transcription factors of the present invention,	 and was used for Agrobacterium -mediated transformation of
which comprise, for example, one or more DNA binding 15 Arabidopsis thaliana.
	domains referenced in Table 6 may be used to regulate the	 Agrobacterium -mediated transformation Arabidopsis
	expression of appropriately designed chimeric promoters. 	 transformation was conducted using the well-known dipping
	
More particularly, such transcription factors may be used to 	 method described in Clough and Bent, 1998. More specifi-
	
regulate the expression of chimeric promoters that comprise, 	 cally, Agrobacterium GV3101 and pCa-EG2aV were cul-
for example, the corresponding cis element referenced in 20 tured in LB medium and monitored by spectrophotometry.
	
Table 6 (or substantially similar sequences). In light of the	 Once the optical density, OD(600), of the culture reached 0.6,
	
foregoing, it should be appreciated that the acidic domain of 	 the culture was collected via centrifugation. The bacterial cell
	
RF2a (or substantially similar sequences) may be linked to 	 pellet was re-suspended in 5% sucrose, 0.2% Silwet 77 solu-
	
any DNA binding domain known in the art (including, with- 	 tion and used for inoculating the flowering Arabidopsis
out limitation, the domains listed in Table 6) to regulate the 25 plants. The transformed Arabidopsis seeds were collected at
	
expression of corresponding promoters (which contain one or 	 maturity and sterilized with 70% ethanol. The sterilized seeds
	
more cis elements that may interact with such DNA binding 	 were germinated on MS medium containing 50 mg/L of
domain to regulate transcription). 	 hygromycin B to select transgenic seedlings. The transgenic
plants were grown to maturity and seeds were collected,
Example 13	 30 which are referred to as T, seeds. The T, seeds were subse-
quently germinated and grown to maturity.
Use of Inducible Promoters with the Gene	 Induction of RF2a expression RF2a expression was
Expression System	 induced in the transgenic Arabidopsis plants described herein
by application of a 1:8000 dilution of the pesticide Intrepid®
The gene expression system of the present invention (in- 35 2F (Dow AgroSciences, Indianapolis, Ind.). The active ingre-
	
cluding the chimeric promoters, gene expression cassettes, 	 dient in Intrepid® 2F pesticide is methoxyfenozide. The
	
and novel transcription factors described above) may, option- 	 methoxyfenozide compound was found to enhance RF2a
	
ally, be used in connection with a plurality of inducible pro-	 expression by interaction with the expressed VGE receptor
	
moters. In certain preferred embodiments, the present inven-	 and chimeric promoter comprising Ga14 DNA binding sites
tion is used in connection with chemically-inducible 4o described above. Accordingly, the methoxyfenozide com-
	
promoters. The following provides a non-limiting example of 	 pound served as an expression-inducing ligand, which func-
such embodiments of the present invention. 	 tioned to enhance expression of the RF2a-encoding sequence.
	
Plasmid construction The coding sequence of RF2a was 	 Upon application of the methoxyfenozide compound, RF2a
	
released from a cassette comprising the CaMV 35S promoter 	 expression was induced, thereby allowing RF2a to interact
operably linked to a RF2a-encoding sequence, p35S::RF2a, 45 with the Box II-containing E fragment, which was operably
	
through EcoRI/BamHI restriction. The excised DNA frag- 	 linked to the uidA sequence.
	
ment was made blunt by Klenow treatment in the presence of 	 Analysis of GUS activity The relative GUS activity in the
	
dNTPs. The resulting fragment was then cloned into plasmid	 transgenic Arabidopsis plants described herein was measured
	
RH3 (Rohm & Haas, Philadelphia, Pa.) to replace a luciferase	 by histochemical analysis. In each of sixty-seven (67) T,
coding sequence. The RH3 plasmid originally comprised a 50 transgenic Arabidopsis plants carrying E:GUS, 5G35Sm:
	
luciferase coding sequence downstream of a chimeric pro- 	 RF2a and Cs:VGE, the 1:8000 dilution of Intrepid® 2F
	
moter that included five (5) repeats of the Ga14 DNA binding 	 described above was applied to one true leaf, while the other
	
site and the CaMV 35S minimal promoter. The chimeric	 leaves in each plant remained untreated. Two-days following
	
promoter comprising the Ga14 DNA binding sites and the	 the application of the expression-inducing ligand, the treated
CaMV 35S minimal promoter is set forth in SEQ ID NO: 92. 55 leaf together with one untreated leaf from the same plant were
	
The RF2a-encoding sequence, together with the chimeric 	 detached and subjected to GUS staining.
	
promoter, were released from the resultant plasmid through 	 More particularly, the plant leaf tissues mentioned above
	
Sal I/BamHI restriction sites and insertedinto vectorpSL301, 	 were submerged in stain solution containing 1 mM of X-Gluc
	
whichwas previously linearized using the same set ofrestric- 	 in 100 mM sodium phosphate buffer (pH 7.0), 2 mM K,Fe
tion enzymes. The chimeric promoter and RF2a-encoding 60 (CN) 6, 2 mM K4Fe(CN)61 0.1% Triton X-100 and 20%
	
sequence are referred to herein as the "5G35Sm:RF2a"	 methanol (Petruccelli et al. 2001). In order to evaluate GUS
	
sequence. The resulting plasmid is identified herein as "pSL- 	 activity, several substrates are available. The most commonly
5G35Sm:RF2a." 	 used are 5-bromo-4-chloro-3-indolyl glucuronide (X-Gluc)
	
A DNA fragment containing the uidA gene operably linked	 and 4-methyl-umbelliferyl-glucuronide (MUG). The reac-
to the E fragment of the RTBV promoter was released from 65 tion of GUS with X-Gluc generates a blue color that is useful
	
pE:GUS through HindIII (blunted)/BamHI restriction. The 	 in histochemical detection of uidA gene activity. uidA activ-
	
excised fragment was then inserted upstream of the 5G35 Sm: 	 ity (GUS expression) is shown in the "Treated" leaf in FIG. 21
US 7,847,064 B2
35
by a grey, shaded color (compared to the predominately
white, "Untreated" leaf). For quantification purposes, MUG
is preferred, because the umbelliferyl radical emits fluores-
cence under UV stimulation, thus providing better sensitivity
and easy measurement by fluorometry. 	 5
Following vacuum infiltration of the previously submerged
leaf tissues, the tissues were incubated at 37° C. overnight
before washing with 70% (v/v) ethanol. In approximately
70% of the sixty-seven (67) plants analyzed, a constitutive
GUS expression pattern was observed in the methoxyfeno- io
cide-treated leaves. See FIG. 21 for a subjective comparison
of GUS expression in "Treated" and "Untreated" leaf tissue.
Quantitative analysis of GUS activity in methoxyfenozide-
treated plants was then conducted. T z generation transgenic
Arabidopsis plants from twelve T, primary lines were 15
selected on hygromycin selection medium. The lines are indi-
vidually referred to herein as EGaV-3, EGaV-5, EGaV-17,
EGaV-31, EGaV-50, EGaV-51, EGaV-56, EGaV-59, EGaV-
63, EGaV-70, EGaV-72, and E:GUS. For each primary line,
eighteen 14-day-old Tz plants were used. Nine plants, in three 20
groups, were cultured in MS hydroponic solution containing
a 1:8000 dilution of Intrepid 2F8. The remaining nine plants,
in three groups, were left untreated and served as controls.
After a three-day treatment period, the GUS activity in leaf
tissue samples from each plant was quantified. 	 25
Each sample of leaf tissue was ground to a powder in liquid
nitrogen. Total protein was extracted from each sample by
adding 300 µl of extraction buffer. Protein concentration of
each sample was quantified using a Dc Protein Assay Kit
(Bio-Rad Laboratories, Hercules, Calif.). GUS activity of 30
each sample was quantified using MUG as substrate and a
fluorescence spectrometer (Molecular Devices, Sunnyvale,
Calif.) (Petruccelli et al., 2001). Among the twelve lines, the
results showed that methoxyfenozide (Intrepid 2F(k) treat-
ment induced GUS expression by an average of 2.1 fold in 35
relation to untreated, control plants (FIG. 22A).
Western Blot analysis To detect the expression of RF2a
in select transgenic lines described above, either treated or
untreated with Intrepid® 2F, 40 µg of protein of each sample
was separated by 12% SDS-PAGE and blotted onto nitrocel- 40
lulose membrane. TheArabidopsis lines analyzedby Western
Blot included EGaV50, EGaV59, EGaV63, EGaV70,
EGaV72, and E: GUS. Rabbit anti-RF2a antibodies were first
applied to the nitrocellulose membrane, incubated, and
washed. Next, anti-rabbit horseradish peroxidase-conjugated 45
secondary antibodies were applied to the membrane, incu-
bated, and washed. Finally, SuperSignal substrate (Pierce,
Rockford, Ill.) was applied to the membrane, incubated, and
washed.
After the substrate was applied to the membrane, the RF2a 50
bands were revealed (See FIG. 22B, top panel). The presence
of RF2a in the leaf tissue samples that were treated with
methoxyfenozide (Intrepid 2F(k) correlates with the induc-
tion of GUS expression observed in similarly treated leaf
tissues (described above).	 55
Example 14
Fragments of the Acidic Domain of RF2a
60
To further demonstrate the versatility of the present gene
expression system and, more particularly, the scope of differ-
ent peptides encompassed by the novel transcription factors
of the invention, fragments of the acidic domain of RF2a were
used to construct several novel transcription factors. More 65
specifically, transcription factors comprising residues 49
through 116; 49 through 96; 68 through 116; or 68 through 96
36
of SEQ ID NO:4 (the full-length RF2a transcription factor)
were constructed (35S-A-2C7 (comprising the full acidic
domain of RF2a); 35S-A1-2C7; 35S-A2-2C7; and 35S-A3-
2C7, respectively).
The foregoing transcription factors further comprised the
synthetic 2C7 protein (SEQ ID NO:75) the synthetic zinc
finger DNA-binding domain described above that specifically
binds to the 2C7 DNA-binding site (SEQ ID NO:74). The
various fragments of the acidic domain of RF2a were fused to
the N-terminus of the 2C7 DNA-binding domain. The gene
expression cassettes encoding such transcription factors
included a CaMV 35S promoter operatively linked to a
sequence encoding the respective fragment of the acidic
domain, which was operatively linked to a sequence encoding
the 2C7 DNA-binding domain (SEQ ID NO:76). The cas-
settes are referred to in this example collectively or individu-
ally as "effector construct."
The various "effector constructs" were prepared using
PCR-based procedures and a plasmid (template DNA) con-
taining a coding sequence for the entire RF2a acidic domain
(SEQ ID NO: 9) operably linked to a coding sequence (SEQ
ID NO: 76) for the 2C7 zinc finger DNA-binding domain
(SEQ ID NO: 75). The various fragments of the RF2a acidic
domain were amplified from such plasmid using the primer
pairs listed in Table 7B below (which are defined in Table
7A).
TABLE 7A
Location within RF2a/
Primer Name SEQ ID NO Restriction Enzyme Site
A-2C7 5' SEQ ID NO: 94 Residue 49/BgIII site
A-2C7 3' SEQ ID NO: 95 Residue 116/BamHI site
A68-2C7 5' SEQ ID NO: 96 Residue 68/Bg/II
A96-2C7 3' SEQ ID NO: 97 Residue 96/BamHI site
TABLE 7B
Effector Construct Location within RF2a 5' Primer	 3' Primer
35S-A-2C7 Residues 49-116 A-2C7 5'	 A-2C7 3'
35S-A1-2C7 Residues 49-96 A-2C7 5'	 A96-2C7 3'
35S-A2-2C7 Residues 68-116 A68-2C7 5'	 A-2C7 3'
35S-A3-2C7 Residues 68-96 A68-2C7 5'	 A96-2C7 3'
The restriction sites listed in Table 7A above, Bg1II and
BamHI, were used to substitute the various fragments of the
acidic domain in place of the full acidic domain.
The "reporter construct," C7er2::GUS, carried the uidA
coding sequence located downstream of a promoter compris-
ing 6x2C7-binding sites ligated with the minimal promoter of
erbB-2 ("er2") (a.k.a. the retinoblastoma minimal promoter).
35S:2C7 encoded the 2C7 protein without an activation
domain, i.e., the acidic domain of RF2a or a fragment thereof,
and served as a control.
Protoplasts isolated from suspension cultures of BY-2 cells
(Nicotiana tabacum L., cv. BrightYellow-2) were transfected
via electroporation using procedures well-known in the art.
More specifically, the protoplasts were co-transfected with a
mixture of DNAs, including 5 ltg of reporter construct, 20 ltg
of a single effector construct (i.e., 35S-A-2C7, 35S-A1-2C7,
35S-A2-2C7, or 35S-A3-2C7), 5 ltg of an internal control
plasmid comprising a CaMV 35S promoter operatively
TABLE 8-continued
Location within RF2a FIG. 24(B) Reference Example 14 Reference
5	 Residues 68-116 355-68/116-2C7 Effector 35S-A2-2C7
Residues 68-96 35S-68/96-2C7 Effector 35S-A3-2C7
Residues 49-84* 35S-49/84-2C7
Residues 56-84* 35S-56/84-2C7
*Not shown in the previous Example 14
10
The effector constructs identified in Table 8 were elec-
troporated into BY-2 protoplasts as described in Example 14
above (along with the "reporter constructs" described
therein), with the exception that a discharge of 125 µF and
15 300V (through disposable 0.4 cm cuvettes) was used. Each
transient assay was repeated three times per experiment and
each experiment was conducted three times. Quantification of
GUS activity was carried out as described in Example 14
above.
20
As shown in FIG. 24(B), the results confirm that the acidic
domain of RF2a, and certain fragments thereof, represent
strong activators of gene expression and, furthermore, that the
fragment comprising residues 56-84 (relative to the full RF2a
25 protein) produce an activation effect as strong as the full
acidic domain.
Location within RF2a FIG. 24(B) Reference Example 14 Reference
Residues 49-116	 35S-49/116-2C7	 Effector 35S-A-2C7
Residues 49-96	 35S-49/96-2C7	 Effector 35S-A1-2C7
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linked to a GFP-encoding sequence, and 10 µg of herring
sperm DNA. The electroporation was conducted using a dis-
charge of 500 µF and 250 V through disposable 0.4 cm
cuvettes. Each transient assay was repeated three times per
experiment and each experiment was conducted two times.
In addition, electroporation was carried out as described
above without effector construct (negative control); without
reporter construct (negative control); or, in place of effector
construct, 35S-VP16 (a sequence encoding the activation
domain of the herpes simplex virus) (positive control).
Quantification of GUS activity in the transfected proto-
plasts was carried out 24 hours after transfection. More spe-
cifically, transfected protoplasts were lysed by freezing and
thawing in GUS extraction buffer (pH 7.7), centrifuged, and
the supernatants used for GUS enzyme assays. GUS activity
was determined by the method of Jefferson et al. (1987). GFP
activity was determined by quantifying fluorescence using
490 nm excitation wavelength and 530 nm emission wave-
length using a standard fluorometer (Molecular Devices,
Sunnyvale, Calif.).
The relative GUS activity in the BY-2 protoplasts contain-
ing reporter and effector construct, as well as the controls
described above, is shown in FIG. 23. The results shown in
FIG. 23 include GUS enzyme activity compared with GFP
activity and are expressed as relative fluorescent units per
second. The results are the average of three independent
transfections (with standard deviations). The results show
that the acidic domain of RF2a is a strong activator of gene
expression (35S-A-2C7) and, more specifically, fragments of
the acidic domain comprising residues 49-96 of SEQ ID
NO:4 (35S-A1-2C7) encompass the majority of such activity.
Example 15
Additional Fragments of the Acidic Domain of RF2a
The results of the previous Example 14 were confirmed in
this Example 15 and, furthermore, the activity of two addi-
tional fragments of the RF2a acidic domain were measured.
The 35S-A-2C7, 35S-A1-2C7, 35S-A2-2C7, and 35S-A3-
2C7 effector constructs were prepared as described in
Example 14 above. The two additional fragments tested in
this Example comprised residues 49-84 (referred to herein as
"35S-49/84-2C7") and 56-84 (referred to herein as "35S-56/
84-2C7") of the full-length RF2a protein (SEQ ID NO:4).
The 35S-56/84-2C7 construct was amplified from the plas-
mid template described in Example 14 using primer pairs
represented by SEQ ID NO:98 and SEQ ID NO:99, whereas
the 35S-49/84-2C7 construct was amplified from such plas-
mid using primer pairs represented by SEQ ID NO:94 and
SEQ ID NO:99.
Table 8 below provides a summary of the effector con-
structs tested in this Example, as well as cross references to
the designations given to those effectors described in
Example 14 above.
TABLES
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Example 16
30	 Expression Activation of the RF2a Acidic Domain in
Plants
This Example further demonstrates that the acidic domain
35 of RF2a may be transferred to unrelated proteins (e.g., DNA
binding domains) and used to regulate gene expression in
plants. In this example, effector constructs were prepared that
comprised the CaMV 35S promoter operatively linked to a
nucleic acid sequence (SEQ ID NO:9) encoding the acidic
40 domain of RF2a (SEQ ID NO:6), which was operatively
linked to a sequence encoding the synthetic 2C7 protein (SEQ
ID NO:75). The reporter construct used in this Example
included the minimal retinoblastoma promoter erbB, which
comprised the 2C7 DNA-binding site (SEQ ID NO:74)
45 (wherein the chimeric promoter is also referred to herein as
"C7er"), operably linked to the uidA gene (i.e., GUS-encod-
ing sequence). The control construct used in this Example
included the enhanced 35S promoter operably linked to the
2C7 zinc finger protein (without the acidic domain of RF2a or
50 any fragment thereof).
The effector constructs are referred to in FIG. 26 as
"C7erG/35S-A2C7" followed by the subject plant line,
namely, 5-5, 9-8, 11-1, or 12-16. The control constructs are
55 referred to in FIG. 26 as "C7erG/35S-2C7."A second control,
including only the reporter construct, is referred to as "C7er:
G" (followed by the subject plant line) in FIG. 26.
The foregoing effector, reporter, and/or control constructs
were transfected into Arabidopsis thaliana plants. More par-
60 ticularly, plasmids containing the effector, reporter, and/or
control constructs were transferred by electroporation into A.
tumefaciens strain GV3101. Agrobacterium isolates that con-
tained the respective plasmid were used to transform A.
thaliana Col-0 by the standard floral dip method (Clough and
65 Bent, 1998). T, seeds were germinated in Murashige and
Skoog medium (Murashige and Skoog, 1962) containing glu-
fosinate ammonium (10 mg/L) and seedlings that survived
US 7,847,064 B2
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the selection were grown in soil in a growth chamber. Leaves
from six week old plants were collected for GUS expression
analysis.
The leaves were homogenized, added to GUS extraction
buffer, and subsequently centrifuged. The resulting superna-
tants were used to determine enzymatic activity by the
method of Jefferson et al. (1987). The enzyme activity was
determined by quantifying fluorescence using a spectrofluo-
rometer (Spectramax Gemini, Molecular Devices Corp.,
Sunnyvale, Calif.), with a 365 nm excitation wavelength and
455 nm emission wavelength.
As shown in FIG. 26, the various effector constructs acti-
vated and/or enhanced GUS expression in the A. thaliana
plants (relative to the C7erG/35S-2C7 controls). In addition,
FIG. 26 shows that each plant line/effector construct combi-
40
minus ("GEA5x2"), (iv) a sequence encoding an A5 trimer
operably linked to a sequence encoding GE (oriented to
express theA5 trimer at the N-terminus (` A5 x3GE") or C-ter-
minus ("GEA5 x3"), and (v) a sequence encoding an A5 tet-
5 rawer operably linked to a sequence encoding GE (oriented to
express the A5 tetramer at the C-terminus ("GEA5 x4"). The
foregoing effector constructs were prepared using standard
DNA cloning and PCR procedures, along with plasmids con-
taining sequences encoding the full length RF2a acidic
to domain (SEQ ID NO: 6) and VGE (SEQ ID NO: 100). Those
of ordinary skill in the art will appreciate, however, that such
effector sequences (and derivatives thereof) may also be con-
structed synthetically using standard procedures.
Table 9 below provides a summary of the various effector
15 constructs, and the amino acid sequences thereof (from the N-
to C-terminus), analyzed in this Example.
TABLE 9
Construct
(FIG. 27) Promoter Novel Transcription Factor Sequence
Termination
Sequence
VGE CsVMV SEQ ID NO: 107 (V) + SEQ ID NO: 103 (GE) Nos
AGE CsVMV SEQ ID NO: 6 (A) + SEQ ID NO: 103 (GE) Nos
A5GE CsVMV SEQ ID NO: 101 (A5) + SEQ ID NO: 103 (GE) Nos
A5 x 2GE CsVMV (2 x SEQ ID NO: 101 (A5)) + SEQ ID NO: 103 (GE) Nos
A5 x 3GE CsVMV (3 x SEQ ID NO: 101 (A5)) + SEQ ID NO: 103 (GE) Nos
GEA CsVMV SEQ ID NO: 103 (GE) + SEQ ID NO: 6 (A) Nos
GEA5 CsVMV SEQ ID NO: 103 (GE) + SEQ ID NO: 101 (A5) Nos
GEA5 x 2 CsVMV SEQ ID NO: 103 (GE) + (2 x SEQ ID NO: 101 (A5)) Nos
GEA5 x 3 CsVMV SEQ ID NO: 103 (GE) + (3 x SEQ ID NO: 101 (A5)) Nos
GEA5 x 4 CsVMV SEQ ID NO: 103 (GE) + (4 x SEQ ID NO: 101 (A5)) Nos
nation produced variable results albeit all well above the
expression levels observed in the C7erG/35S-2C7 controls.
Example 17
RF2a Acidic Domain Fragments/Ecdysone Receptor
Fusion Proteins
In this Example, fragments of the RF2a acidic domain and
the chimeric VGE receptor (SEQ ID NO: 100) were used to
create novel transcription factors. More particularly, the chi-
meric VGE receptor was mutated to replace the "V" domain
with (i) the full acidic domain of RF2a, (ii) a minimal acidic
domain of RF2a ("A5") (amino acids 56-84 relative to the full
RF2a protein) (SEQ ID NO: 101), or (iii) a dimer, trimer, or
tetramer of the A5 minimal acidic domain (at the N- and
C-termini, e.g., to create AGE and GEA proteins). As used
herein, the "V" domain of the VGE chimeric receptorrefers to
the VP16 acidic activation domain of the SV40 animal virus,
"G" refers to the DNA binding domain of the Gal4 protein
from Bakers yeast, and "E" refers to the ecdysone receptor
("EcR") from Cloristoneura fumiferana. The GE domain is
represented herein by SEQ ID N6:103 (and encoded by SEQ
ID NO: 104), while the E domain is represented by SEQ ID
NO: 105 (and encoded by SEQ ID NO: 106).
FIG. 27(A) provides a diagram of the various "effector"
constructs used in this Example (with the exception of the
constructs comprising a full RF2a acidic domain). As shown
therein, the effector constructs included the CsVMV pro-
moter (SEQ ID NO:67) operably linked to (i) a sequence
encoding the full VGE protein (the positive control), (ii) a
sequence encoding A5 operably linked to a sequence encod-
ing GE (oriented to express A5 at the N-terminus (`A5GE")
or C-terminus ("GEA5"), (iii) a sequence encoding an A5
dimer operably linked to a sequence encoding GE (oriented to
express the A5 dimer at the N-terminus (A5 x2GE") or C-ter-
FIG. 27(A) further shows a diagram of the reporter con-
struct, namely, 5XG-35S:GUS, which was transformed into
35 BY-2 protoplasts along with the effector constructs. As used
herein, "5XG" is represented by SEQ ID NO: 108 and refers
to a pentameric tandem repeat of the nucleic acid sequence
that is recognized by, and binds with, the Gal4 protein/domain
(from Bakers yeast) (SEQ ID NO: 107). "35S" refers to the
40 minimal CaMV 35S promoter (-4548). Of course, the GUS-
encoding uidA sequence was operably linked to the CaMV
35S promoter.
Protoplasts were co-transfected, by electroporation as
described in Example 14 above, with 5 µg of reporter con-
45 struct DNA, 20 µg of a single effector construct, 5 µg of a
35S-GFP plasmid, and 10 µg of herring sperm DNA. Meth-
oxyfenozide ("MOF") was provided to the transformed pro-
toplasts at a final dilution of 1:25,000 (providing a 2.452 µM
final concentration of MOF). Quantification of GUS activity
50 from protoplast extracts 24 hours after transfection was per-
formed.
The results of such quantification are shown in FIG. 27(B),
which are expressed as the amount of GUS enzyme activity
compared with GFP activity—expressed as relative fluores-
55 cent units per second. The results are the average of three
independent transfections+/–standard deviation. The pres-
ence of MOF is represented in FIG. 27(B) by "+I" (wherein
"I" means Inducer), whereas the absence of MOF is repre-
sented by "–P'. For example, ` AGE+I" represents protoplasts
60 transfected with the AGE effector construct and cultured in
the presence of MOF, whereas `AGE–P' represents proto-
plasts transfected with the AGE effector construct and cul-
tured in the absence of MOF.
As shown in FIG. 27(B), the fusion of the acidic domain of
65 RF2a at the amino-terminal position of GE activates GUS
expression in the presence of the MOF inducer. Although the
activation provided by the RF2a acidic domain (and frag-
US 7,847,064 B2
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ments thereof) was not as strong as that of VP16, those skilled
in the art will appreciate that the RF2a acidic domain (and
fragments thereof) produced a level of activation that is, at
least, comparable to that of VP16 (and induced less back-
ground).
In addition, as shown in FIG. 27(B), the presence of two
tandem repeats of A5 had an activation effect as strong as the
full acidic domain. Furthermore, as shown in FIG. 27(B),
proteins having the RF2a acidic domain (or fragment thereof)
at the N-terminus (e.g., AGE proteins) were shown to be more
active than proteins having the RF2a acidic domain (or frag-
ment thereof) at the C-terminus (e.g., GEA proteins).
Example 18
RF2a Acidic Domain/Ecdysone Receptor Fusion
Proteins in Plants
In this Example, Arabidopsis thaliana Col-0 plants were
transformed with A. tumefaciens bacterium (strain GV3101)
containing effector constructs comprising the CsVMV pro-
moter operably linked to a nucleic acid sequence (SEQ ID
NO: 104) encoding the GE protein, plus (i) a nucleic acid
sequence encoding the VP16 acidic activation domain of the
herpes simplex virus, (ii) a sequence (SEQ ID NO: 9) encod-
ing the full RF2a acidic domain, or (iii) a sequence (2xSEQ
ID NO: 102) encoding a dimer of the A5 minimal acidic
domain of RF2a (`A5A5"). The foregoing VP16 acidic
domain-, RF2a acidic domain-, and A5A5 domain-encoding
sequences were oriented to express such domains at the N-ter-
minal of the GE protein. FIG. 28 refers to these constructs as
VGE, AGE, and A5A5GE, respectively.
The foregoing effector constructs were prepared using
standard DNA cloning and PCR procedures, and plasmids
containing nucleic acid sequences encoding the VP16 acidic
domain, the full length RF2a acidic domain (SEQ ID NO: 6),
the A5A5 domain (2xSEQ ID NO: 101), and the GE domain
(SEQ ID NO: 103). Those of ordinary skill in the art will
appreciate, however, that such effector sequences (and
derivatives thereof) may also be constructed synthetically
using standard procedures. The reporter construct described
in Example 17 above, 5XG-35S:GUS, was used in this
Example.
Table 10 below provides a summary of the various effector
constructs, and the amino acid sequences thereof (from the N-
to C-terminus), analyzed in this Example.
TABLE 10
Construct	 Novel Transcription	 Termination
(FIG. 27)	 Promoter	 Factor Sequence	 Sequence
VGE	 CsVMV	 SEQ ID NO: 100	 Nos
AGE	 CsVMV	 SEQ ID NO: 6 (A) +	 Nos
SEQ ID NO: 103 (GE)
A5A5GE	 CsVMV	 (2 x SEQ ID NO: 101 (A5)) + Nos
SEQ ID NO: 103 (GE)
Next, plasmids containing the effector and reporter con-
structs described above were transferred by electroporation
into A. tumefaciens strain GV3101. Agrobacterium isolates
that contained the respective plasmids were used to transform
A. thaliana Col-0 using a standard floral dip method (Clough
and Bent, 1998). Seeds from the T, generation were collected
and germinated in Murashige and Skoog medium (Murashige
and Skoog, 1962) containing a selective component (hygro-
mycin B (30 ltg/mL).
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The seedlings that survived the selection were grown in soil
in a growth chamber and allowed to self-fertilize. Next, T2
generation seeds were collected and germinated in Murashige
and Skoog medium, which contained hygromycin B (30
5 ltg/mL). The seedlings that survived the selection in a 3:1
segregation pattern were grown in soil in a growth chamber
(under 12 hours of light/12 hours of dark per day, at 22° C.,
50% humidity).
10 Analysis of T, Generation Plants In this Example, 22 T,
plants were analyzed for methoxyfenozide (MOF) induced
gene expression. More particularly, leaf samples from each of
the 22 plants were taken before and after induction with MOF
(MOF was applied by drenching the soil with a 1:10,000
15 dilution of MOF (61.3 ltM of MOF) for 60 hours). The leaves
were homogenized and added to GUS extraction buffer. The
supernatants were analyzed for GUS enzymatic activity as
described in Example 16 above.
FIG. 28 shows the relative GUS activity of each plant
20 grown in the presence of MOF compared to the relative GUS
activity of each plant grown in the absence of MOK As shown
in FIG. 28, the fusion of the acidic domain of RF2a to the
amino-terminal position of the GE protein (`AGE'; middle
graph), or the presence of two tandem repeats of A5
25 ("A5A5GE"; bottom graph), activated GUS expression in the
presence of the MOF inducer as strong as VP16 ("WE"; top
graph).
Analysis of Tz Generation Plants A total of 16 different
plants from a T z generation plant line (having a segregation of
30 the reporter/effector constructs of 3:1), wherein each plant
contained a VGE, AGE, or A5A5GE effector construct, were
induced with MOF and analyzed for GUS activity (as
described above). Referring to FIG. 29, the VGE construct
was tested using plant line #11, the AGE construct was tested
35 using plant line #11, and the A5A5GE construct was tested
using plant line #18. As shown in FIG. 29, the fusion of the
acidic domain of RF2a to the amino-terminal position of the
GE protein ("AGE"; middle graph), or the presence of two
tandem repeats of A5 ("A5A5GE"; bottom graph), activated
40 GUS expression (in the T z generation plants) in the presence
of the MOF inducer as strong as VP16 ("WE"; top graph).
The many aspects and benefits of the invention are apparent
from the detailed description, and thus, it is intended for the
following claims to cover all such aspects and benefits of the
45 invention which fall within the scope and spirit of the inven-
tion. In addition, because numerous modifications and varia-
tions will readily occur to those skilled in the art, the claims
should not be construed to limit the invention to the exact
construction and operation illustrated and described herein.
50 Accordingly, all suitable modifications and equivalents
should be understood to fall within the scope of the invention
as claimed herein.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 109
<210> SEQ ID NO 1
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
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46
-continued
<400> SEQUENCE: 1
ccagtgtgcc cctgg	 15
<210> SEQ ID NO 2
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 2
ccagtgtggc gctgg	 15
<210> SEQ ID NO 3
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 3
ggagtgtgcc ccttc	 15
<210> SEQ ID NO 4
<211> LENGTH: 368
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 4
Met Asn Arg Glu Lys Ser Pro Ile Pro Gly Asp Gly Gly Asp Gly Leu
1	 5	 10	 15
Pro Pro Gin Ala Thr Arg Arg Ala Gly Pro Pro Ala Ala Ala Ala Ala
20	 25	 30
Ala Glu Tyr Asp Ile Ser Arg Met Pro Asp Phe Pro Thr Arg Asn Pro
35	 40	 45
Gly His Arg Arg Ala His Ser Glu Ile Leu Ser Leu Pro Glu Asp Leu
50	 55	 60
Asp Leu Cys Ala Ala Gly Gly Gly Asp Gly Pro Ser Leu Ser Asp Glu
65	 70	 75	 80
Asn Asp Glu Glu Leu Phe Ser Met Phe Leu Asp Val Glu Lys Leu Asn
85	 90	 95
Ser Thr Cys Gly Ala Ser Ser Glu Ala Glu Ala Glu Ser Ser Ser Ala
100	 105	 110
Ala Ala His Gly Ala Arg Pro Lys His Gin His Ser Leu Ser Met Asp
115	 120	 125
Glu Ser Met Ser Ile Lys Ala Glu Glu Leu Val Gly Ala Ser Pro Gly
130	 135	 140
Thr Glu Gly Met Ser Ser Ala Glu Ala Lys Lys Ala Val Ser Ala Val
145	 150	 155	 160
Lys Leu Ala Glu Leu Ala Leu Val Asp Pro Lys Arg Ala Lys Arg Ile
165	 170	 175
Trp Ala Asn Arg Gin Ser Ala Ala Arg Ser Lys Glu Arg Lys Met Arg
180	 185	 190
Tyr Ile Ala Glu Leu Glu Arg Lys Val Gin Thr Leu Gin Thr Glu Ala
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48
-continued
195	 200	 205
Thr Thr Leu Ser Ala Gin Leu Ala Leu Leu Gin Arg Asp Thr Ser Gly
210	 215	 220
Leu Thr Thr Glu Asn Ser Glu Leu Lys Leu Arg Leu Gin Thr Met Glu
225	 230	 235	 240
Gin Gin Val His Leu Gin Asp Ala Leu Asn Asp Thr Leu Lys Ser Glu
245	 250	 255
Val Gin Arg Leu Lys Val Ala Thr Gly Gin Met Ala Asn Gly Gly Gly
260	 265	 270
Met Met Met Asn Phe Gly Gly Met Pro His Gin Phe Gly Gly Asn Gin
275	 280	 285
Gin Met Phe Gin Asn Asn Gin Ala Met Gin Ser Met Leu Ala Ala His
290	 295	 300
Gin Leu Gin Gin Leu Gin Leu His Pro Gin Ala Gin Gin Gin Gin Val
305	 310	 315	 320
Leu His Pro Gin His Gin Gin Gin Gin Pro Leu His Pro Leu Gin Ala
325	 330	 335
Gin Gin Leu Gin Gin Ala Ala Arg Asp Leu Lys Met Lys Ser Pro Met
340	 345	 350
Gly Gly Gin Ser Gin Trp Gly Asp Gly Lys Ser Gly Ser Ser Gly Asn
355	 360	 365
<210> SEQ ID NO 5
<211> LENGTH: 329
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 5
Met Gin Glu Pro Lys His Thr Asp Pro Ala Ala Met Arg Gly Ala His
1	 5	 10	 15
His Arg Arg Ala Arg Ser Glu Val Ala Phe Arg Leu Pro Asp Asp Leu
20	 25	 30
Asp Leu Gly Gly Gly Gly Ala Gly Ala Phe Asp Glu Ile Gly Ser Glu
35	 40	 45
Asp Asp Leu Phe Ser Thr Phe Met Asp Ile Glu Lys Ile Ser Ser Gly
50	 55	 60
Pro Ala Ala Ala Gly Gly Ser Asp Arg Asp Arg Ala Ala Glu Thr Ser
65	 70	 75	 80
Ser Pro Pro Arg Pro Lys His Arg His Ser Ser Ser Val Asp Gly Ser
85	 90	 95
Gly Phe Phe Ala Ala Ala Arg Lys Asp Ala Ala Ala Ser Leu Ala Glu
100	 105	 110
Val Met Glu Ala Lys Lys Ala Met Thr Pro Glu Gin Leu Ser Asp Leu
115	 120	 125
Ala Ala Ile Asp Pro Lys Arg Ala Lys Arg Ile Leu Ala Asn Arg Gin
130	 135	 140
Ser Ala Ala Arg Ser Lys Glu Arg Lys Ala Arg Tyr Ile Thr Glu Leu
145	 150	 155	 160
Glu Arg Lys Val Gin Thr Leu Gin Thr Glu Ala Thr Thr Leu Ser Ala
165	 170	 175
Gin Leu Thr Leu Phe Gin Arg Asp Thr Thr Gly Leu Ser Ala Glu Asn
180	 185	 190
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-continued
Ala Glu Leu Lys Ile Arg Leu Gin Ala Met Glu Gin Gin Ala Gin Leu
195	 200	 205
Arg Asp Ala Leu Asn Asp Ala Leu Lys Gin Glu Leu Glu Arg Leu Lys
210	 215	 220
Leu Ala Thr Gly Glu Met Thr Asn Ser Asn Glu Thr Tyr Ser Met Gly
225	 230	 235	 240
Leu Gin His Val Pro Tyr Asn Thr Pro Phe Phe Pro Leu Ala Gin His
245	 250	 255
Asn Ala Ala Arg Gin Asn Gly Gly Thr Gin Leu Pro Pro Gin Phe Gin
260	 265	 270
Pro Pro Arg Pro Asn Val Pro Asn His Met Leu Ser His Pro Asn Gly
275	 280	 285
Leu Gin Asp Ile Met Gin Gin Asp Pro Leu Gly Arg Leu Gin Gly Leu
290	 295	 300
Asp Ile Ser Lys Gly Pro Leu Val Val Lys Ser Glu Ser Ser Ser Ile
305	 310	 315	 320
Ser Ala Ser Glu Ser Ser Ser Thr Phe
325
<210> SEQ ID NO 6
<211> LENGTH: 67
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 6
Met Gly His Arg Arg Ala His Ser Glu Ile Leu Ser Leu Pro Glu Asp
1	 5	 10	 15
Leu Asp Leu Cys Ala Ala Gly Gly Gly Asp Gly Pro Ser Leu Ser Asp
20	 25	 30
Glu Asn Asp Glu Glu Leu Phe Ser Met Phe Leu Asp Val Glu Lys Leu
35	 40	 45
Asn Ser Thr Cys Gly Ala Ser Ser Glu Ala Glu Ala Glu Ser Ser Ser
50	 55	 60
Ala Ala Ala
65
<210> SEQ ID NO 7
<211> LENGTH:	 1107
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE:	 7
atgaacaggg agaaatcccc gatcccggga gacggcggcg acgggttgcc gccgcaggcc 60
acccgccggg cgggccctcc ggcggcggcg gcggcggcgg agtacgacat cagccgcatg 120
ccggatttcc cgacgaggaa ccccggccac aggcgcgccc actccgagat cctgagcctc 180
cccgaggacc tcgacctgtg cgcggccggc ggcggcgacg ggccgtcgct gtcggacgag 240
aacgacgagg agctcttctc catgttcctc gacgtggaga agctgaacag cacgtgcggg 300
gcgtcgtcgg aggcggaggc ggagtcgtcg tccgccgccg cccatggagc gaggccgaag 360
caccagcaca gcctgtccat ggatgagtcg atgtcgatca aggctgagga gctcgtcggg 420
gcgtcgcccg ggacggaggg gatgtcgtcg gcggaggcca agaaggccgt gtccgcggtc 480
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aagctcgccg agcttgctct cgtcgatccc aagagggcga aaaggatttg ggctaacaga 	 540
caatctgcgg caagatcaaa ggaaaggaaa atgcgatata ttgctgaact tgagcgcaag 	 600
gtgcaaaccc tgcaaacaga agcaacaaca ctgtcagccc agttggcact gctacagaga 	 660
gataccagtg ggctaactac tgagaatagt gaactgaagc tacgtctgca gaccatggag 	 720
cagcaagtcc acttgcaaga tgctttgaat gacaccctga agtctgaggt tcagcggctt 	 780
aaggttgcaa ccggtcaaat ggcgaatggt ggagggatga tgatgaactt cggtggcatg 	 840
ccacaccaat tcggaggcaa ccagcagatg ttccagaaca accaggccat gcaatctatg 	 900
ctggcagcac accagctgca acagctccag cttcatcctc aggctcagca gcagcaggtg 	 960
ctgcaccctc agcatcagca gcagcagcca ttgcaccctc tacaagcgca gcagctccag 	 1020
caggcggcac gagacctcaa gatgaaatcg ccgatgggcg gccagagcca gtggggagat 	 1080
ggcaagtcag gaagcagcgg caactga	 1107
<210> SEQ ID NO 8
<211> LENGTH:	 990
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE:	 8
atgcaggagc caaagcacac cgatccggcg gccatgcgcg gggcgcacca ccgccgggcc 60
agatctgagg tcgccttccg cctgcccgac gacctcgacc tcggcggcgg cggcgcgggg 120
gcgttcgacg agatcggctc cgaggacgac ctcttctcca ccttcatgga catcgagaag 180
atctcctccg gccccgccgc cgcggggggc tccgaccggg accgcgccgc ggagacgtcc 240
tcgccgccgc gccccaagca ccgccacagc agctccgtcg acggctccgg gttcttcgcc 300
gccgcgcgga aggacgccgc cgcatcgctg gcggaggtca tggaggctaa gaaggccatg 360
acccccgagc agctctccga tctcgccgcc atcgacccca agcgcgccaa aagaattctg 420
gcgaacagac aatctgcagc tcggtcaaaa gagagaaaag ctcgttacat aacagaactt 480
gagcggaagg ttcaaactct tcagactgaa gccactactc tctcagcaca actcacacta 540
tttcagagag acacaactgg gctttctgca gaaaatgcag agctcaagat acggttgcag 600
gccatggaac aacaggctca actgcgagat gctctgaatg atgcactaaa gcaggaactg 660
gagaggctta agctcgctac tggtgagatg acaaattcca atgagacata tagcatggga 720
ctgcaacatg tcccatacaa cacccctttc ttccctctcg cccagcataa tgcagcccgc 780
cagaacggtg gaacccagtt gccaccacaa ttccaaccac cccgtcctaa tgtgcccaat 840
cacatgctat cccatccaaa cggtttgcaa gatatcatgc agcaagaccc tcttggccgg 900
cttcagggtt tggacatcag caaagggcct ctagttgtga aatcagagag cagctcgatc 960
tctgcaagtg aaagcagcag caccttctaa 990
<210> SEQ ID NO 9
<211> LENGTH: 201
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 9
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atgggccaca ggcgcgccca ctccgagatc ctgagcctcc ccgaggacct cgacctgtgc 60
gcggccggcg gcggcgacgg gccgtcgctg tcggacgaga acgacgagga gctcttctcc 120
atgttcctcg acgtggagaa gctgaacagc acgtgcgggg cgtcgtcgga ggcggaggcg 180
gagtcgtcgt ccgccgccgc c 201
<210> SEQ ID NO 10
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 10
ctccttatat actggagttc attatacact cttac	 35
<210> SEQ ID NO 11
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 11
gtaagagtgt ataatgaact ccagtatata aggag 	 35
<210> SEQ ID NO 12
<211> LENGTH:	 209
<212> TYPE: DNA
<213> ORGANISM: Rice tungro bacilliform virus
<400> SEQUENCE:	 12
acgaatcaat aaagaaggac cagaagatat aaagctggaa catcttcaca tgctaccaca 60
tggctagcat ctttacttta gcatctctat tattgtaaga gtgtataatg accagtgtgc 120
ccctggactc cagtatataa ggagcaccag agtagtgtaa tagatcatcg atcaagcaag 180
cgagagctca aacttctaag agagcaaga 209
<210> SEQ ID NO 13
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 13
gatttcacgg gttggggttt cta	 23
<210> SEQ ID NO 14
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 14
tcattccagg ggcacactgg atacactctt acaataa	 37
<210> SEQ ID NO 15
<211> LENGTH: 37
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<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 15
tgtatccagt gtgcccctgg aatgaactcc agtatat	 37
<210> SEQ ID NO 16
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 16
atacaccagg ggcacactgg ctcttacaat aatagag	 37
<210> SEQ ID NO 17
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 17
aagagccagt gtgcccctgg tgtataatga actccag	 37
<210> SEQ ID NO 18
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 18
caataccagg ggcacactgg atagagatgc taaagta	 37
<210> SEQ ID NO 19
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 19
tctatccagt gtgcccctgg tattgtaaga gtgtata	 37
<210> SEQ ID NO 20
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 20
atagaccagg ggcacactgg gatgctaaag taaagat	 37
<210> SEQ ID NO 21
<211> LENGTH: 37
<212> TYPE: DNA
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<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 21
gcatcccagt gtgcccctgg tctattattg taagagt	 37
<210> SEQ ID NO 22
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 22
tgctaccagg ggcacactgg gccatgtggt agcatgt	 37
<210> SEQ ID NO 23
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 23
atggcccagt gtgcccctgg tagcatcttt actttag	 37
<210> SEQ ID NO 24
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 24
gcatgccagg ggcacactgg tgaagatgtt ccagctt	 37
<210> SEQ ID NO 25
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 25
cttcaccagt gtgcccctgg catgctacca catggct	 37
<210> SEQ ID NO 26
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 26
tggtcccagg ggcacactgg cttctttatt gattcgt	 37
<210> SEQ ID NO 27
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
US 7,847,064 B2
59	 60
-continued
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 27
agaagccagt gtgcccctgg gaccagaaga tataaag	 37
<210> SEQ ID NO 28
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 28
tgatcaaagc ttccagtgtg cccctggacg aatcaataaa gaag 	 44
<210> SEQ ID NO 29
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 29
tgatcaaagc ttccagtgtg cccctggacg aatcaataaa gaag 	 44
<210> SEQ ID NO 30
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 30
ctctgccagg ggcacactgg gtgctcctta tatactg	 37
<210> SEQ ID NO 31
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 31
agcacccagt gtgcccctgg cagagtagtg taataga	 37
<210> SEQ ID NO 32
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 32
ttacaccagg ggcacactgg ctactctggt gctcctt	 37
<210> SEQ ID NO 33
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
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<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 33
agtagccagt gtgcccctgg tgtaatagat catcgat	 37
<210> SEQ ID NO 34
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 34
ttgctccagg ggcacactgg tgatcgatga tctatta	 37
<210> SEQ ID NO 35
<211> LENGTH: 37
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 35
gatcaccagt gtgcccctgg agcaagcgag agctcaa 	 37
<210> SEQ ID NO 36
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 36
gatttcacgg gttggggttt cta	 23
<210> SEQ ID NO 37
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 37
tgatcaaagc ttccagtgtg cccctggtcg caagaccctt cctc	 44
<210> SEQ ID NO 38
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 38
tgatcaaagc ttccagtgtg cccctggatc cttcgcaaga ccct	 44
<210> SEQ ID NO 39
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
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created by the inventors.
<400> SEQUENCE: 39
tgatcaaagc ttccagtgtg cccctgggac gcacaatccc acta 	 44
<210> SEQ ID NO 40
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 40
tgatcaaagc ttccagtgtg cccctggggg atgacgcaca atcc	 44
<210> SEQ ID NO 41
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 41
tgatcaaagc ttccagtgtg cccctggatc tccactgacg taag 	 44
<210> SEQ ID NO 42
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 42
tgatcaaagc ttccagtgtg cccctgggtg atatctccac tgac	 44
<210> SEQ ID NO 43
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 43
tgatcaaagc ttatccttcg caagaccct	 29
<210> SEQ ID NO 44
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 44
tgatcaaagc ttgggatgac gcacaatcc	 29
<210> SEQ ID NO 45
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
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<400> SEQUENCE: 45
tgatcaaagc ttgtgatatc tccactgac	 29
<210> SEQ ID NO 46
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 46
gccgcccata tggagaagat gaacagggag aaatcc	 36
<210> SEQ ID NO 47
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 47
gccgcccata tggagaagat gggccacagg cgc	 33
<210> SEQ ID NO 48
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 48
gccgcccata tggagaagat gtccgccgcc gcc	 33
<210> SEQ ID NO 49
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 49
cgcggatcct cagttgccgc tgcttcctga	 30
<210> SEQ ID NO 50
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 50
cgcggatcct cagtgtggca tgccaccgaa	 30
<210> SEQ ID NO 51
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
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<400> SEQUENCE: 51
tgatcaaagc ttccagtgtg cccctggtcg caagaccctt cctc	 44
<210> SEQ ID NO 52
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 52
gatttcacgg gttggggttt cta	 23
<210> SEQ ID NO 53
<211> LENGTH: 44
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 53
tgatcaaagc ttccagtgtg cccctggtcg caagaccctt cctc	 44
<210> SEQ ID NO 54
<211> LENGTH: 48
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 54
Met Asn Arg Glu Lys Ser Pro Ile Pro Gly Asp Gly Gly Asp Gly Leu
1	 5	 10	 15
Pro Pro Gin Ala Thr Arg Arg Ala Gly Pro Pro Ala Ala Ala Ala Ala
20	 25	 30
Ala Glu Tyr Asp Ile Ser Arg Met Pro Asp Phe Pro Thr Arg Asn Pro
35	 40	 45
<210> SEQ ID NO 55
<211> LENGTH: 87
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 55
Met Gin Phe Gly Gly Asn Gin Gin Met Phe Gin Asn Asn Gin Ala Met
1	 5	 10	 15
Gin Ser Met Leu Ala Ala His Gin Leu Gin Gin Leu Gin Leu His Pro
20	 25	 30
Gin Ala Gin Gin Gin Gin Val Leu His Pro Gin His Gin Gin Gin Gin
35	 40	 45
Pro Leu His Pro Leu Gin Ala Gin Gin Leu Gin Gin Ala Ala Arg Asp
50	 55	 60
Leu Lys Met Lys Ser Pro Met Gly Gly Gin Ser Gin Trp Gly Asp Gly
65	 70	 75	 80
Lys Ser Gly Ser Ser Gly Asn
85
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<210> SEQ ID NO 56
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 56
gccagatcta tgggccacag gcgcgccc	 28
<210> SEQ ID NO 57
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 57
cgcggatcct ccatgggcgg cggcg	 25
<210> SEQ ID NO 58
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 58
gccagatcta tgaacaggga gaaatcccc	 29
<210> SEQ ID NO 59
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 59
cgcggatccg gggttcctcg tcgggaa	 27
<210> SEQ ID NO 60
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 60
gccagatcta tgcaattcgg aggcaaccag c	 31
<210> SEQ ID NO 61
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 61
cgcggatccg ttgccgctgc ttcctga	 27
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<210> SEQ ID NO 62
<211> LENGTH:	 775
<212> TYPE: DNA
<213> ORGANISM: Rice tungro bacilliform virus
<400> SEQUENCE:	 62
agatcttcta caaaagggag tagtaatatt taatgagctt gaaggaggat atcaactctc 60
tccaaggttt attggagacc tttatgctca tggttttatt aaacaaataa acttcacaac 120
caaggttcct gaagggctac cgccaatcat tgcggaaaaa cttcaagact ataagttccc 180
tggatcaaat accgtcttaa tagaacgaga gattcctcgc tggaacttca atgaaatgaa 240
aagagaaaca cagatgagga ccaacttata tatcttcaag aattatcgct gtttctatgg 300
ctattcacca ttaaggccat acgaacctat aactcctgaa gaatttgggt ttgattacta 360
cagttgggaa aatatggttg atgaagacga aggagaagtt gtatacatct ccaagtatac 420
taagattatc aaagtcacta aagagcatgc atgggcttgg ccagaacatg atggagacac 480
aatgtcctgc accacatcaa tagaagatga atggatccat cgtatggaca atgcttaaag 540
aagctttatc aaaagcaact ttaagtacga atcaataaag aaggaccaga agatataaag 600
ctggaacatc ttcacatgct accacatggc tagcatcttt actttagcat ctctattatt 660
gtaagagtgt ataatgacca gtgtgcccct ggactccagt atataaggag caccagagta 720
gtgtaataga tcatcgatca agcaagcgag agctcaaact tctaagagag caaga 775
<210> SEQ ID NO 63
<211> LENGTH:	 209
<212> TYPE: DNA
<213> ORGANISM: Rice tungro bacilliform virus
<400> SEQUENCE:	 63
acgaatcaat aaagaaggac cagaagatat aaagctggaa catcttcaca tgctaccaca 60
tggctagcat ctttacttta gcatctctat tattgtaaga gtgtataatg accagtgtgg 120
cgctggactc cagtatataa ggagcaccag agtagtgtaa tagatcatcg atcaagcaag 180
cgagagctca aacttctaag agagcaaga 209
<210> SEQ ID NO 64
<211> LENGTH:	 209
<212> TYPE: DNA
<213> ORGANISM: Rice tungro bacilliform virus
<400> SEQUENCE:	 64
acgaatcaat aaagaaggac cagaagatat aaagctggaa catcttcaca tgctaccaca 60
tggctagcat ctttacttta gcatctctat tattgtaaga gtgtataatg aggagtgtgc 120
cccttcactc cagtatataa ggagcaccag agtagtgtaa tagatcatcg atcaagcaag 180
cgagagctca aacttctaag agagcaaga 209
<210> SEQ ID NO 65
<211> LENGTH: 194
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 65
acgaatcaat aaagaaggac cagaagatat aaagctggaa catcttcaca tgctaccaca 	 60
tggctagcat ctttacttta gcatctctat tattgtaaga gtgtataatg aactccagta 	 120
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tataaggagc accagagtag tgtaatagat catcgatcaa gcaagcgaga gctcaaactt 	 180
ctaagagagc aaga	 194
<210> SEQ ID NO 66
<211> LENGTH: 108
<212> TYPE: DNA
<213> ORGANISM: Cauliflower mosaic virus
<400> SEQUENCE: 66
ttgatgtgat atctccactg acgtaaggga tgacgcacaa tcccactatc cttcgcaaga 	 60
cccttcctct atataaggaa gttcatttca tttggagagg acacgctg 	 108
<210> SEQ ID NO 67
<211> LENGTH:	 552
<212> TYPE: DNA
<213> ORGANISM: Cassava vein mosaic virus
<400> SEQUENCE:	 67
ccaagatgta gcatcaagaa tccaatgttt acgggaaaaa ctatggaagt attatgtgag 60
ctcagcaaga agcagatcaa tatgcggcac atatgcaacc tatgttcaaa aatgaagaat 120
gtacagatac aagatcctat actgccagaa tacgaagaag aatacgtaga aattgaaaaa 180
gaagaaccag gcgaagaaaa gaatcttgaa gacgtaagca ctgacgacaa caatgaaaag 240
aagaagataa ggtcggtgat tgtgaaagag acatagagga cacatgtaag gtggaaaatg 300
taagggcgga aagtaacctt atcacaaagg aatcttatcc cccactactt atccttttat 360
atttttccgt gtcatttttg cccttgagtt ttcctatata aggaaccaag ttcggcattt 420
gtgaaaacaa gaaaaaattt ggtgtaagct attttctttg aagtactgag gatacaactt 480
cagagaaatt tgtaagtttg taatgttttt agtttttata ataatatgtt tatgtttgtt 540
ttaataatga gt 552
<210> SEQ ID NO 68
<211> LENGTH: 320
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 68
Met Gly His Arg Arg Ala His Ser Glu Ile Leu Ser Leu Pro Glu Asp
1	 5	 10	 15
Leu Asp Leu Cys Ala Ala Gly Gly Gly Asp Gly Pro Ser Leu Ser Asp
20	 25	 30
Glu Asn Asp Glu Glu Leu Phe Ser Met Phe Leu Asp Val Glu Lys Leu
35	 40	 45
Asn Ser Thr Cys Gly Ala Ser Ser Glu Ala Glu Ala Glu Ser Ser Ser
50	 55	 60
Ala Ala Ala His Gly Ala Arg Pro Lys His Gin His Ser Leu Ser Met
65	 70	 75	 80
Asp Glu Ser Met Ser Ile Ala Glu Glu Leu Val Gly Ala Ser Pro Gly
85	 90	 95
Thr Glu Gly Met Ser Ser Ala Glu Ala Lys Lys Ala Val Ser Ala Val
100	 105	 110
Lys Leu Ala Glu Leu Ala Leu Val Asp Pro Lys Arg Ala Lys Arg Ile
115	 120	 125
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Trp Ala Asn Arg Gin Ser Ala Ala Arg Ser Lys Glu Arg Lys Met Arg
130	 135	 140
Tyr Ile Ala Glu Leu Glu Arg Lys Val Gin Thr Leu Gin Thr Glu Ala
145	 150	 155	 160
Thr Thr Leu Ser Ala Gin Leu Ala Leu Leu Gin Arg Asp Thr Ser Gly
165	 170	 175
Leu Thr Thr Glu Asn Ser Glu Leu Lys Leu Arg Leu Gin Thr Met Glu
180	 185	 190
Gin Gin Val His Leu Gin Asp Ala Leu Asn Asp Thr Leu Lys Ser Glu
195	 200	 205
Val Gin Arg Leu Lys Val Ala Thr Gly Gin Met Ala Asn Gly Gly Gly
210	 215	 220
Met Met Met Asn Phe Gly Gly Met Pro His Gin Phe Gly Gly Asn Gin
225	 230	 235	 240
Gin Met Phe Gin Asn Asn Gin Ala Met Gin Ser Met Leu Ala Ala His
245	 250	 255
Gin Leu Gin Gin Leu Gin Leu His Pro Gin Ala Gin Gin Gin Gin Val
260	 265	 270
Leu His Pro Gin His Gin Gin Gin Gin Pro Leu His Pro Leu Gin Ala
275	 280	 285
Gin Gin Leu Gin Gin Ala Ala Arg Asp Leu Lys Met Lys Ser Pro Met
290	 295	 300
Gly Gly Gin Ser Gin Trp Gly Asp Gly Lys Ser Gly Ser Ser Gly Asn
305	 310	 315	 320
<210> SEQ ID NO 69
<211> LENGTH: 283
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 69
Met Asn Arg Glu Lys Ser Pro Ile Pro Gly Asp Gly Gly Asp Gly Leu
1	 5	 10	 15
Pro Pro Gin Ala Thr Arg Arg Ala Gly Pro Pro Ala Ala Ala Ala Ala
20	 25	 30
Ala Glu Tyr Asp Ile Ser Arg Met Pro Asp Phe Pro Thr Arg Asn Pro
35	 40	 45
Gly His Arg Arg Ala His Ser Glu Ile Leu Ser Leu Pro Glu Asp Leu
50	 55	 60
Asp Leu Cys Ala Ala Gly Gly Gly Asp Gly Pro Ser Leu Ser Asp Glu
65	 70	 75	 80
Asn Asp Glu Glu Leu Phe Ser Met Phe Leu Asp Val Glu Lys Leu Asn
85	 90	 95
Ser Thr Cys Gly Ala Ser Ser Glu Ala Glu Ala Glu Ser Ser Ser Ala
100	 105	 110
Ala Ala His Gly Ala Arg Pro Lys His Gin His Ser Leu Ser Met Asp
115	 120	 125
Glu Ser Met Ser Ile Lys Ala Glu Glu Leu Val Gly Ala Ser Pro Gly
130	 135	 140
Thr Glu Gly Met Ser Ser Ala Glu Ala Lys Lys Ala Val Ser Ala Val
145	 150	 155	 160
Lys Leu Ala Glu Leu Ala Leu Val Asp Pro Lys Arg Ala Lys Arg Ile
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165	 170	 175
Trp Ala Asn Arg Gin Ser Ala Ala Arg Ser Lys Glu Arg Lys Met Arg
180	 185	 190
Tyr Ile Ala Glu Leu Glu Arg Lys Val Gin Thr Leu Gin Thr Glu Ala
195	 200	 205
Thr Thr Leu Ser Ala Gin Leu Ala Leu Leu Gin Arg Asp Thr Ser Gly
210	 215	 220
Leu Thr Thr Glu Asn Ser Glu Leu Lys Leu Arg Leu Gin Thr Met Glu
225	 230	 235	 240
Gin Gin Val His Leu Gin Asp Ala Leu Asn Asp Thr Leu Lys Ser Glu
245	 250	 255
Val Gin Arg Leu Lys Val Ala Thr Gly Gin Met Ala Asn Gly Gly Gly
260	 265	 270
Met Met Met Asn Phe Gly Gly Met Pro His Gin
275	 280
<210> SEQ ID NO 70
<211> LENGTH: 261
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 70
Met Ser Ser Ser Ala Ala Ala His Gly Ala Arg Pro Lys His Gin His
1	 5	 10	 15
Ser Leu Ser Met Asp Glu Ser Met Ser Ile Lys Ala Glu Glu Leu Val
20	 25	 30
Gly Ala Ser Pro Gly Thr Glu Gly Met Ser Ser Ala Glu Ala Lys Lys
35	 40	 45
Ala Val Ser Ala Val Lys Leu Ala Glu Leu Ala Leu Val Asp Pro Lys
50	 55	 60
Arg Ala Lys Arg Ile Trp Ala Asn Arg Gin Ser Ala Ala Arg Ser Lys
65	 70	 75	 80
Glu Arg Lys Met Arg Tyr Ile Ala Glu Leu Glu Arg Lys Val Gin Thr
85	 90	 95
Leu Gin Thr Glu Ala Thr Thr Leu Ser Ala Gin Leu Ala Leu Leu Gin
100	 105	 110
Arg Asp Thr Ser Gly Leu Thr Thr Glu Asn Ser Glu Leu Lys Leu Arg
115	 120	 125
Leu Gin Thr Met Glu Gin Gin Val His Leu Gin Asp Ala Leu Asn Asp
130	 135	 140
Thr Leu Lys Ser Glu Val Gin Arg Leu Lys Val Ala Thr Gly Gin Met
145	 150	 155	 160
Ala Asn Gly Gly Gly Met Met Met Asn Phe Gly Gly Met Pro His Gin
165	 170	 175
Phe Gly Gly Asn Gin Gin Met Phe Gin Asn Asn Gin Ala Met Gin Ser
180	 185	 190
Met Leu Ala Ala His Gin Leu Gin Gin Leu Gin Leu His Pro Gin Ala
195	 200	 205
Gin Gin Gin Gin Val Leu His Pro Gin His Gin Gin Gin Gin Pro Leu
210	 215	 220
His Pro Leu Gin Ala Gin Gin Leu Gin Gin Ala Ala Arg Asp Leu Lys
225	 230	 235	 240
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Met Lys Ser Pro Met Gly Gly Gin Ser Gin Trp Gly Asp Gly Lys Ser
245	 250	 255
Gly Ser Ser Gly Asn
260
<210> SEQ ID NO 71
<211> LENGTH: 236
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 71
Met Gly His Arg Arg Ala His Ser Glu Ile Leu Ser Leu Pro Glu Asp
1	 5	 10	 15
Leu Asp Leu Cys Ala Ala Gly Gly Gly Asp Gly Pro Ser Leu Ser Asp
20	 25	 30
Glu Asn Asp Glu Glu Leu Phe Ser Met Phe Leu Asp Val Glu Lys Leu
35	 40	 45
Asn Ser Thr Cys Gly Ala Ser Ser Glu Ala Glu Ala Glu Ser Ser Ser
50	 55	 60
Ala Ala Ala His Gly Ala Arg Pro Lys His Gin His Ser Leu Ser Met
65	 70	 75	 80
Asp Glu Ser Met Ser Ile Lys Ala Glu Glu Leu Val Gly Ala Ser Pro
85	 90	 95
Gly Thr Glu Gly Met Ser Ser Ala Glu Ala Lys Lys Ala Val Ser Ala
100	 105	 110
Val Lys Leu Ala Glu Leu Ala Leu Val Asp Pro Lys Arg Ala Lys Arg
115	 120	 125
Ile Trp Ala Asn Arg Gin Ser Ala Ala Arg Ser Lys Glu Arg Lys Met
130	 135	 140
Arg Tyr Ile Ala Glu Leu Glu Arg Lys Val Gin Thr Leu Gin Thr Glu
145	 150	 155	 160
Ala Thr Thr Leu Ser Ala Gin Leu Ala Leu Leu Gin Arg Asp Thr Ser
165	 170	 175
Gly Leu Thr Thr Glu Asn Ser Glu Leu Lys Leu Arg Leu Gin Thr Met
180	 185	 190
Glu Gin Gin Val His Leu Gin Asp Ala Leu Asn Asp Thr Leu Lys Ser
195	 200	 205
Glu Val Gin Arg Leu Lys Val Ala Thr Gly Gin Met Ala Asn Gly Gly
210	 215	 220
Gly Met Met Met Asn Phe Gly Gly Met Pro His Gin
225	 230	 235
<210> SEQ ID NO 72
<211> LENGTH: 176
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 72
Met Ser Ser Ser Ala Ala Ala His Gly Ala Arg Pro Lys His Gin His
1	 5	 10	 15
Ser Leu Ser Met Asp Glu Ser Met Ser Ile Lys Ala Glu Glu Leu Val
20	 25	 30
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Gly Ala Ser Pro Gly Thr Glu Gly Met Ser Ser Ala Glu Ala Lys Lys
35	 40	 45
Ala Val Ser Ala Val Lys Leu Ala Glu Leu Ala Leu Val Asp Pro Lys
50	 55	 60
Arg Ala Lys Arg Ile Trp Ala Asn Arg Gin Ser Ala Ala Arg Ser Lys
65	 70	 75	 80
Glu Arg Lys Met Arg Tyr Ile Ala Glu Leu Glu Arg Lys Val Gin Thr
85	 90	 95
Leu Gin Thr Glu Ala Thr Thr Leu Ser Ala Gin Leu Ala Leu Leu Gin
100	 105	 110
Arg Asp Thr Ser Gly Leu Thr Thr Glu Asn Ser Glu Leu Lys Leu Arg
115	 120	 125
Leu Gin Thr Met Glu Gin Gin Val His Leu Gin Asp Ala Leu Asn Asp
130	 135	 140
Thr Leu Lys Ser Glu Val Gin Arg Leu Lys Val Ala Thr Gly Gin Met
145	 150	 155	 160
Ala Asn Gly Gly Gly Met Met Met Asn Phe Gly Gly Met Pro His Gin
165	 170	 175
<210> SEQ ID NO 73
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 73
ttcacacagg aaacagctat gac 	 23
<210> SEQ ID NO 74
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 74
gcgtgggcgg cgtgggcg 	 18
<210> SEQ ID NO 75
<211> LENGTH: 172
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 75
Met Leu Glu Leu Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg
1	 5	 10	 15
Phe Ser Lys Ser Ala Asp Leu Lys Arg His Ile Arg Ile His Thr Gly
20	 25	 30
Gin Lys Pro Phe Gin Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser
35	 40	 45
Asp His Leu Thr Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe
50	 55	 60
Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys
65	 70	 75	 80
US 7,847,064 B2
83
	
84
-continued
Arg His Thr Lys Ile His Thr Gly Glu Lys Pro Tyr Ala Cys Pro Val
85	 90	 95
Glu Ser Cys Asp Arg Arg Phe Ser Lys Ser Ala Asp Leu Lys Arg His
100	 105	 110
Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met
115	 120	 125
Arg Asn Phe Ser Arg Ser Asp His Leu Thr Thr His Ile Arg Thr His
130	 135	 140
Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala
145	 150	 155	 160
Arg Ser Asp Glu Arg Lys Arg His Thr Lys Ile His
165	 170
<210> SEQ ID NO 76
<211> LENGTH:	 516
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE:	 76
atgctcgagc tcccctatgc ttgccctgtc gagtcctgcg atcgccgctt ttctaagtcg 60
gctgatctga agcgccatat ccgcatccac acaggccaga agcctttcca gtgtcgaata 120
tgcatgcgta acttcagtcg tagtgaccac cttaccaccc acatccgcac ccacacaggc 180
gagaagcctt ttgcctgtga catttgtggg aggaagtttg ccaggagtga tgaacgcaag 240
aggcatacca aaatccatac cggtgagaag ccctatgctt gccctgtcga gtcctgcgat 300
cgccgctttt ctaagtcggc tgatctgaag cgccatatcc gcatccacac aggccagaag 360
cccttccagt gtcgaatatg catgcgtaac ttcagtcgta gtgaccacct taccacccac 420
atccgcaccc acacaggcga gaagcctttt gcctgtgaca tttgtgggag gaagtttgcc 480
aggagtgatg aacgcaagag gcataccaaa atccat 516
<210> SEQ ID NO 77
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 77
ccccaaagtc cagcttgaaa t 	 21
<210> SEQ ID NO 78
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 78
ttaatccaac ttggaaaatg 	 20
<210> SEQ ID NO 79
<211> LENGTH: 11
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
US 7,847,064 B2
85
	
86
-continued
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 79
ccaccacccc c	 11
<210> SEQ ID NO 80
<211> LENGTH: 15
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 80
cttcaccacc ccact	 15
<210> SEQ ID NO 81
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 81
tggaccctac ca	 12
<210> SEQ ID NO 82
<211> LENGTH: 13
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 82
aggtcacccc att	 13
<210> SEQ ID NO 83
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 83
tggatgtgga agacagca	 18
<210> SEQ ID NO 84
<211> LENGTH: 65
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 84
Met Asp Glu Lys Arg Arg Ala Gin His Asn Glu Val Glu Arg Arg Arg
1	 5	 10	 15
Arg Asp Lys Ile Asn Asn Trp Ile Val Gin Leu Ser Lys Ile Ile Pro
20	 25	 30
Asp Ser Ser Met Glu Ser Thr Lys Ser Gly Gin Ser Lys Gly Gly Ile
35	 40	 45
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Leu Ser Lys Ala Ser Asp Tyr Ile Gin Glu Leu Arg Gin Ser Asn His
50	 55	 60
Arg
65
<210> SEQ ID NO 85
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 85
cacccggtca cgtggcctac a 	 21
<210> SEQ ID NO 86
<211> LENGTH: 62
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 86
Lys Ala Glu Arg Lys Arg Met Arg Asn Arg Ile Ala Ala Ser Lys Ser
1	 5	 10	 15
Arg Lys Arg Lys Leu Glu Arg Ile Ala Arg Leu Glu Glu Lys Val Lys
20	 25	 30
Thr Leu Lys Ala Gin Asn Ser Glu Leu Ala Ser Thr Ala Asn Met Leu
35	 40	 45
Arg Glu Gin Val Ala Gin Leu Lys Gin Lys Val Met Asn His
50	 55	 60
<210> SEQ ID NO 87
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 87
cgtcgatgac gtcatcgacg 	 20
<210> SEQ ID NO 88
<211> LENGTH: 90
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 88
Met Glu Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe
1	 5	 10	 15
Ser Gin Lys Thr Asn Leu Asp Thr His Ile Arg Ile His Thr Gly Gin
20	 25	 30
Lys Pro Phe Gin Cys Arg Ile Cys Met Arg Asn Phe Ser Gin His Thr
35	 40	 45
Gly Leu Asn Gin His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala
50	 55	 60
Cys Asp Ile Cys Gly Arg Lys Phe Ala Thr Leu His Thr Arg Asp Arg
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65	 70	 75	 80
His Thr Lys Ile His Leu Arg Gin Lys Asp
85	 90
<210> SEQ ID NO 89
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 89
gacgctataa aaggag 	 16
<210> SEQ ID NO 90
<211> LENGTH: 76
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 90
Pro Pro Gly Thr Pro Ser Arg His Glu Lys Ser Leu Gly Leu Leu Thr
1	 5	 10	 15
Thr Lys Phe Val Ser Leu Leu Gin Glu Ala Lys Asp Gly Val Leu Asp
20	 25	 30
Leu Lys Leu Ala Ala Asp Thr Leu Ala Val Arg Gin Lys Arg Arg Ile
35	 40	 45
Tyr Asp Ile Thr Asn Val Leu Glu Gly Ile Gly Leu Ile Glu Lys Lys
50	 55	 60
Ser Lys Asn Ser Ile Gin Trp Lys Gly Val Gly Pro
65	 70	 75
<210> SEQ ID NO 91
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 91
attttcgcgc ggtttt	 16
<210> SEQ ID NO 92
<211> LENGTH: 163
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 92
gctcggagga cagtactccg ctcggaggac agtactccgc tcggaggaca gtactccgct 60
cgaggacagt actccgctcg gaggacagta ctccgatccg tagatctgca agacccttcc 120
tctatataag gaagttcatt tcatttggag aggacacgct gaa 163
<210> SEQ ID NO 93
<211> LENGTH: 2595
<212> TYPE: DNA
<213> ORGANISM: Artificial
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<220> FEATURE:
<223> OTHER INFORMATION: This sequence was artificially derived and/or
created by the inventors.
<400> SEQUENCE: 93
atggcccccc cgaccgatgt cagcctgggg gacgaactcc acttagacgg cgaggacgtg 	 60
gcgatggcgc atgccgacgc gctagacgat ttcgatctgg acatgttggg ggacggggat 	 120
tccccaggtc cgggatttac cccccacgac tccgccccct acggcgctct ggatatggcc 	 180
gacttcgagt ttgagcagat gtttaccgat gcccttggaa ttgacgagta cggtgggaag 	 240
cttctaggta cctccagaag aatatcaggc ggggaattcg gcgggatgaa gctactgtct 	 300
tctatcgaac aagcatgcga tatttgccga cttaaaaagc tcaagtgctc caaagaaaaa 	 360
ccgaagtgcg ccaagtgtct gaagaacaac tgggagtgtc gctactctcc caaaaccaaa 	 420
aggtctccgc tgactagggc acatctgaca gaagtggaat caaggctaga aagactggaa 	 480
cagctatttc tactgatttt tcctcgagaa gaccttgaca tgattttgaa aatggattct 	 540
ttacaggata taaaagcatt gttaacagga ttatttgtac aagataatgt gaataaagat 	 600
gccgtcacag atagattggc ttcagtggag actgatatgc ctctaacatt gagacagcat 	 660
agaataagtg cgacatcatc atcggaagag agtagtaaca aaggtcaaag acagttgact 	 720
gtatcgggcg ggtctagaag aatatcgtgg cctgagtgcg tagtacccga gactcagtgc 	 780
gccatgaagc ggaaagagaa gaaagcacag aaggagaagg acaaactgcc tgtcagcacg 	 840
acgacggtgg acgaccacat gccgcccatt atgcagtgtg aacctccacc tcctgaagca 	 900
gcaaggattc acgaagtggt tccaaggttt ctctccgaca agctgttgga gacaaaccgg 	 960
cagaaaaaca tcccccagtt gacagccaac cagcagttcc ttatcgccag gctcatctgg 	 1020
taccaggacg ggtacgagca gccttctgat gaagatttga agaggattac gcagacgtgg 	 1080
cagcaagcgg acgatgaaaa cgaagagtct gacactccct tccgccagat cacagagatg 	 1140
actatcctca cggtccaact tatcgtggag ttcgcgaagg gattgccagg gttcgccaag 	 1200
atctcgcagc ctgatcaaat tacgctgctt aaggcttgct caagtgaggt aatgatgctc 	 1260
cgagtcgcca gatacgatgc ggcctcagac agtgttctgt tcgcgaacaa ccaagcgtac 	 1320
actcgcgaca actaccgcaa ggctggcatg gcctacgtca tcgaggatct actgcacttc 	 1380
tgccggtgca tgtactctat ggcgttggac aacatccatt acgcgctgct cacggctgtc 	 1440
gtcatctttt ctgaccggcc agggttggag cagccgcaac tggtggaaga aatccagcgg 	 1500
tactacctga atacgctccg catctatatc ctgaaccagc tgagcgggtc ggcgcgttcg 	 1560
tccgtcatat acggcaagat cctctcaatc ctctctgagc tacgcacgct cggcatgcaa 	 1620
aactccaaca tgtgcatctc cctcaagctc aagaacagaa agctgccgcc tttcctcgag 	 1680
gagatctggg atgtggcagg acatgtcgca cacccaaccg ccgcctatct cgagtccccc 	 1740
acgaatctct agtgacaatc tcccttcacc cgtccccgtt gtcgacccct tccccccata 	 1800
ttccaggtta acttcccctt cttaagcagc aagaatccca agtggtccca ggtttctttc 	 1860
ctgcaagccg ttggagtcaa ccggccgaaa aacttccccc agttggcagc caaccagcag 	 1920
tccctattct ccaggctctt ctggtaccag gacgggtacg agcagccttc tgatgaggat 	 1980
ttgaagggga ttacgcagac gtggcagcaa gcggacgatg aaatcgaaga gtctgacact 	 2040
cctttccgcc agatcacaga gatgactatc ctcacggtcc aacttatcgt ggagttcgcg 	 2100
aagggattgc cagggttcgc caagatctcg cagcctgatc aaattacgct acttaaggct 	 2160
ttctcaagtg aggtaatgat gctccgagtc gcgcgacgat acgatgcgcc ctcagacagt 	 2220
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gttctggtcg cgaacaacca agcgtacact cgcgacaact accgcaaggc tggcatggcc 	 2280
tacgtcatcg aggatctact gcacttctgc cggtgcatgt actctatggc gttggacaac 	 2340
atccattacg cgctgctcac ggctgtcgtc atcttttctg accggccagg gttggagcag 	 2400
ccgcaactgg tggaagagat ccagcggtac tacctgaata cgctccgcat ctatatcctg 	 2460
aaccagctga gcgggtcggc gcgttcgtcc gtcatatacg gcaagatcct ctcaatcctc 	 2520
tctgagctac gcacgctcgg catgcaaaac tccaacatgt gcatctccct caagctcaag 	 2580
aacagaaagc tgtaa	 2595
<210> SEQ ID NO 94
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer sequence that hybridizes to the coding
sequence for the synthetic 2C7 zinc finger protein
<400> SEQUENCE: 94
gccagatcta tgggccacag gcgcgccc	 28
<210> SEQ ID NO 95
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer sequence that hybridizes to the coding
sequence for the synthetic 2C7 zinc finger protein
<400> SEQUENCE: 95
cgcggatcct ccatgggcgg cggcg	 25
<210> SEQ ID NO 96
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer sequence that hybridizes to the coding
sequence for the synthetic 2C7 zinc finger protein
<400> SEQUENCE: 96
cgcagatcta tggcggccgc cggcggc 	 27
<210> SEQ ID NO 97
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer sequence that hybridizes to the coding
sequence for the synthetic 2C7 zinc finger protein
<400> SEQUENCE: 97
cgcggatccg ttcagcttct ccacgtcg	 28
<210> SEQ ID NO 98
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer used to amplify sequence from rice
(Ordyza sp.)
<400> SEQUENCE: 98
cgcagatcta tggagatcct gagcctcccc 	 30
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<210> SEQ ID NO 99
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Primer used to amplify sequence from Rice
(Ordyza sp.)
<400> SEQUENCE: 99
cgcggatccc tcctcgtcgt tctcgtc 	 27
<210> SEQ ID NO 100
<211> LENGTH: 584
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Chimeric VGE receptor, comprising the acidic
domain of the SV40 virus (Simian virus 40), the Ga14 protein from
Baker's yeast (Salmonella sp.), and the ecdysone receptor of
Cloristoneura fumiferana
<400> SEQUENCE: 100
Met Ala Pro Pro Thr Asp Val Ser Leu Gly Asp Glu Leu His Leu Asp
1	 5	 10	 15
Gly Glu Asp Val Ala Met Ala His Ala Asp Ala Leu Asp Asp Phe Asp
20	 25	 30
Leu Asp Met Leu Gly Asp Gly Asp Ser Pro Gly Pro Gly Phe Thr Pro
35	 40	 45
His Asp Ser Ala Pro Tyr Gly Ala Leu Asp Met Ala Asp Phe Glu Phe
50	 55	 60
Glu Gin Met Phe Thr Asp Ala Leu Gly Ile Asp Glu Tyr Gly Gly Lys
65	 70	 75	 80
Leu Leu Gly Thr Ser Arg Arg Ile Ser Gly Gly Glu Phe Gly Gly Met
85	 90	 95
Lys Leu Leu Ser Ser Ile Glu Gin Ala Cys Asp Ile Cys Arg Leu Lys
100	 105	 110
Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys
115	 120	 125
Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu
130	 135	 140
Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu
145	 150	 155	 160
Gin Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu
165	 170	 175
Lys Met Asp Ser Leu Gin Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe
180	 185	 190
Val Gin Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser
195	 200	 205
Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gin His Arg Ile Ser Ala
210	 215	 220
Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gin Arg Gin Leu Thr
225	 230	 235	 240
Val Ser Gly Gly Ser Arg Arg Ile Ser Trp Pro Glu Cys Val Val Pro
245	 250	 255
Glu Thr Gin Cys Ala Met Lys Arg Lys Glu Lys Lys Ala Gin Lys Glu
260	 265	 270
Lys Asp Lys Leu Pro Val Ser Thr Thr Thr Val Asp Asp His Met Pro
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275	 280	 285
Pro Ile Met Gin Cys Glu Pro Pro Pro Pro Glu Ala Ala Arg Ile His
290	 295	 300
Glu Val Val Pro Arg Phe Leu Ser Asp Lys Leu Leu Glu Thr Asn Arg
305	 310	 315	 320
Gin Lys Asn Ile Pro Gin Leu Thr Ala Asn Gin Gin Phe Leu Ile Ala
325	 330	 335
Arg Leu Ile Trp Tyr Gin Asp Gly Tyr Glu Gin Pro Ser Asp Glu Asp
340	 345	 350
Leu Lys Arg Ile Thr Gin Thr Trp Gin Gin Ala Asp Asp Glu Asn Glu
355	 360	 365
Glu Ser Asp Thr Pro Phe Arg Gin Ile Thr Glu Met Thr Ile Leu Thr
370	 375	 380
Val Gin Leu Ile Val Glu Phe Ala Lys Gly Leu Pro Gly Phe Ala Lys
385	 390	 395	 400
Ile Ser Gin Pro Asp Gin Ile Thr Leu Leu Lys Ala Phe Ser Ser Glu
405	 410	 415
Val Met Met Leu Arg Val Ala Arg Arg Tyr Asp Ala Ala Ser Asp Ser
420	 425	 430
Val Leu Phe Ala Asn Asn Gin Ala Tyr Thr Arg Asp Asn Tyr Arg Lys
435	 440	 445
Ala Gly Met Ala Tyr Val Ile Glu Asp Leu Leu His Phe Cys Arg Cys
450	 455	 460
Met Tyr Ser Met Ala Leu Asp Asn Ile His Tyr Ala Leu Leu Thr Ala
465	 470	 475	 480
Val Val Ile Phe Ser Asp Arg Pro Gly Leu Glu Gin Pro Gin Leu Val
485	 490	 495
Glu Glu Ile Gin Arg Tyr Tyr Leu Asn Thr Leu Arg Ile Tyr Ile Leu
500	 505	 510
Asn Gin Leu Ser Gly Ser Ala Arg Ser Ser Val Ile Tyr Gly Lys Ile
515	 520	 525
Leu Ser Ile Leu Ser Glu Leu Arg Thr Leu Gly Met Gin Asn Ser Asn
530	 535	 540
Met Cys Ile Ser Leu Lys Leu Lys Asn Arg Lys Leu Pro Pro Phe Leu
545	 550	 555	 560
Glu Glu Ile Trp Asp Val Ala Asp Met Ser His Thr Gin Pro Pro Pro
565	 570	 575
Ile Leu Glu Ser Pro Thr Asn Leu
580
<210> SEQ ID NO 101
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Oryza sp.
<400> SEQUENCE: 101
Glu Ile Leu Ser Leu Pro Glu Asp Leu Asp Leu Cys Ala Ala Gly Gly
1	 5	 10	 15
Gly Asp Gly Pro Ser Leu Ser Asp Glu Asn Asp Glu Glu
20	 25
<210> SEQ ID NO 102
<211> LENGTH: 87
<212> TYPE: DNA
<213> ORGANISM: Oryza sp.
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<400> SEQUENCE: 102
gagatcctga gcctccccga ggacctcgac ctgtgcgcgg ccggcggcgg cgacgggccg 	 60
tcgctgtcgg acgagaacga cgaggag	 87
<210> SEQ ID NO 103
<211> LENGTH: 488
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: A combination of the Ga14 protein and Ecdysone
receptor
<400> SEQUENCE: 103
Lys Leu Leu Ser Ser Ile Glu Gin Ala Cys Asp Ile Cys Arg Leu Lys
1	 5	 10	 15
Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys
20	 25	 30
Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu
35	 40	 45
Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu
50	 55	 60
Gin Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu
65	 70	 75	 80
Lys Met Asp Ser Leu Gin Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe
85	 90	 95
Val Gin Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser
100	 105	 110
Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gin His Arg Ile Ser Ala
115	 120	 125
Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gin Arg Gin Leu Thr
130	 135	 140
Val Ser Gly Gly Ser Arg Arg Ile Ser Trp Pro Glu Cys Val Val Pro
145	 150	 155	 160
Glu Thr Gin Cys Ala Met Lys Arg Lys Glu Lys Lys Ala Gin Lys Glu
165	 170	 175
Lys Asp Lys Leu Pro Val Ser Thr Thr Thr Val Asp Asp His Met Pro
180	 185	 190
Pro Ile Met Gin Cys Glu Pro Pro Pro Pro Glu Ala Ala Arg Ile His
195	 200	 205
Glu Val Val Pro Arg Phe Leu Ser Asp Lys Leu Leu Glu Thr Asn Arg
210	 215	 220
Gin Lys Asn Ile Pro Gin Leu Thr Ala Asn Gin Gin Phe Leu Ile Ala
225	 230	 235	 240
Arg Leu Ile Trp Tyr Gin Asp Gly Tyr Glu Gin Pro Ser Asp Glu Asp
245	 250	 255
Leu Lys Arg Ile Thr Gin Thr Trp Gin Gin Ala Asp Asp Glu Asn Glu
260	 265	 270
Glu Ser Asp Thr Pro Phe Arg Gin Ile Thr Glu Met Thr Ile Leu Thr
275	 280	 285
Val Gin Leu Ile Val Glu Phe Ala Lys Gly Leu Pro Gly Phe Ala Lys
290	 295	 300
Ile Ser Gin Pro Asp Gin Ile Thr Leu Leu Lys Ala Phe Ser Ser Glu
305	 310	 315	 320
Val Met Met Leu Arg Val Ala Arg Arg Tyr Asp Ala Ala Ser Asp Ser
325	 330	 335
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Val Leu Phe Ala Asn Asn Gln Ala Tyr Thr Arg Asp Asn Tyr Arg Lys
340	 345	 350
Ala Gly Met Ala Tyr Val Ile Glu Asp Leu Leu His Phe Cys Arg Cys
355	 360	 365
Met Tyr Ser Met Ala Leu Asp Asn Ile His Tyr Ala Leu Leu Thr Ala
370	 375	 380
Val Val Ile Phe Ser Asp Arg Pro Gly Leu Glu Gln Pro Gln Leu Val
385	 390	 395	 400
Glu Glu Ile Gln Arg Tyr Tyr Leu Asn Thr Leu Arg Ile Tyr Ile Leu
405	 410	 415
Asn Gln Leu Ser Gly Ser Ala Arg Ser Ser Val Ile Tyr Gly Lys Ile
420	 425	 430
Leu Ser Ile Leu Ser Glu Leu Arg Thr Leu Gly Met Gln Asn Ser Asn
435	 440	 445
Met Cys Ile Ser Leu Lys Leu Lys Asn Arg Lys Leu Pro Pro Phe Leu
450	 455	 460
Glu Glu Ile Trp Asp Val Ala Asp Met Ser His Thr Gln Pro Pro Pro
465	 470	 475	 480
Ile Leu Glu Ser Pro Thr Asn Leu
485
<210> SEQ ID NO 104
<211> LENGTH: 1464
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Nucleic acid sequence encoding SEQ ID NO:103 (a
combination of the Ga14 protein and ecdysone receptor)
<400> SEQUENCE: 104
aagctactgt cttctatcga acaagcatgc gatatttgcc gacttaaaaa gctcaagtgc 	 60
tccaaagaaa aaccgaagtg cgccaagtgt ctgaagaaca actgggagtg tcgctactct 	 120
cccaaaacca aaaggtctcc gctgactagg gcacatctga cagaagtgga atcaaggcta 	 180
gaaagactgg aacagctatt tctactgatt tttcctcgag aagaccttga catgattttg 	 240
aaaatggatt ctttacagga tataaaagca ttgttaacag gattatttgt acaagataat 	 300
gtgaataaag atgccgtcac agatagattg gcttcagtgg agactgatat gcctctaaca 	 360
ttgagacagc atagaataag tgcgacatca tcatcggaag agagtagtaa caaaggtcaa 	 420
agacagttga ctgtatcggg cgggtctaga agaatatcgt ggcctgagtg cgtagtaccc 	 480
gagactcagt gcgccatgaa gcggaaagag aagaaagcac agaaggagaa ggacaaactg 	 540
cctgtcagca cgacgacggt ggacgaccac atgccgccca ttatgcagtg tgaacctcca 	 600
cctcctgaag cagcaaggat tcacgaagtg gtcccaaggt ttctctccga caagctgttg 	 660
gagacaaacc ggcagaaaaa catcccccag ttgacagcca accagcagtt ccttatcgcc 	 720
aggctcatct ggtaccagga cgggtacgag cagccttctg atgaagattt gaagaggatt 	 780
acgcagacgt ggcagcaagc ggacgatgaa aacgaagagt ctgacactcc cttccgccag 	 840
atcacagaga tgactatcct cacggtccaa cttatcgtgg agttcgcgaa gggattgcca 	 900
gggttcgcca agatctcgca gcctgatcaa attacgctac ttaaggcttt ctcaagtgag 	 960
gtaatgatgc tccgagtcgc gcgacgatac gatgcggcct cagacagtgt tctgttcgcg 	 1020
aacaaccaag cgtacactcg cgacaactac cgcaaggctg gcatggccta cgtcatcgag 	 1080
gatctactgc acttctgccg gtgcatgtac tctatggcgt tggacaacat ccattacgcg 	 1140
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ctgctcacgg ctgtcgtcat cttttctgac cggccagggt tggagcagcc gcaactggtg 	 1200
gaagagatcc agcggtacta cctgaatacg ctccgcatct atatcctgaa ccagctgagc 	 1260
gggtcggcgc gttcgtccgt catatacggc aagatcctct caatcctctc tgagctacgc 	 1320
acgctcggca tgcaaaactc caacatgtgc atctccctca agctcaagaa cagaaagctg 	 1380
ccgcctttcc tcgaggagat ctgggatgtg gcggacatgt cgcacaccca accgccgcct 	 1440
atcctcgagt cccccacgaa tctc 	 1464
<210> SEQ ID NO 105
<211> LENGTH: 334
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Ecdysone receptor domain from Cloristoneura
fumiferana
<400> SEQUENCE: 105
Pro Glu Cys Val Val Pro Glu Thr Gin Cys Ala Met Lys Arg Lys Glu
1	 5	 10	 15
Lys Lys Ala Gin Lys Glu Lys Asp Lys Leu Pro Val Ser Thr Thr Thr
20	 25	 30
Val Asp Asp His Met Pro Pro Ile Met Gin Cys Glu Pro Pro Pro Pro
35	 40	 45
Glu Ala Ala Arg Ile His Glu Val Val Pro Arg Phe Leu Ser Asp Lys
50	 55	 60
Leu Leu Glu Thr Asn Arg Gin Lys Asn Ile Pro Gin Leu Thr Ala Asn
65	 70	 75	 80
Gin Gin Phe Leu Ile Ala Arg Leu Ile Trp Tyr Gin Asp Gly Tyr Glu
85	 90	 95
Gin Pro Ser Asp Glu Asp Leu Lys Arg Ile Thr Gin Thr Trp Gin Gin
100	 105	 110
Ala Asp Asp Glu Asn Glu Glu Ser Asp Thr Pro Phe Arg Gin Ile Thr
115	 120	 125
Glu Met Thr Ile Leu Thr Val Gin Leu Ile Val Glu Phe Ala Lys Gly
130	 135	 140
Leu Pro Gly Phe Ala Lys Ile Ser Gin Pro Asp Gin Ile Thr Leu Leu
145	 150	 155	 160
Lys Ala Phe Ser Ser Glu Val Met Met Leu Arg Val Ala Arg Arg Tyr
165	 170	 175
Asp Ala Ala Ser Asp Ser Val Leu Phe Ala Asn Asn Gin Ala Tyr Thr
180	 185	 190
Arg Asp Asn Tyr Arg Lys Ala Gly Met Ala Tyr Val Ile Glu Asp Leu
195	 200	 205
Leu His Phe Cys Arg Cys Met Tyr Ser Met Ala Leu Asp Asn Ile His
210	 215	 220
Tyr Ala Leu Leu Thr Ala Val Val Ile Phe Ser Asp Arg Pro Gly Leu
225	 230	 235	 240
Glu Gin Pro Gin Leu Val Glu Glu Ile Gin Arg Tyr Tyr Leu Asn Thr
245	 250	 255
Leu Arg Ile Tyr Ile Leu Asn Gin Leu Ser Gly Ser Ala Arg Ser Ser
260	 265	 270
Val Ile Tyr Gly Lys Ile Leu Ser Ile Leu Ser Glu Leu Arg Thr Leu
275	 280	 285
Gly Met Gin Asn Ser Asn Met Cys Ile Ser Leu Lys Leu Lys Asn Arg
US 7,847,064 B2
105	 106
-continued
290	 295	 300
Lys Leu Pro Pro Phe Leu Glu Glu Ile Trp Asp Val Ala Asp Met Ser
305	 310	 315	 320
His Thr Gin Pro Pro Pro Ile Leu Glu Ser Pro Thr Asn Leu
325	 330
<210> SEQ ID NO 106
<211> LENGTH: 1002
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Nucleic acid sequence encoding the ecdysone
receptor domain from Cloristoneura fumiferana
<400> SEQUENCE: 106
cctgagtgcg tagtacccga gactcagtgc gccatgaagc ggaaagagaa gaaagcacag 	 60
aaggagaagg acaaactgcc tgtcagcacg acgacggtgg acgaccacat gccgcccatt 	 120
atgcagtgtg aacctccacc tcctgaagca gcaaggattc acgaagtggt cccaaggttt 	 180
ctctccgaca agctgttgga gacaaaccgg cagaaaaaca tcccccagtt gacagccaac 	 240
cagcagttcc ttatcgccag gctcatctgg taccaggacg ggtacgagca gccttctgat 	 300
gaagatttga agaggattac gcagacgtgg cagcaagcgg acgatgaaaa cgaagagtct 	 360
gacactccct tccgccagat cacagagatg actatcctca cggtccaact tatcgtggag 	 420
ttcgcgaagg gattgccagg gttcgccaag atctcgcagc ctgatcaaat tacgctactt 	 480
aaggctttct caagtgaggt aatgatgctc cgagtcgcgc gacgatacga tgcggcctca 	 540
gacagtgttc tgttcgcgaa caaccaagcg tacactcgcg acaactaccg caaggctggc 	 600
atggcctacg tcatcgagga tctactgcac ttctgccggt gcatgtactc tatggcgttg 	 660
gacaacatcc attacgcgct gctcacggct gtcgtcatct tttctgaccg gccagggttg 	 720
gagcagccgc aactggtgga agagatccag cggtactacc tgaatacgct ccgcatctat 	 780
atcctgaacc agctgagcgg gtcggcgcgt tcgtccgtca tatacggcaa gatcctctca 	 840
atcctctctg agctacgcac gctcggcatg caaaactcca acatgtgcat ctccctcaag 	 900
ctcaagaaca gaaagctgcc gcctttcctc gaggagatct gggatgtggc ggacatgtcg 	 960
cacacccaac cgccgcctat cctcgagtcc cccacgaatc tc	 1002
<210> SEQ ID NO 107
<211> LENGTH: 154
<212> TYPE: PRT
<213> ORGANISM: Salmonella sp.
<400> SEQUENCE: 107
Lys Leu Leu Ser Ser Ile Glu Gin Ala Cys Asp Ile Cys Arg Leu Lys
1	 5	 10	 15
Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys
20	 25	 30
Asn Asn Trp Glu Cys Arg Tyr Ser Pro Lys Thr Lys Arg Ser Pro Leu
35	 40	 45
Thr Arg Ala His Leu Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu
50	 55	 60
Gin Leu Phe Leu Leu Ile Phe Pro Arg Glu Asp Leu Asp Met Ile Leu
65	 70	 75	 80
Lys Met Asp Ser Leu Gin Asp Ile Lys Ala Leu Leu Thr Gly Leu Phe
85	 90	 95
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Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser
100	 105	 110
Val Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala
115	 120	 125
Thr Ser Ser Ser Glu Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr
130	 135	 140
Val Ser Gly Gly Ser Arg Arg Ile Ser Trp
145	 150
<210> SEQ ID NO 108
<211> LENGTH: 93
<212> TYPE: DNA
<213> ORGANISM: Salmonella sp.
<400> SEQUENCE: 108
ctcggaggac agtactccgc tcggaggaca gtactccgct cgaggacagt actccgctcg 	 60
aggacagtac tccgctcgga ggacagtact ccg	 93
<210> SEQ ID NO 109
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Sequence signature of the DNA-binding regions
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(4)
<223> OTHER INFORMATION: Xaa can be naturally occurring amino acid
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (7)..(8)
<223> OTHER INFORMATION: Xaa can be naturally occurring amino acid
<400> SEQUENCE: 109
Asn Xaa Xaa Xaa Ser Ala Xaa Xaa Ser Lys
1	 5	 10
40
What is claimed is: 7. A protein capable of regulating the expression level of at
1. A protein capable of regulating the expression level of at least one gene of interest, which comprises:
least one gene of interest, which comprises: (i) an amino acid sequence that comprises SEQ ID
(i) an amino acid sequence consisting of SEQ ID NO: 6; and 45 NO: 101; and
(ii) a DNA binding domain selected from the group con- (ii) a DNA binding domain selected from the group con-
sisting of a 2C7 DNA binding domain and a GAL4 DNA sisting of a 2C7 DNA binding domain and a GAL4 DNA
binding domain, wherein the DNA binding domain is binding domain, wherein the DNA binding domain is
capable of recognizing and binding to a nucleic acid 50 capable of recognizing and binding to a nucleic acid
sequence, wherein the nucleic acid sequence is capable sequence, wherein the nucleic acid sequence is capable
of regulating the expression level of at least one gene of of regulating the expression level of at least one gene of
interest. interest.
2. The protein of claim 1, wherein the nucleic acid 8• The protein of claim 7, wherein the nucleic acid
sequence is a promoter.	 55 sequence is a promoter.
3. The protein of claim 1, which further comprises an 9. The protein of claim 8, which further comprises an
ecdysone receptor domain. ecdysone receptor domain.
4. The protein of claim 3, wherein the ecdysone receptor 10. The protein of claim 9, wherein the ecdysone receptor
domain comprises an amino acid of SEQ ID NO: 105.	 60 domain comprises an amino acid sequence of SEQ ID
NO: 105.5. The protein of claim 4, wherein the nucleic acid
sequence comprises a Gal4 binding domain, which comprises
a nucleic acid sequence of SEQ ID NO: 108.
6. The protein of claim 1, wherein the nucleic acid 65
sequence comprises a C7er domain, which comprises a
sequence of SEQ ID NO:74.
11. The protein of claim 8, which further comprises a 2C7
zinc finger domain.
12. The protein of claim 11, wherein the promoter com-
prises a C7er domain, which comprises a nucleic acid
sequence of SEQ ID NO:74.
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13. The protein of claim 7, which comprises two or more	 (ii) an ecdysone receptor domain; and
repetitions of SEQ ID NO: 101.
14. A protein capable of regulating the expression level of 	 (iii) a Gal4 protein.
at least one gene of interest, which comprises:
(i) an amino acid sequence representedby SEQ ID NO:6 or 5
a fragment thereof which consists of SEQ ID NO: 101;
